BIOPHARMACEUTICAL MICROBICIDES FOR TOPICAL HIV PREVENTION:PRE-CLINICAL EVALUATIONS AND FORMULATION DEVELOPMENT by Sassi, Alexandra Britto
 BIOPHARMACEUTICAL MICROBICIDES FOR TOPICAL HIV PREVENTION: 
PRE-CLINICAL EVALUATIONS AND FORMULATION DEVELOPMENT 
 
 
 
 
 
 
 
by 
Alexandra B. Sassi 
Pharmacy-Biochemistry, 1998, University of Sao Paulo 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Pharmacy School in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2008 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF PHARMACY 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Alexandra B. Sassi 
 
 
 
It was defended on 
November 24, 2008 
and approved by 
Song Li, Ph.D., Department of Pharmaceutical Sciences, School of Pharmacy 
Michael Mokotoff Ph.D., Department of Pharmaceutical Sciences, School of Pharmacy 
Samuel Poloyac, Pharm.D., Ph.D., Dept. of Pharmaceutical Sciences, School of Pharmacy 
Frank Bedu-Addo, Ph.D., President and CEO, PDS Biotechnology Corporation 
Sharon L. Hillier, Ph.D., Department of Obstetrics and Gynecology, School of Medicine 
Dissertation Advisor: Lisa C. Rohan, Ph.D., Assistant Professor, Department of 
Pharmaceutical Sciences, School of Pharmacy 
 ii 
Copyright © by Alexandra B. Sassi 
2008 
 iii 
BIOPHARMACEUTICAL MICROBICIDES FOR TOPICAL HIV PREVENTION: 
PRE-CLINICAL EVALUATIONS AND FORMULATION DEVELOPMENT 
Alexandra B. Sassi 
University of Pittsburgh, 2008
 
Over 60 million people have been infected with HIV since the beginning of the epidemic. 
Currently available methods for prevention have not been sufficient to stop the progression of 
this pandemic.  Considering that many women are unable to negotiate condom use with their 
partners and are more susceptible to HIV, strategies to prevent heterosexual transmission of HIV 
must include female-controlled methods.  A promising strategy is the development of a topical 
microbicide to prophylactically inhibit transmission of sexually transmitted infections, including 
HIV. 
The work presented makes significant contributions to the microbicide research field, 
focusing on product development, preformulation strategies, stability in biological fluids, and 
drug targeting.  We investigated two biomolecule (protein/peptide) microbicide candidates: PSC-
RANTES, a chemokine analog of RANTES; and RC-101, a circular θ-defensin analog.   
We hypothesized that the use of a drug delivery system will protect the microbicide 
candidate against degradation before administration, and in biological fluids after administration, 
while maintaining drug activity.  Further, the interaction of the microbicide candidates with 
human vaginal fluids can result in chemical modification of the drug. 
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Identification of degradation pathways for PSC-RANTES and RC-101 was conducted by 
performing preformulation studies under selected conditions of temperature, pH, and oxidative 
conditions.  Analytical methods used included HPLC, MALDI-TOF MS, CD, and SDS-PAGE.  
Chemical modifications of RC-101 were evaluated in the presence of human vaginal fluid 
collected from healthy female volunteers and detected by LC-MS/MS.  RC-101 was formulated 
in a quick-dissolving vaginal film and showed short term stability, efficacy in vitro and safety in 
vivo in an animal model.  Tissue localization of RC-101 was evaluated using excised human 
(ectocervical and endometrium) and monkey (vaginal and endometrium) tissues.   
Major findings from this work show that: RC-101 formulated in a film drug delivery 
system protected the peptide from degradation prior to administration; anti-HIV activity of RC-
101 was maintained in the formulation; RC-101 was stable at least for 48 h in the presence of 
human vaginal fluid; and penetration of RC-101 into epithelial tissue was demonstrated.  These 
results contribute to the development of RC-101 into a successful microbicide product and 
provide a systematic tool for the development of other microbicide molecules.  
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1.0  INTRODUCTION AND PROJECT SPECIFIC AIMS 
 1 
 1.1 HIV INFECTION – A MAJOR HEALTH PROBLEM WORLDWIDE 
In the summer of 1981, in California, young men began falling ill with opportunistic infections, 
especially pneumonia caused by Pneumocystis pneumonia (1).  Upon more detailed examination, 
doctors discover that these men lack CD4+ T-cells, a sub-group of lymphocytes that play an 
important role in the immune system.  Several similar cases emerge in other parts of the country 
with the additional diagnosis of a rare and aggressive form of cancer called “Kaposi’s sarcoma” 
(1-5).  The only identified common link for all these patients is that they are either homosexuals 
or intravenous drug users.  Suddenly, this mysterious disease receives the stigma of “gay 
plague”.   
These first cases were noted in 1981, but evidence has shown that the earliest case of 
Human Immunodeficiency Virus (HIV) positive infection had appeared a couple of decades 
before.  Plasma samples taken in 1959 from a man living in Leopoldville, Belgian Congo (now 
Democratic Republic of Congo) that had died from an undiagnosed disease, were analyzed after 
HIV testing was developed.  The blood sample from 1959 was confirmed later on as reactive 
with HIV-1 by established assays (6, 7). 
In the early 1980s, the number of infected people started to increase rapidly.  At that 
time, the Center for Disease Control (CDC) began to receive a number of reports of this 
mysterious disease, which resulted in a recommendation from the CDC to give the name of 
Acquired Immunodeficiency Syndrome (AIDS) in 1982 (1, 8).  Later that year, indications were 
found that AIDS was an infectious disease, and it was transmitted by contact with body fluids 
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including contaminated blood (8).  At that point, it was still unclear what caused the 
development of AIDS. 
From being stigmatized as a homosexual and drug user disease, AIDS was only gradually 
seen as a more global epidemic when the first documented AIDS case by heterosexual 
transmission appeared in 1983 (9).  Several researchers were investigating this new virus; 
however, the identification of HIV occurred only in 1984 when Robert Gallo at the National 
Institute of Health (NIH) and Jay Levy at the University of California San Francisco (UCSF) 
isolated the virus (3-5).  After the discovery of HIV, the development of AIDS was more 
understood.  AIDS emerges from the progression of an infection caused by HIV.  In that year, 
the United States secretary of Health and Human Services, Margaret M. Heckler, optimistically 
predicted that a vaccine against HIV would be available within 2 years.  Unfortunately, that 
prediction proved to be wrong. 
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Figure 1-1. Estimated number of people (in millions) living with HIV worldwide 
from 1990 to 2007. Adapted from the World Health Organization (WHO) 2008 Annual AIDS Report 
(10). 
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From a few isolated cases, HIV quickly spread and became a pandemic (Figure 1-1).  
Twenty seven years have passed since the first few cases of HIV, and AIDS has become a 
significant medical problem and global concern.  Over 60 million people have been infected with 
HIV since the beginning of the epidemic, and more than 25 million people have died of AIDS 
(11).  Unfortunately, no cure or vaccine is available so far (12-14), and the traditional methods of 
prevention have not been sufficient as can be concluded from the alarming number of HIV 
infected people.  In 2007, the number of people living with HIV was estimated at 33 million, 
with a total of 2.5 million new infections (Table 1-1), while the underdeveloped regions of the 
globe are affected the most by the AIDS pandemic.  Sub-Saharan Africa accounts for more than 
70% of the HIV infected people worldwide.     
 
Table 1-1. Global summary of the AIDS epidemic, December 2007. 
People living with HIV in 2007 
Total 33.2 million [30.6 – 36.1 million]
Adults 30.8 million [28.2 – 33.6 million]
Women 15.4 million [13.9 – 16.6 million]
Children under 15 years 2.5 million [2.2 – 2.6 million]
 
People newly infected with HIV in 2007 
Total 2.5 million [1.8 – 4.1 million]
Adults 2.1 million [1.4 – 3.6 million]
Children under 15 years 420,000 [350,000 – 540,000]
 
Adapted from the World Health Organization (WHO) 2008 Annual AIDS Report (11). 
 
Recently, a feminization of the epidemic has been observed.  In sub-Saharan Africa, 
almost 61% of adults living with HIV in 2007 were women, and in the Caribbean, that 
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percentage was 43% in 2007 compared with 37% in 2001.  According to recent statistics, more 
than 80% of new infections are spread through unprotected sex (11), where heterosexual 
intercourse represents the primary source of infection for women (15). 
Efforts have been made to develop a vaccine to prevent acquisition of HIV.  However, 
limited success in animal models has been achieved thus far, highlighting the need to develop an 
alternative strategy to reduce or prevent the spread of the disease. 
1.2 TOPICAL MICROBICIDES – A PROMISING APPROACH FOR HIV 
PREVENTION 
Prevention of HIV has not been very successful, as evidenced by the increasing number of HIV 
infections every year (11, 16, 17).  Prevention strategies currently being investigated include not 
only the development of a vaccine but also pre-exposure prophylaxis, behavior change, male 
circumcision, and female condom use. 
Vaccines to prevent HIV have been studied in the past few years, but no successful 
vaccine has been developed yet (13, 14, 18).  HIV has an extraordinary degree of diversity and 
rapid mutation rate, which makes the development of a vaccine a strenuous challenge (14).  The 
strongest evidence of this challenge appeared in September 2007, when an HIV vaccine being 
developed by Merck failed, causing the company to stop the progress of a large and once-
promising clinical trial.  The vaccine was unable to decrease HIV infections in the group 
receiving the vaccine when compared to control groups, and did not reduce the amount of HIV in 
the bloodstream of those infected (19). 
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Pre-exposure malaria prophylaxis is a standard practice in travelers to malaria-endemic 
countries.  The same idea of a prophylactic drug has been investigated for HIV infection, leading 
to the hypothesis that transmission could be decreased if treatment is delivered before exposure 
to the virus.  Studies have demonstrated that pre-exposure to antiretroviral drugs in primates are 
efficacious against HIV (20-22).  The use of prophylaxis therapy in humans has raised concerns 
due to the consequences of extended use of antiretroviral therapy in healthy people.  
Circumcision is associated with reduced risk of HIV acquisition by virtue of decreasing 
the large surface area of inner foreskin mucosal epithelium, which is a favorable environment for 
viral sequestration.  Several clinical trials have been conducted to evaluate the benefits of 
circumcision as a prophylactic tool for HIV prevention.  Results have indicated that the risk of 
HIV acquisition decreases when circumcision is performed.  However, a number of issues have 
been raised (religious, cost, effectiveness, hospital conditions) when applying this practice over 
an entire population (23, 24).  
Prevention strategies available so far do not specifically address the increasing percent of 
infected women.  The only female-initiated HIV prevention currently available is the female 
condom.  They have been introduced in many countries; however, female condoms tend to be 
more expensive than male condoms, and their use is still not a common practice.   
Considering that many women are unable to negotiate condom use with their partners and 
are more susceptible to HIV, strategies to prevent heterosexual transmission of HIV must include 
female-controlled methods (25).  A promising current strategy is the development of a topical 
microbicide to prophylactically inhibit transmission of sexually transmitted infections (STIs), 
including HIV (26-28).  The product would be applied intravaginally before intercourse by 
women and would inactivate pathogens deposited into the genital tract.   
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The microbicide movement was formed when Dr. Zena Stein et al. (29) identified the 
need for a method for women that would protect them against heterosexual infection with HIV.  
The term initially used was a “virucide”, but it was decided that if the product also protects 
against other STDs then “microbicide” would be a more appropriate term.  Nowadays, the term 
microbicide has been expanded to include not only the development of vaginally applied 
products but also rectal and penile microbicides (30-32).  This dissertation work focuses on the 
development of a topical vaginal microbicide product.  
Recently, a surprising setback occurred in the vaginal microbicides field.  In January 
2007, the Contraceptive Research and Development Program (CONRAD) announced that two 
Phase 3 clinical trials of the candidate microbicide cellulose sulfate, a poly-anion, were stopped 
(33).  Cellulose sulfate use was associated with a trend towards an increase in HIV infectivity.  
Unfortunately, this was not the first product in the microbicides field to fail.  Nonoxynol-9, a 
nonionic surfactant, was initially tested for anti-HIV activity in clinical trials after being used in 
the market for over 25 years as a contraceptive.  Studies concluded that the therapeutic window 
for N-9 was very narrow, and toxicity included induction of inflammatory responses and 
cytotoxicity to epithelial cells (34-36).  In February 2008 another unexpected setback occurred 
with a second poly-anionic compound derived from seaweed, Carraguard.  The completion of a 
Carraguard Phase 3 clinical trial showed that no significant protection against HIV was observed 
when the product was compared to a placebo; however, Carraguard product showed to be safe 
for use in humans, and is still being investigated as a vehicle for other microbicide candidates 
(37, 38). 
Lessons learned from those trials are being carefully evaluated to improve preclinical 
studies, animal models used, and the design of clinical trials.  Investigations in the microbicide 
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field are still addressing several questions about HIV mucosal transmission, infectivity rate, and 
how to assess products in vitro.  Ongoing research will contribute to the development of safe, 
efficacious, affordable, and acceptable microbicide products.  The microbicide field has 
extensively discussed and inquired women about the ideal characteristics of a microbicide 
product (39-42).  Some of the most important desired characteristics are compiled below: 
? Potent activity against most of the HIV strains. 
? Preferably broad activity against other sexually transmitted diseases. 
? As effective as the (male) condom. 
? Compounds must retain activity in the presence of vaginal fluids and semen, and over a 
broad pH range, ideally for several hours. 
? Not disruptive to the normal vaginal flora. 
? Compatible for use with condoms. 
? Absence of local toxic effects. 
? Low cost. 
? Long shelf life. 
? Easy to use. 
? Products must not be too messy, smelly, easily detectable, strong tasting, or interfere with 
sexual pleasure in other ways. 
? Noncarcinogenic. 
? Not irritable to vaginal mucosa. 
? No adverse effects on reproductive health. 
? Acceptable to all sexual partners.  
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The long-term goal of our project is the development of a successful and safe topical 
vaginal microbicide product, keeping in mind the characteristics of an ideal microbicide product.    
1.3 VAGINAL ANATOMY, PHYSIOLOGY, AND IMMUNOLOGY 
The lower genital tract in women involves four distinct anatomical regions (Figure 1-2): 1) the 
introitus, which is covered by a keratinized, stratified squamous epithelium resembling skin, 2) 
the vaginal epithelium, which is covered by a nonkeratinized stratified squamous epithelium, 3) 
the ectocervix, which is covered by a mucosal layer histologically similar to that of the vagina, 
and 4) the endocervix, which consists of a simple columnar epithelium with numerous glands 
(43-45). 
Normal cervical stratified squamous epithelium consists of several layers of epithelial 
cells.  The layers can be subdivided into four different classes according to the stage of 
maturation: basal, parabasal, intermediate, and superficial.  Basal cells are separated from the 
stroma by the basal lamina, layer of collagen fibers.  They have the largest nuclear-to-cytoplasm 
ratio of the normal squamous cells.  During maturation, cells move from the basal layer to the 
superficial layer, becoming flatter, with smaller nucleus, and a larger volume of the cell.  Tight 
junctions are predominant in the superficial layers closer to the lumen.  The thickness of cervical 
squamous epithelium varies; the most values are in the range of 0.2 and 0.5 mm.  Age is one of 
the main parameters to determine epithelium thickness.  After menopause the volume of the 
cytoplasm decreases, and the epithelium becomes atrophic, consisting only of a few layers (46). 
The vagina is a thin-walled, collapsed fibromuscular tube (7 to 10 cm), extending from 
the body exterior to the uterus.  The inner mucosal layer is subdivided into the epithelium and 
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lamina propria.  The most external epithelium layer consists of squamous stratified epithelium, 
similar to the ectocervical epithelium.  During perimenopausal (3 to 5 years preceding 
menopause), there is a reduction in the estrogen levels, which contributes to a reduction of 
epithelium thickness.  
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Figure 1-2. Schematic representation of the female reproductive tract. 
In detail, the three areas of the cervical tissue: endocervix (single layer of columnar epithelium), 
transformation zone, and ectocervix (squamous epithelium).   
Illustration by Rosaria Rita Siervo Sassi. 
 
The vagina is kept moist predominantly by the transudation of fluid through the vaginal 
epithelium and by cervical secretion.  The amount, consistency, and characteristics of the fluid 
that accumulates in the vagina are difficult to describe because these parameters change with the 
menstrual cycle and with reproductive age (47, 48).  Vaginal fluid may include contributions 
from vaginal transudate, Bartholin’s and Skenes’s glands, exfoliated epithelial cells, residual 
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urine, and fluids from the upper reproductive tract such as cervical mucus and endometrial and 
tubal fluids (49, 50).  The contribution of cervical mucus to the vaginal fluid has never been fully 
quantified.  The major component of cervical mucus is water, but it also contains mucin, 
glycoproteins, plasma proteins, enzymes, amino acids, cholesterol, lipids and a range of 
inorganic ions (51-53).  Vaginal fluids play a dual role in preventing HIV infection.  On one 
hand, the vaginal fluids inhibit HIV transmission by acting as a natural mechanism of protection.  
Several antimicrobial peptides have been detected in the reproductive tissues and cervico-vaginal 
fluids, including lysozyme in cervical mucus (54), β-defensins in the endometrium (55, 56), 
defensins in endocervix and endometrium tissues (57), and secretory leukocyte peptidase 
inhibitor in cervical mucus (58) and in endometrium (59).  On the other hand, enzymatic activity 
in the vaginal fluid has been identified as a major barrier for the delivery and absorption of 
proteins and peptide drugs from mucosal sites.  Enzymatic levels in human cervical mucus is 
higher during the ovulation period (48).  Proteins when administered intravaginally might suffer 
degradation by two major mechanisms, which include proteases enzymes present in the vagina, 
and oxidation by hydrogen peroxide produced from Lactobacillus, which are a major constituent 
of the normal vaginal flora.  The identification and quantification of enzymes present in the 
vagina is not very well elucidated, but it is known that lysozyme and antitrypsin are present in 
human cervical mucus (60).  Other enzymes such as aminopeptidases are present in both vaginal 
and cervical secretions and their activity may also vary with the menstrual cycle (61, 62).  
Certainly, enzymatic activity of vaginal fluid in combination with hydrogen peroxide has the 
potential to reduce biological activity of microbicide candidates. Of specific concern is vaginal 
administration of proteins and peptides (63). 
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The mucosal surface is the portal of entry for STIs, being the interface between host and 
environment.  The immune system of the genital tract is part of the larger mucosal immune 
system that lines the mucosal membranes of the human body (64).  The human female genital 
tract which includes the vaginal fluids present and vaginal mucosa, contains all the essential 
elements for an effective immune response against genital pathogens (65).  Studies using 
immunohistochemistry and flow cytometry have shown that T cells and antigen-presenting cells 
(APC) are present throughout the human cervical and vaginal mucosa (66-69); however, the 
precise localization and quantity of these cells is still under investigation (70).  It has been 
estimated that leucocytes represent 6 to 20% of the total number of cells in fallopian tubes, 
endometrium, cervix and vaginal mucosa.  T cells account for about 50% of the leucocytes, with 
CD8+ cells predominant over CD4+ cells.  A study conducted by Johansson et al. showed a band 
of CD4+ and CD8+ cells under the epithelium of vaginal and ectocervical tissues (64, 65).  In 
addition, Langerhans cells (LC) have been shown to be present within the epithelial mucosa (71-
73).  Considering this complex immunological machinery, one might wonder how HIV can still 
be transmitted through the mucosa and proliferate.  Surprisingly, it can.  It is proven that the 
female genital tract is the primary route of heterosexual transmission of HIV (10, 29, 74).    
1.4 HIV VIROLOGY 
Currently, two types of HIV exist: HIV-1 and HIV-2.  Both are transmitted through the same 
routes; however, HIV-2 is much more difficult to transmit and the development of HIV-2 into 
AIDS is more prolonged.  The predominant virus type is HIV-1, and it can be divided in three 
groups: the major (M), the outlier (O), and the new group (N).  More than 90% of HIV-1 
 12 
infections belong to group M.  Each group is subdivided into subtypes that are genetically 
distinct.  Throughout this dissertation work, the abbreviation HIV will refer to HIV-1. 
HIV-1 has a spherical morphology of 100 to 120 nm in diameter and consists of a lipid 
bilayer membrane that surrounds a dense core which contains the ribonucleic acid (RNA), and 
enzymes such as viral protease, reverse transcriptase, and integrase, and other cellular factors.  
The membrane contains approximately 72 spikes of the viral envelope (Env) glycoproteins 
(gp120 and gp41) (75).   
1.5 HIV MUCOSAL TRANSMISSION 
Two main chemokines, CCR5 and CXCR4, mediate the attachment of HIV to the host cell acting 
as a co-receptor.  The virus that uses the co-receptor CCR5 has been named as R5 HIV, and the 
virus that uses the co-receptor CXCR4 has been named as X4 HIV.  Other chemokine receptors 
can be used, but CCR5 has been shown to be the major co-receptor for sexual HIV-1 
transmission, and most common in the early stages of the disease.  CXCR4 co-receptor usage 
occurs more in the late stages of the disease and it has been associated with more rapid 
progression of AIDS (76, 77).  A few rare HIV-1 isolates can also use other co-receptors (CCR1, 
CCR2b, CCR3, CXCR6), as shown in in vitro studies; although it is still uncertain if HIV-1 
would use such co-receptors in vivo (78).  
During male to female transmission, virus in semen will penetrate the stratified squamous 
epithelium of the vagina and ectocervix or the columnar epithelium of the endocervix to infect 
target immune cells (target cells: macrophages, T cells, and dendritic cells (DCs)) within and 
below the epithelium (79, 80).  Macrophages, T cells, and DCs can be infected with HIV-1.  The 
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majority of these cells are located in the subepithelial layers of vaginal and cervical mucosa.  
Studies have confirmed the presence of Langerhans cells (LCs) in the epithelial mucosa (72, 81).  
However, it is still uncertain if the virus must cross the epithelium or if the LCs will reach out for 
the virus.  It is known that the majority of the target cells are located in the subepithelial layers of 
vaginal and cervical mucosa, but studies have also shown the presence of LCs in the epithelial 
mucosa (72, 81).  Literature suggests that HIV-1 could directly infect epithelial cells (82, 83); 
however, studies conducted by Dezzutti et al. (66), and Wu et al. (84) have shown that HIV-1 
was unable to infect epithelial cell lines, due to the lack of CD4 receptors in epithelial cells.  
Hladik et al. have shown that HIV-1 rapidly penetrates both intra-epithelial vaginal Langerhans 
and CD4+ T cells in an ex vivo human organ culture system (85).   
Several mechanisms have been proposed, however it is still uncertain if these 
mechanisms fully explain the HIV-1 transmission in vivo.  Suggested mechanisms are illustrated 
in Figure 1-3.  It has been suggested that transmission may occur by: 
? direct infection to epithelial cells 
? transcytosis through epithelial cells, 
? epithelial transmigration, 
? uptake by intra-epithelial Langerhans cells, 
? circumvention of the epithelial barrier through physical breaches, which will both 
expose target cells to HIV-1 and trigger subsequent migration (82). 
 
 
 
 14 
Endocervical tissue (columnar epithelium)A) B)
infection
transcytosis transmigration
Dendritic cell
Macrophage
Ectocervical and vaginal tissue (stratified epithelium)
Physical abrasion
 
Figure 1-3. Schematic representation of HIV-1 mechanisms for mucosal transmission 
in female reproductive tract.  A) Represents endocervical tissue (columnar epithelium), and B) 
represents ectocervical and vaginal tissue (stratified epithelium).   
Illustration by Rosaria Rita Siervo Sassi. 
 
The HIV-1 envelope is composed of a surface glycoprotein, gp120, and a transmembrane 
subunit, gp41.  These glycoproteins are responsible for the fusion of the cellular and the viral 
membranes.  HIV-1 infection of target cells requires fusion of the virus envelope and cell 
membrane by sequential interaction of the virus envelope with the cell surface CD4+ and one of 
the two chemokine co-receptor molecules (CCR5 or CXCR4).  The fusion of the virus into the 
host cell occurs through the formation of a six-helix bundle formation of the two heptad repeats 
(HRs): HR1 and HR2 domains in three gp41 subunits.  After fusion of viral and host cell 
membrane, the viral RNA genome enters the cell, and undergoes reverse transcription, followed 
by integration of the pro-viral DNA into the host chromosome.  After translation, the viral 
proteins assemble at the cell membrane, and the immature viral particle containing the RNA 
genome and viral enzymes egresses the cell.  After virion budding, a structural rearrangement of 
the virion generates a mature viral particle that is ready to infect other cells and proliferate (86, 
87), as illustrated in Figure 1-4.  The targets in the HIV life cycle for a microbicide candidate are 
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fusion inhibitors, reverse transcriptase inhibitors, integrase inhibitors and protease inhibitors (15, 
82, 86).  
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Figure 1-4. Schematic representation of HIV-1 life cycle.  
Illustration by Rosaria Rita Siervo Sassi. 
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1.6 MICROBICIDE CANDIDATES UNDER INVESTIGATION 
Several microbicide agents have been identified for and showed activity against HIV-1 in vitro 
by targeting the virus in different stages of its life cycle (27, 88-93).  The mechanism of action of 
each microbicide agent is one property that will define the appropriate vaginal drug delivery 
system for those products.  If a microbicide agent acts by blocking the receptor or co-receptor in 
the target host cells (macrophages, T cells, and dendritic cells), it is imperative that the delivery 
system is able to deliver the drug to the site of action, i.e. it must penetrate the epithelial barrier.  
Conversely, a microbicide agent that disrupts the viral membrane before attachment of the virus 
to the host cell can be delivered to the vaginal lumen without deeper penetration in the vaginal 
mucosa. 
Microbicide candidates currently being investigated target the virus via different 
mechanisms of action and are classified as virucides, entry/fusion inhibitors, reverse 
transcriptase inhibitors, integrase inhibitors, and protease inhibitors.  A complete list of 
microbicides in preclinical and drug discovery phase is provided in Appendix A.  
1.7 PROTEIN AND PEPTIDE MICROBICIDE AGENTS AND THEIR MECHANISM 
OF ACTION 
1.7.1 PSC-RANTES 
RANTES (Regulated upon Activation, Normal T Expressed and Secreted), CCL5, is a natural 
chemokine member of the interleukin-8 super family of cytokines.  RANTES consists of 68 
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amino acid residues including four cysteines, the first two being located adjacently to form the 
sequence unique to the CC-chemokine family.  RANTES is a selective protein attractant for 
memory T lymphocytes and monocytes.  It has been shown in vitro that RANTES inhibits R5 
tropic HIV by binding to the co-receptor CCR5 and competitively inhibiting fusion of the virus 
(81, 94, 95).  Consequently, several analogs of chemokine ligands of CCR5 with enhanced anti-
HIV activity have been investigated (96).  The first was AOP-RANTES, the aminooxypentane 
oxime of [glyoxylyl1] RANTES.  This molecule was designed to incorporate a more 
hydrophobic and nearly isosteric replacement for the side chain of the N-terminal methionine of 
Met- RANTES, a known CCR5 antagonist.  All of the analogs have hydrophobic extensions to 
the N-terminal region, and most do not act as simple receptor antagonists.  Instead, their 
inhibitory mechanism has the additional potential to induce intracellular sequestration of CCR5 
(96, 97).   
The rationale to use CCR5 inhibitors as a microbicide product is the low toxicity from 
this type of molecules.  Some healthy individuals possess a mutated allele (Δ32) of the CCR5 
gene, making these individuals unable to express the co-receptor CCR5 on cell surfaces.  
CCR5Δ32 homozygotes appear to be resistant to R5 virus infection, whereas CCR5Δ32 
heterozygotes show a much slower progression of the disease when infected (98, 99).   
PSC-RANTES, (N-α-(nonanoyl)-des-Ser1-[L-thioproline2, L-α-cyclohexyl-glycine3] 
RANTES), molecular mass of 7,876.63 Da, is chemically identical to native RANTES except for 
the substitution of a nonanoyl moiety, a thioproline, and a cyclohexyl glycine for the first three 
N-terminal amino acids of the native protein (Figure 1-5) (91, 96). 
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Figure 1-5. PSC-RANTES structure and aminoacid sequence. 
A) Represents PSC-RANTES and the three groups that replaced the first three amino acids of 
RANTES.  B) Represents the amino acid sequence of RANTES (4 – 68). 
 
The mechanism of action of PSC-RANTES occurs by binding of the N-terminal portion 
of PSC-RANTES to the co-receptor CCR5 causing internalization of the co-receptor.  In 
addition, PSC-RANTES inhibits expression of CCR5 promoting a more prolonged sequestration 
of the co-receptor when compared to RANTES and other RANTES analogs (91).  PSC-RANTES 
exhibits in vitro antiviral activity, against some HIV-1 isolates in the picomolar range (97).  
However, when challenged with HIV-1/SIV chimeric virus (SHIV) the PSC-RANTES 
concentration required for in vivo protection from infection (1 mM) in Rhesus macaques was 
106-fold greater than that needed in vitro (91). 
1.7.2 RC-101 
Defensins are a component of host defense against bacterial infections (100).  They are cysteine-
rich cationic antimicrobial peptides expressed by the leucocytes and epithelial cells of birds and 
mammals (100, 101).  There are three main subfamilies of defensins: α- and β-defensins, and 
circular θ-defensins, depending on the cysteine pairing and the length of the peptide fragments 
between the cysteines (100, 102).  It has been shown that α-defensins expressed by human CD8+ 
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T cells may prevent the development of AIDS.  Human α-defensins were shown to protect cells 
from in vitro HIV-1 infection (102).  Human β-defensins are highly expressed in the oral mucosa 
and are induced by bacterial products, and by pro-inflammatory cytokines normally produced in 
response to infection (103, 104).  In addition, human β-defensins-1 isolated from the epithelial 
layers of the vagina, cervix, uterus, and fallopian tubes, suggest that defensins play a role in 
microbial host defense in the female reproductive tract (105).  β-defensins have shown to possess 
a high antiviral activity, inhibiting both X4 and R5 strains of HIV-1 (104). 
The third subfamily of defensins is the circular θ-defensins, and are only found in non-
human primates (100).  θ-defensins are peptides that contain 18 residues, tetracyclic with three 
cysteine disulfide bonds.  Retrocyclin, a θ-defensin peptide, has the ability to competitively bind 
with high affinity to CD4, galactosylceramide (alternative cell surface receptor for CD4- cells), 
and gp120; and thereby confers protection against HIV-1 (106).  Several analogs of retrocyclin 
have been investigated for their bioactivity against HIV.  One of the analogs, RC-101 (Figure 
1-6), possesses a single amino acid substitution from an arginine (R) to a lysine (K) on one of the 
β turns, conferring stronger bioactivity.  The binding site of RC-101 to the gp120 and CD4 is still 
not completely elucidates; and smaller fractions of RC-101 have not shown to be as effective as 
the complete circular sequence of RC-101 (personal communication – Dr. Alexander Cole, 
University of Central Florida).   
The binding of retrocyclin to CD4, galactosylceramide and gp120 is a reversible process, 
and the mechanism of protection against HIV occurs by a competitive inhibition.  It has been 
shown that RC-101 has a higher affinity to gp120 than the retrocyclin.  In addition, the affinity of 
RC-101 to the glycoprotein is 6- to 25- fold higher than the affinity of HIV isolates (107).   
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It has been shown that RC-101 is non-hemolytic for human red blood cells and non-
cytotoxic against several human cell lines at maximum concentrations of 500 µg/mL.  RC-101 
operates by preventing six-helix bundle formation of gp41 (a 41,000 MW glycoprotein), 
suggesting a promising antiretroviral drug.  The advantage of developing a gp41 target molecule 
as a microbicide is that the drug will be effective against both R5 and X4 virus types.  
Furthermore, gp41 sequence is more conservative than gp120, which has been shown to generate 
a lower incidence of mutation in that region and consequently lowering the chance for viral 
resistance development based on gp41 mutations (108).  RC-101 can inhibit infection in vitro by 
over two dozen primary isolates of HIV-1 representing most known viral clades and subtypes 
(107, 109).  In addition, RC-101 effectively inhibits HIV-1 infection of explant human 
cervicovaginal tissue (109). 
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Figure 1-6. RC-101 3D predicted structure and amino acid sequence. 
A) Represents RC-101 predicted structure using ChemDraw Ultra, version 11.0.1, Cambridgesoft 
Corp. (Cambridge, MA).  B) Amino acid sequence of RC-101 
1.8 VAGINAL DOSAGE FORMS AS MICROBICIDE PRODUCTS 
1.8.1 Vaginal drug delivery 
Vaginal drug delivery has been used for a number of therapeutic agents, mostly for local delivery 
of drugs such as antibacterial, antifungal, spermicidal, and steroids (110, 111).  There are unique 
challenges to vaginal drug delivery that must be considered when developing a dosage form.  
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The vaginal pH is normally between 3.5 and 5.0, but it can change under disease state and  in the 
presence of semen (50).  In addition to pH, other physiological factors may impact the absorption 
and efficacy of vaginally delivered drugs.  Cyclical changes, associated to age, phase of the 
menstrual cycle, and pregnancy, are known to modify the epithelial thickness and composition of 
vaginal fluids, changing absorption of drugs (112-118). 
The most common vaginal dosage forms utilized are also being currently investigated as 
microbicides.  Most of the vaginal microbicides being developed are formulated as gels (119-
121).  This semi-solid dosage form is largely associated with messiness and leakage of the 
product which represents a large disadvantage.  More recently, new dosage forms have been 
investigated such as vaginal rings, foams, vaginal tablets, ovules, and polymeric films (122-125).  
The choice of dosage form is directly dependent on the physical and chemical characteristics of 
the agent to be delivered as well as patient acceptability.  Vaginal rings currently available in the 
US market as contraceptive products are being investigated as controlled release products for 
vaginal microbicide application.  These microbicide vaginal ring products would provide a long-
term release of the drug which results in less frequent need for application and, in the end, 
improved patient compliance.  Vaginal films have the potential advantages of easier application, 
lower product cost, increased patient acceptability, increased retention time, and increased drug 
stability. 
Delivery of biopharmaceuticals (proteins or peptides) has additional challenges.  The 
simplest way to formulate a protein is in a lyophilized powder to be reconstituted in a solution 
prior to administration. However, liquid dosage forms will unlikely have the appropriate 
environment to guarantee protein stability, and would not be suitable for a vaginal delivery of the 
drug.  When applied vaginally, a solution would be prone to leakiness, causing a poor retention 
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of the drug in the vaginal lumen (26, 110, 111, 122).  In addition, the use of a traditional dosage 
form (hydrogel) for vaginal delivery of proteins or peptides will compromise the stability of the 
drug due to the high water content in these formulations.  As an alternative, formulation of a 
non-aqueous based semi-solid might eliminate the water content problem, but will decrease 
patient acceptability and interaction of the product with vaginal fluids present in the vaginal 
lumen.  A novel delivery system should be used to avoid degradation of the protein in the vehicle 
and maintain the ideal characteristics of the microbicide product. 
1.8.2 Quick-dissolving polymeric films 
With the advances in the field of polymer science, there is an increasing interest in the 
development of drug delivery systems that utilize newly available polymeric materials.  
Polymeric films have recently become a widely accepted dosage form, and have been utilized in  
the oral delivery of vitamins, minerals, herbal remedies, supplements, cold remedies, pain 
medications, gastric disturbance medications, treatment of halitosis, antimicrobial agents, and for 
topical applications (126, 127).  Polymeric films form a thick, bioadhesive solution upon contact 
with cervicovaginal fluids, resulting in rapid release of the drug from the delivery system. 
Bioadhesive properties of films can increase the retention time of the drug at the target tissue.    
The use of vaginal films has several advantages: convenience for women to use without 
the use of an applicator, lower cost per dose, portability, absence of messiness relative to other 
current gel vaginal products, increased stability of the drug, and increased retention time of drug 
in the vagina. 
To ensure successful use as female-controlled products, vaginal microbicides need to be 
designed for women’s convenience.  In recent years, women’s preferences regarding the vaginal 
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formulations have been researched (128-130).  The consumer’s perspectives and their choice of 
formulation vary depending on the individual, partners, cultural norms, age, and economical, 
social and climatic conditions of the specific geographical region.  In many parts of the world, 
vaginal films are preferred over other dosage forms due to their unique advantages of portability, 
ease of application, ease of storage and handling.  An acceptability study conducted at the 
University of Alabama and at the University of Zambia (130) has shown that film formulations 
are more likely to be accepted by women than other vaginal formulations, such as gels, foams, 
and suppositories.  A more detailed discussion of the dosage form chosen for this dissertation 
work has been included in Chapter 5.  
1.9 HYPOTHESIS AND SPECIFIC AIMS 
Strategies to prevent infection with human immunodeficiency virus (HIV) have largely been 
limited to behavior change and condom use.  New strategies are being investigated and include 
the development of topical microbicides to prophylactically inhibit transmission of sexually 
transmitted infections (STIs), including HIV (15, 17, 74).  The product is designed to be applied 
intravaginally by women before sexual intercourse.  HIV-1 infection of target cells requires 
fusion of the virus membrane and cell membrane by sequential interaction of the virus envelope 
glycoproteins with the cell surface CD4 receptor and one of the two chemokine co-receptor 
molecules (CCR5 or CXCR4) (40, 131).  Several microbicide agents that target the virus in 
different stages of the virus life cycle have been developed. 
We are investigating two biopharmaceutical (peptide/protein) microbicide candidates: 1) 
PSC-RANTES, a chemokine analog of RANTES, which binds to co-receptor CCR5, inhibiting 
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virus fusion; and 2) RC-101, a circular θ-defensin analog peptide, which prevents six-helix 
bundle formation of gp41, conferring strong protection against HIV-1.   
The delivery of topical microbicide agents represents several challenges.  The product 
must overcome physical and chemical barriers such as the presence of mucus and enzymatic 
degradation in addition to effectively delivering the active pharmaceutical compound to the site 
of action.  Furthermore, it is well known that formulation and delivery of biopharmaceuticals 
(proteins/peptides) can be difficult due to degradation.  Stability of the biopharmaceutical seems 
to be the first obstacle for development of a microbicide product.  Protection of the protein or 
peptide in the formulation may prevent degradation and consequently preserve the activity of the 
formulation during its shelf life or in use.  Our research focused on the interaction of proteins and 
peptides with biological fluids, the development of a novel vaginal delivery system for proteins 
and peptides, and the investigation of the efficacy of the drug delivery system in delivering the 
active substance to the site of action. 
 
 
Hypothesis  
We hypothesize that the use of a drug delivery system will protect a biopharmaceutical 
(protein/peptide) microbicide candidate against degradation before administration, and in 
biological fluids after administration, while maintaining drug activity.  We further hypothesize 
that the interaction of biopharmaceutical microbicides with human vaginal fluids can result in 
chemical modification of the drug. 
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Specific aim 1. Identify degradation pathways for biopharmaceutical microbicide 
candidates (PSC-RANTES and RC-101) by performing preformulation studies under selected 
conditions of temperature, pH, and oxidative conditions. (Chapters 2 and 3) 
 
Specific aim 2.  Evaluate chemical modifications to RC-101 in the presence of human 
vaginal fluid collected from female volunteers. (Chapter 4) 
 
Specific aim 3.  Develop a formulation for RC-101 that delivers the peptide and protects 
it from degradation prior to administration as well as in the presence of biological fluids, 
maintaining bioactivity. (Chapters 5 and 6) 
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2.0  PREFORMULATION EVALUATION OF PSC-RANTES 
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 2.1 INTRODUCTION 
Regulated upon Activation, Normal T Expressed and Secreted (RANTES, CCL5) is a natural 
chemokine, that attracts memory T lymphocytes and monocytes (132).  RANTES consists of 68 
amino acid residues including four cysteine residues, the first two being located adjacently to 
form the sequence unique to the CC-chemokine family (132).  It has been shown in vitro that 
RANTES inhibits R5 tropic HIV-1 by blocking the CCR5 co-receptor, thus preventing HIV 
infection (94, 95).  HIV-1 infection requires fusion of the virus membrane and cell membrane by 
sequential interaction of the virus envelope glycoproteins with the cell surface receptor CD4 and 
one of the two chemokine coreceptor molecules (CXCR4 or CCR5).  Several analogs of 
RANTES have been developed to improve the affinity of the drug to the co-receptor CCR5 (95).  
These analogs, unlike the natural chemokine, have the additional capacity to inhibit the recycling 
of internalized CCR5, resulting in more profound and prolonged sequestration of CCR5 (133).  
PSC-RANTES, (N-α-(nonanoyl)-des-Ser1-[L-thioproline2, L-α-cyclohexyl-glycine3] RANTES), 
is chemically identical to native RANTES except for the substitution of a nonanoyl moiety, a 
thioproline, and a cyclohexyl glycine for the first three N-terminal amino acids of the native 
protein (96).  The sequence of PSC-RANTES is shown in Figure 2-1. 
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Figure 2-1. PSC-RANTES structure and RANTES amino acid sequence. 
A) Represents PSC-RANTES and the three groups that replaced the first three amino acids of 
RANTES.  B) Represents the amino acid sequence of RANTES (4 – 68). 
 
PSC-RANTES exhibits antiviral activity in vitro for some HIV-1 isolates in the 
picomolar range (97).  In studies conducted in rhesus monkeys peripheral blood mononuclear 
cells (PBMCs), PSC-RANTES inhibited propagation of the SHIV SF162 R5 tropic virus and 
completely blocked SHIV F162 replication, with median inhibitory concentration (IC50) values 
in the picomolar range (91).  However, when challenged with SHIV vaginal transmission in 
rhesus macaques, the PSC-RANTES concentration necessary for in vivo activity (1 mM) was 
106-fold greater than that needed in vitro (91). 
Reduced potency observed in vivo may reflect: 1) protein modification due to 
conformational changes, including aggregation; 2) protein modification due to covalent chemical 
changes; 3) proteolytic inactivation in the vaginal lumen, 4) low penetration of the drug into the 
mucosal tissue, and/ or 5) drug binding (134).  The purpose of this study was to understand how 
potential formulation conditions as well as the vaginal environment could impact both physical 
and chemical stability of PSC-RANTES.  This data will be required in the formulation of an 
eventual microbicide product.  This study evaluated selected conditions of temperature, pH, ionic 
strength, presence of hydrogen peroxide, and presence of enzymes to establish rate and extent of 
degradation, and identify potential degradation pathways of PSC-RANTES.  Protective effects of 
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excipients against oxidation were also investigated.  Chemical and physical stability were 
evaluated by high performance liquid chromatography (HPLC), circular dichroism (CD), UV-
spectroscopy, SDS-PAGE, and MALDI-TOF MS.  In addition, the anti-microbiological activity 
of PSC-RANTES to normal vaginal flora and possible pathogens present in the vaginal lumen 
was determined.  Overall, these results will be crucial to establish a preformulation data set to 
expedite formulation development of a suitable dosage form for PSC-RANTES as a microbicide 
product. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
PSC-RANTES was synthesized by the Peptide Synthesis Facility at the University of Pittsburgh 
(Pittsburgh, PA), and the molecular mass confirmed by mass spectrometry.  Acetonitrile (HPLC 
grade), trifluoroacetic acid (TFA), sodium phosphate dibasic, sodium phosphate monobasic, 
phosphoric acid 85%, sodium acetate, formic acid, sodium hydroxide, hydrochloric acid, ß-
mercaptoethanol, urea, and glacial acetic acid were purchased from Fisher Scientific (Fair Lawn, 
NJ).  Vitamin E tocopheryl polyethylene glycol succinate (TPGS) was purchased from Eastman 
Chemical Company (Kingsport, TN).  Aprotinin and insulin were purchased from MP 
Biomedicals (Solon, OH).  Polypeptide SDS-PAGE molecular mass standards, 30% 
acrylamide/bisacrylamide solution (29:1), tricine sample buffer, silver staining kit, and 
N,N,N',N'-tetramethylethylenediamine (TEMED) were purchased from Bio-Rad Laboratories 
(Hercules, CA).  All other chemicals were purchased from Sigma (St. Louis, MO).  De-ionized 
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water was prepared from house-distilled water with a Milli Q (Millipore, Milford, MA) water 
system operating at 18.2 MΩ.cm.  
2.2.2 High performance liquid chromatography  
A high performance liquid chromatography (HPLC) system (Waters Corporation, Milford, MA) 
was used for the analysis of PSC-RANTES.  The HPLC system was equipped with an 
autoinjector model 717 (Waters), a quaternary pump model 600 (Waters), and an ultraviolet 
(UV) detector model 2487 (Waters) operated at 280 nm. Separation of the PSC-RANTES peak 
from degradant products was achieved using a Phenomenex Jupiter Proteo 4 µm 90 Å (4.6 x 250 
mm) column (Phenomenex, Torrance, CA) protected by a Jupiter C12 (4.0 x 3 mm) guard 
cartridge (Phenomenex).  The gradient consisted of mobile phase A (0.1% TFA in water (v/v)), 
and mobile phase B (0.1% TFA in acetonitrile (v/v)) pumped at a flow rate of 1.0 mL/min.  
Elution conditions started at A:B (70:30) and linearly changed to A:B (57:43) over the first 25 
min, followed by a linear decrease to A:B (70:30) in 5 min, and maintaining isocratic condition 
at A:B (70:30) for 10 min to allow equilibration of the system prior to injection of the next 
sample.  After completion of each sample set, a cleaning step was performed with 90% mobile 
phase B to guarantee that the more hydrophobic impurities would be eliminated from the 
column.  The retention time of PSC-RANTES was 18 min and the total run time was 40 min.  
Empower Pro 2 software (Waters Corporation) was used to control the HPLC system.  To ensure 
that the method was suitable for the intended purposes of quantitation and separation of 
degradants, the accuracy, precision, repeatability, Limit of Quantification (LOQ), and Limit of 
Detection (LOD) were determined in addition to other suitability parameters defined by the 
United States Pharmacopeia (USP) (135).  Forced degradation studies at extreme conditions of 
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temperature, pH and oxidative potential were initially conducted to confirm that the HPLC 
analysis was suitable as a stability-indicating assay to separate and detect potential degradant 
products. 
2.2.3 SDS-PAGE 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) was performed for 
PSC-RANTES samples.  PSC-RANTES was analyzed under reduced and non-reduced 
conditions on a Tris/Tricine gel with two layers: a stacking layer (3.10% T, 3.25% C) and a 
separating layer (14.75% T, 0.34% C), where T is the total percentage of acrylamide and 
bisacrylamide in the gel, and C is the bisacrylamide concentration with respect to T.  The 
reduced samples of PSC-RANTES were prepared from 5 µl of PSC-RANTES solution and 95 µl 
of SDS reducing buffer (Tricine sample buffer:β-mercaptoethanol (95:5)).  The sample was 
heated for 5 min at 95 °C and cooled to room temperature, followed by transferring 15 µl of the 
sample to the well.  The non-reduced sample of PSC-RANTES was prepared with 5 µl of PSC-
RANTES solution and 95 µl of water.  Standards in their reduced form were prepared from 
Polypeptide SDS-PAGE molecular mass standards (Bio-Rad).  Detection was performed by 
silver staining procedure.  Gel images were collected with a Geldoc Imaging system (Bio-Rad).   
2.2.4 Circular Dichroism Spectroscopy 
Circular Dichroism (CD) was used to monitor conformational changes in the secondary structure 
of the proteins. CD measurements were performed on an AVIV Circular dichroism 
spectrophotometer model 202 (AVIV Biomedical, Lakewood, NJ) equipped with a 0.1 cm path 
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length quartz cell.  Spectra were recorded between 198 and 300 nm at 25 °C from a 500 μg/mL 
protein solution in 10 mM phosphate buffer at pH 3.0, 7.0, and 12.0.  Three scans were averaged 
and subtracted from buffer background over the same wavelength range. 
2.2.5 MALDI-TOF MS 
Matrix assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometric 
(MS) experiments were performed in the positive-ion linear mode on a Voyager DE-PRO mass 
spectrometer (Applied Biosystems, Foster City, CA).  Samples were prepared by pipetting 1 μL 
of sample and 1 μL of matrix on an MS stainless steel sample probe.  Matrix was prepared by 
dissolving sinapinic acid in a solution of 0.5% trifluoroacetic acid in acetonitrile:water (1:1 v/v).  
The probe containing the sample was left to dry completely in air.  The spectra were calibrated 
using external calibration with Insulin B chain oxidized (Sigma) and Aprotinin (Sigma), and 
Sequazime Peptide Mass Standard calibration mixture 3 (Applied Biosystems).  The following 
parameters were used: accelerating voltage 20 kV with delayed extraction, mass range of 1,000–
20,000 Da, and 400 laser shots spectrum. 
2.2.6 UV-spectroscopy 
PSC-RANTES in concentrations of 0.125 to 2.5 mg/mL was prepared in buffer solutions and UV 
scans were performed by using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies Inc, Wilmington, DE).  Scans were performed from 220 to 700 nm.  NanoDrop 
software was used to control the spectrophotometer. 
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2.2.7 Stability of PSC-RANTES 
For all stability studies described below, triplicate solutions of PSC-RANTES were prepared by 
adding PSC-RANTES at a concentration of 500 µg/mL (63.3 µM) in either water or an aqueous 
buffer solution.  The pH of each solution was measured after solubilization of PSC-RANTES in 
the vehicle.  All samples were used within 5 min of preparation, and analyzed by HPLC using 
the method described in Section 2.2.2.  Additional analytical techniques (MALDI-TOF MS, UV-
spectroscopy, CD, and SDS-PAGE) were used to confirm results obtained by HPLC. 
 
Effect of temperature 
PSC-RANTES solutions in water were placed in incubation chambers for thermal 
degradation studies conducted at 25, 40, and 65 °C for a minimum period of 1 week.  Samples 
were removed from each chamber 30 min prior to analysis by HPLC to allow the samples to 
equilibrate to ambient temperature.  Thermal degradation samples were also evaluated by 
MALDI-TOF MS. 
 
Effect of pH 
The effect of pH on the stability of PSC-RANTES was evaluated over the pH range from 
3 to 12 using 10 mM phosphate buffer solutions.  All buffers were prepared using sodium 
phosphate to avoid interference of other salts in the solution.  Knowing that phosphate buffer is 
not a strong buffer at certain pHs, the pH values were confirmed at time 0 and at the end of each 
experiment.  PSC-RANTES samples over the pH range from 3 to 12 were also evaluated by 
MALDI-TOF MS, SDS-PAGE, CD, and UV spectroscopy. 
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Effect of ionic strength 
PSC-RANTES solutions at concentrations ranging from 0.125 to 2.5 mg/mL were 
prepared in water and phosphate buffers (pH 4, 7, and 12) at low (50 mmol/kg) and high (500 
mmol/kg) ionic strength to evaluate the effect of ionic strength on PSC-RANTES stability.  
Additionally, PSC-RANTES was prepared in phosphate buffered saline (PBS) (pH 7.4, 290 
mmol/kg).  Effect of high ionic strength was evaluated by UV-spectroscopy analysis to 
determine the formation of insoluble aggregates. 
 
Effect of hydrogen peroxide 
The stability profile of PSC-RANTES under oxidative conditions was evaluated by 
exposing PSC-RANTES solutions to concentrations of 3.0, 0.80, 0.02, and 0.002% (v/v) 
hydrogen peroxide (H2O2).  A minimum of five time points were taken from each triplicate 
solution over a 5-hour period and analyzed by HPLC.   Oxidative PSC-RANTES samples were 
also evaluated by MALDI-TOF MS. 
 
Protective effect of antioxidants 
Solutions of PSC-RANTES were prepared followed by the addition of antioxidants 
commonly used in pharmaceutical products.  These solutions were then exposed to 0.8% or 
0.02% hydrogen peroxide.  The antioxidants used in this study were: sodium metabisulfite, 
ascorbic acid, methionine, cysteine, glutathione, and vitamin E TPGS.  Samples were analyzed 
by HPLC at times 0, 40 and 80 min after exposure to 0.8% H2O2, and at specified times for a 6-
hour period after exposure to 0.02% H2O2.  The concentrations of antioxidants used in the final 
solution were: 500 µg/mL of sodium metabisulfite, 1000 µg/mL of ascorbic acid, 92.7 μg/mL or 
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463.5 μg/mL of DL-methionine, 92.7 μg/mL of DL-cysteine, 90.9 μg/mL of L-glutathione, or 
90.9 μg/mL of Vitamin E TPGS.  Concentration of sodium metabisulfite, ascorbic acid, and 
vitamin E TPGS were selected based on the inactive ingredient list for FDA drug approved 
products (http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm - last accessed on 
10/22/2008) and the Handbook of Pharmaceutical Excipients (136).  Concentration of 
methionine, cysteine, and glutathione were based on literature reviews on the use of amino acids 
as competitive inhibitors of oxidation (137, 138). 
 
Effect of light exposure  
PSC-RANTES solution (500 µg/mL) prepared in 50 mM acetate buffer pH 4 was placed 
in an environmental control chamber Caron 6010 (Caron Inc., Marietta, OH) at 40 °C.  A D65 
light source provided continuous irradiation over the course of one week at an overall 
illumination of not less than 1.2 x 106 lux.h and an integrated near-ultraviolet energy of not less 
than 200 watt.h/m2.  Samples were removed from the chamber 30 min prior to HPLC analysis to 
allow equilibration to ambient conditions. 
 
Effect of freeze-thaw cycles 
PSC-RANTES solutions (500 µg/mL) prepared in water were stored at -80 °C and 
allowed to freeze for at least 1 h.  Samples were thawed immediately prior to HPLC analysis.  
Six freeze-thaw cycles were used for this study.  After completion of six freeze-thaw cycles, 
PSC-RANTES solutions were analyzed by CD. 
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Effect of enzymatic degradation 
PSC-RANTES solutions (500 µg/mL) in water were prepared followed by the addition of 
enzymes commonly present in human vaginal fluid. The enzymes used in this study were: 
aminopeptidase, lysozyme, and proteinase K.  Samples were tested by MALDI-TOF MS at time 
0 and after 1 h exposure at 37 °C. 
2.2.8 Microbiological activity 
Both reference strains and fresh clinical isolates of bacteria were used in microbiological 
evaluations of PSC-RANTES.  Lactobacillus jensenii (ATCC 25258), Lactobacillus crispatus 
(ATCC 20225 and ATCC 33197), Lactobacillus iners (BCRC 1202 and BCRC 2146), 
Gardenerella Vaginalis (ATCC 14018), and Neisseria gonorrhoeae (ATCC 19424, and ATCC 
49226) were tested.  PSC-RANTES solutions in water were tested as reported previously (139).  
Briefly, bacteria were cultured on an appropriate medium overnight at 37 °C in air containing 5% 
CO2.  Isolated colonies were suspended in 0.5 mM N-(2-acetamido)-2-aminoethanesulfonic acid 
(ACES) buffer pH 7.0 to a density of 0.5 McFarland units.  Samples were diluted 1:10 in the 
same buffer and 10 µl of cells were added to 90 µl of the test solutions and incubated as 
described above for 30 min.  Samples were taken (25 µl) and placed on the appropriate medium 
and spread using an inoculation loop.   
2.2.9 Statistical analysis 
HPLC data obtained from the preformulation studies were expressed as the average percentage 
(%) of the peak area from time 0 ± standard deviation, n = 3.  Results were analyzed by one-way 
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analysis of variance (ANOVA), with multiple comparisons of individual time points by using 
post hoc Bonferroni correction to detect significant differences under different conditions.  P-
values ≤ 0.05 were considered to be statistically significant, unless specified otherwise.  
2.3 RESULTS 
High Performance Liquid Chromatography (HPLC) assay 
Linearity of response was shown by analyzing serial dilutions of a standard aqueous PSC-
RANTES solution ranging from 10 to 500 µg/mL (1.27 to 63.3 µM).  Results for the assay 
qualification are shown in Table 2-1.  The coefficient of regression (R²) and the residual (%) 
from the observed values to the back-calculated standard curve were determined.  Accuracy was 
determined by the mean of the response areas from ten injections of PSC-RANTES 10 µg/mL 
solution.  Precision was determined from the coefficient of variation (CV) of the response areas 
of those ten injections.  The Limit of Detection (LOD) was calculated as three times the ratio of 
area standard deviation to the slope of the calibration curve (140).  The Limit of Quantitation 
(LOQ) was defined as 10 times the ratio of the area standard deviation to the slope of the 
calibration curve (140) Repeatibility was demonstrated by analysis of calibration curves on 
different days, and reproducibility was measured by analyzing calibration curves on different 
instruments by different analysts.  The results demonstrate that the method is suitable for the 
intended purpose.  
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 Table 2-1. Qualification of HPLC method for PSC-RANTES 
Factor Criteria Results 
k 2 < k < 10 9.1 
N > 4000 14228 
Rs > 2 3.3 
T < 1.5 1.3 
R2 > 0.999 0.99973 
Residual < 10 % 3.45% 
CV < 1%   0.76% 
LOD  0.24 µg/ mL (30.3 pM) 
LOQ  0.79 µg/ mL (100.7 pM) 
 
Where k = retention factor, N = number of theoretical plates, Rs = resolution, T = tailing factor, R2 = 
coefficient of correlation, Residual = the average difference between the observed values for the 
standard and the calculated standard curve, CV = coefficient of variation of the response of 10 
injections at 10 µg/mL PSC-RANTES concentration, LOD = Limit of Detection, and LOQ = Limit of 
Quantification.   
 
A blank (water) and a PSC-RANTES (500 µg/mL in water) control solution 
chromatograms are shown in Figure 2-2 and Figure 2-3, respectively.  PSC-RANTES 
chromatogram elutes two peaks: a main peak (PSC-RANTES) at 18.3 min and a secondary peak 
pertinent to PSC-RANTES (peak 1) at 17.5 min. 
 
 40 
 Figure 2-2. Representative HPLC chromatogram of a blank solution. 
 
 
Figure 2-3. Representative HPLC chromatogram of PSC-RANTES (500 µg/mL) in water. 
 
SDS-PAGE assay qualification  
The range of detection, specificity and repeatability of the SDS-PAGE method for PSC-
RANTES was evaluated.  The intensities of the bands increased with amount of protein loaded 
0.06 μg (0.51 μM) to 1.2 μg (10.26 μM), as shown in Figure 2-4, wells 2 to 6.  The log-
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molecular masses of the standards were plotted against their mobility.  The mobility of each 
protein was calculated by dividing the distance the protein traveled from the well, by the distance 
between the marker and the well, and the molecular mass was calculated.  Specificity was 
confirmed by visual inspection of the bands.  PSC-RANTES control samples had a calculated 
average molecular mass (n = 4) of 7,134 ± 411 Daltons (mean ± SD). 
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PSC-RANTES
 
Figure 2-4. Detection limit of reduced PSC-RANTES on SDS-PAGE. 
PSC-RANTES detected by silver staining on a SDS-PAGE gel.  From left to right: 1) Polypeptide 
SDS-PAGE Standards, 2 to 6) PSC-RANTES 1.2, 0.6, 0.36, 0.12, and 0.06 µg, respectively. 
 
 
Stability – Effect of temperature 
The effect of temperature on the stability of PSC-RANTES solutions (500 µg/mL in water, pH 
4.5) is shown in Figure 2-5.  The graph represents the amount of PSC-RANTES (% relative to 
the amount at time 0).  The decrease of PSC-RANTES observed over a period of 1 week (168 h) 
at room temperature was not statistically significant (ANOVA, p > 0.38).  PSC-RANTES was 
stable at 40 °C (97.6 % PSC-RANTES remaining in the aqueous solution) for the first 24 h; 
however, statistically significant protein loss was observed after one week (p < 0.001).  PSC-
RANTES was stable for the first 2 h of exposure at 65 °C (97.5% PSC-RANTES remaining in 
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the aqueous solution).  Post hoc, Bonferroni correction for multiple comparisons were conducted 
for the 24 and 168 h time points, and statistically significant differences were observed among 
room temperature, 40 °C, and 65 °C (p < 0.05).   
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Figure 2-5. Effect of temperature on PSC-RANTES.  
PSC-RANTES (500 µg/mL) in water stored over time at 25 °C (■), 40 °C (●), and 65 °C (○), analyzed 
by HPLC (n=3) 
 
 
The log concentration versus time was plotted for each temperature condition (Figure 
2-6).  The slope of each curve was calculated to confirm the statistical results obtained from 
Figure 2-5, and to estimate the rate of degradation (rate constant, k) under each condition.  
Chemical stability is generally expressed by rate constant to estimate rate of drug degradation.  
Assuming first order kinetics, rate constant (k) can be calculated by the slope of the curve from a 
plot of log concentration versus time.   
Slope = -k / 2.303 
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The calculated rate constant is used to predict stability for a longer time period.  Results 
show that at 25 °C, the slope of the curve was not statistically significant different than zero; and 
the rate constant was zero, indicating no degradation over time.  At 40 and 65 °C, the rate 
constants were 0.005 h-1 and 0.014 h-1 respectively.   
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Figure 2-6. Effect of temperature on PSC-RANTES, log concentration versus time (h). 
Obtained from Figure 2-5 for each temperature condition 25 °C (■), 40 °C (●), and 65 °C (○), 
analyzed by HPLC (n=3) 
 
The chemical degradation of PSC-RANTES observed by HPLC was confirmed by 
MALDI-TOF MS.  Figure 2-7 shows the spectrum of sinapinic acid, blank matrix used in the 
analysis of PSC-RANTES.  No peaks were detected in the blank sample that could interfere with 
the PSC-RANTES samples.  
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 Figure 2-7. MALDI-TOF MS spectrum of blank, sinapinic acid matrix.  
100% intensity = 1752 counts. 
 
The spectra of PSC-RANTES after 7 days at 25 °C (Figure 2-8), 40 °C (Figure 2-9), and 
65 °C (Figure 2-10) show the intensity (%) of the m/z fragments of PSC-RANTES.  Samples at 
25 and 40 °C showed similar fragments, including the presence of a dimer (15,789 m/z for 25 °C, 
and 15,938 m/z for 40 °C), and a smaller fragment around 3,900 m/z [M + H]2+. 
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 Figure 2-8. MALDI-TOF MS spectrum of PSC-RANTES (500 µg/mL), 25 °C for 7 days.  
100% intensity = 8375 counts. 
 
 
 
Figure 2-9. MALDI-TOF MS spectrum of PSC-RANTES (500 µg/mL), 40 °C for 7 days.  
100% intensity = 8034 counts. 
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 Figure 2-10. MALDI-TOF MS spectrum of PSC-RANTES (500 µg/mL), 65 °C for 7 days.  
100% intensity = 2069 counts. 
 
Stability – Effect of pH 
Solutions of PSC-RANTES were made at a concentration of 500 µg/mL in phosphate buffer, and 
the pH was confirmed before starting incubation at room temperature and at the end of the 
experiment.  The pH for each buffer solution after addition of PSC-RANTES was no more than 
0.5 units different than the initial buffer pH.  All solutions were stored in a glass container, as it 
was shown that no absorption to the container occurred during the period of time of the study.  
Samples at pH 8 could not be analyzed by HPLC due to a precipitation observed in all samples 
prior to the 24 h sampling point.  A decrease in the amount of PSC-RANTES remaining in the 
solution was observed at pH 3, 4, 5, and 7 over a period of 168 h, indicating loss of stability over 
time.  It was also observed that the initial concentration of PSC-RANTES at pH 7 was 
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consistently 20% lower than expected (Figure 2-11).  No additional peaks were detected by 
HPLC in any of the pH conditions. 
The log concentration at each pH condition (3 to 7) was plotted against time (Figure 
2-12), for the calculation of the rate constant.  The rate constant for each pH value (Table 2-2) 
was not significantly different from zero (p < 0.001), suggesting that the degradation observed at 
pH 7 is immediate and not dependent on time.  
 
0
100
200
300
400
0 20 40 60 80 100 120 140 160 180
Time (h)
PS
C
-R
A
N
TE
S 
(u
g/
m
l)
500
600
pH 3
pH 4
pH 5
pH 7
 
Figure 2-11. pH profile of PSC-RANTES. Concentration (µg/mL) versus time (h). 
PSC-RANTES (500 µg/mL) prepared in 10 mM phosphate buffers pH 3, 4, 5 and 7. Analyzed by 
HPLC (n = 3). 
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Figure 2-12. pH profile of PSC-RANTES. Log concentration versus time (h). 
Obtained from Figure 2-11 for each pH buffer condition. 
 
 
Table 2-2. Rate constant for PSC-RANTES exposed to pH buffer. 
-0.0006
-0.0008
-0.0007
-0.001
Slope
1.4 x 10-3pH 7
1.8 x 10-3pH 5
1.6 x 10-3pH 4
2.3 x 10-3pH 3
Rate constantPSC-RANTES in buffer 
 
 
 
 
Slopes were calculated from the Log concentration of PSC-RANTES over time (Figure 2-12)  
for each pH buffer.  Rate constant (h-1) were calculated from the slope of the curve.  
 
 
Further investigations with SDS-PAGE, CD, MALDI-TOF, and UV spectroscopy were 
conducted to determine if there was any immediate degradation of PSC-RANTES at pH 7.  PSC-
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RANTES solutions at pH 3, 4, 5, 7, and 12 were prepared following the same procedure as 
described in Section 2.2.7.  Samples were analyzed by SDS-PAGE under reducing conditions 
(Figure 2-13), at time 0 and after 168 h to observe changes in molecular mass or the appearance 
of any additional bands.  No additional bands were observed for any of the PSC-RANTES 
samples studied.  The mobility of the PSC-RANTES band was calculated, resulting in a 
molecular mass of 7,625 Daltons at time 0 and 7,844 Daltons after 1 week exposure.   
 
Figure 2-13. pH profile of PSC-RANTES on SDS-PAGE. 
Separation of polypeptide standards and PSC-RANTES on SDS-PAGE, detected by silver staining. 
A)  From left to right: 1) Polypeptide SDS-PAGE Standards, 2) PSC-RANTES control 1.2μg; 3) 
PSC-RANTES pH 3; 4) PSC-RANTES pH 4; 6) PSC-RANTES pH 5; 8) PSC-RANTES pH 7; 10) 
PSC-RANTES pH 7.4 PBS; 12) PSC-RANTES pH12.  Note: wells 5, 7, 9, and 11 were blank.  
B)  PSC-RANTES pH profile after 1 week. Separation of polypeptide standards and PSC-RANTES 
on SDS-PAGE, detected by silver staining.  From left to right: 1) Polypeptide SDS-PAGE Standards, 
3) PSC-RANTES pH 4; 5) PSC-RANTES pH 7; 7) PSC-RANTES pH 12.  Note: wells 2, 4, and 6 were 
blank. 
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CD was conducted on PSC-RANTES (500 μg/mL) solutions at pH 3 and pH 7 phosphate 
buffers.  Under both conditions, the protein showed a random conformation, with a maximum 
lower absorbance at 200 nm for pH 3 and 202 nm for pH 7 (Figure 2-14).  The shift in maximum 
wavelength (λmax) as well as the decrease observed in the absolute signal for the sample at pH 7 
suggests conformational changes.   
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Figure 2-14. CD spectra demonstrating the effect of pH on PSC-RANTES (500 µg/mL) 
in solution. Average of 3 individual spectra after subtraction of background control (pH 3 or pH 7 
phosphate buffer).  ( ___ ) PSC-RANTES in pH 3 buffer; (- - -) PSC-RANTES in pH 7 buffer. 
 
 
 
MALDI-TOF MS was employed to analyze PSC-RANTES samples in water (Figure 
2-15), pH 4 (Figure 2-16), and pH 7 (Figure 2-17).  The highest intensity peaks observed for 
PSC-RANTES samples in water and pH 4 represent the m/z [M + H]1+ of PSC-RANTES.  A 
dimer and a smaller fragment are also observed in those conditions.  However, MALDI-TOF 
mass spectrometry showed degradation, as evidenced by completed fragmentation, of PSC-
RANTES to lower molecular mass peptides after 7 days exposure at pH 7 (Figure 2-17).  
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 Figure 2-15. Representative MALDI-TOF MS spectrum of PSC-RANTES in water.  
100% intensity = 12574 counts. 
 
 
Figure 2-16. MALDI-TOF MS spectrum of PSC-RANTES in pH 4 
10mM phosphate buffer, after 7 days.  100% Intensity = 18175 counts. 
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Figure 2-17. MALDI-TOF MS spectrum of PSC-RANTES in pH 7 
A) PSC-RANTES after 7 days exposure to 10mM phosphate buffer pH 7, spectrum from 2000 to 
20000 m/z.  B) Expanded spectrum A, region 2000 to 6000 m/z, to facilitate visualization of peaks.  
100% Intensity = 2156 counts 
 
Further studies were conducted to verify if the fragments observed in MALDI-TOF MS 
under pH 7 buffer condition corresponded to the potential sites of degradation of PSC-RANTES.  
 53 
Figure 2-18 shows the amino acid sequence of PSC-RANTES and the amino acids highlighted 
that are more susceptible to degradation by hydrolysis and oxidation degradation pathways.  
With this information, the predicted fragments were calculated and presented in Table 2-3.  
Based on the high number of fragments obtained from MALDI-TOF MS for PSC-RANTES 
samples at pH 7 buffer, it was difficult to predict the sites of degradation.  However, the several 
analytical methods utilized (HPLC, CD, UV, and MALDI-TOF MS) have clearly shown that 
PSC-RANTES is unstable in pH 7 buffer. 
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Figure 2-18. PSC-RANTES amino acid sequence and potential sites of degradation 
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Table 2-3. Predicted fragments for PSC-RANTES after degradation  
 Position Potential mechanism Fragments (m/z) 
Ser4 
 
Hydrolysis 
 
  482.14 
7394.49 
Ser5 
 
Hydrolysis 
 
  569.22 
7307.41 
Cys10 
 
Oxidation 
 
1085.77 
6790.86 
Cys11 
 
Oxidation 
 
1187.91 
6688.72 
His23 
 
Oxidation 
 
2581.58 
5295.05 
Ser31 
 
Hydrolysis 
 
3613.72 
4262.91 
Cys34 
 
Oxidation 
 
3901.08 
3975.55 
Ser35 
 
Hydrolysis 
 
3988.16 
3888.47 
Asn36 
 
Hydrolysis 
 
4102.26 
3774.37 
Asn46 
 
Hydrolysis 
 
5214.59 
2662.04 
Arg47 
 
Oxidation 
 
5370.78 
2505.85 
Gln48 
 
Hydrolysis 
 
5498.91 
2377.72 
Cys50 
 
Oxidation 
 
5771.26 
2105.37 
Asn52 
 
Hydrolysis 
 
5982.48 
1894.15 
Trp57 
 
Oxidation 
 
6554.14 
1322.48 
Asn63 
 
Hydrolysis 
 
7329.00 
  547.63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies of the stability of PSC-RANTES at pH 12 were conducted as a forced 
degradation study.  Results showed no detectable PSC-RANTES by HPLC analysis in two out of 
three samples after 2 h exposure to phosphate buffer pH 12.  One PSC-RANTES sample was 
undetectable after a 6-hour period.  In all three PSC-RANTES samples, fast degradation under 
high pH conditions was observed.  CD analyses were conducted to verify changes in secondary 
structure at this pH.  PSC-RANTES in pH 12 buffer after 2 and 24 h exposure (Figure 2-19) 
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revealed a decrease in absorbance, indicating conformational changes of the protein.  MALDI-
TOF MS spectrum confirmed the degradation observed in HPLC and CD.  The spectrum showed 
a complete fragmentation of PSC-RANTES into smaller fragments (Figure 2-20).   
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Figure 2-19. CD spectra of PSC-RANTES (500 µg/mL) in phosphate buffer pH 12.  
Average of 3 individual spectra after subtraction of background control (pH 12 phosphate buffer)  
 
 
Figure 2-20. MALDI-TOF MS spectrum of PSC-RANTES in pH 12  
10mM phosphate buffer after 24 h exposure. 100% Intensity = 3230 counts. 
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Stability - Effect of ionic strength 
The effect of ionic strength on the stability of PSC-RANTES was evaluated by UV-spectroscopy 
and the results for time 0 are shown in Figure 2-21 (low ionic strength and high ionic strength).  
UV scans of PSC-RANTES in water, and in pH 4 and pH 12 phosphate buffers at low ionic 
strength (50 mmol/kg) showed similar profiles for all concentrations tested.  However, UV scans 
for PSC-RANTES in pH 7 phosphate buffer solutions (at low ionic strength) showed a higher 
absorbance from 300 to 600 nm, indicating the presence of insoluble aggregates.   
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Figure 2-21. Effect of pH and ionic strength on PSC-RANTES analyzed by UV-spectroscopy.  
PSC-RANTES 500 µg/mL solutions in water, and in phosphate buffer solutions at pH 4, 7, and 12.  
A) UV scans for low ionic strength buffer, 50 mmol/kg. B) UV scans for high ionic strength buffer, 
500 mmol/kg.  On graph A, PSC-RANTES in water and in pH 4 buffer are superimposed.  
 
At high ionic strength buffers (500 mmol/kg), UV-scans of PSC-RANTES in phosphate 
buffer pH 7 did not show the same increase in absorbance from 300 to 600 nm as observed for 
low ionic strength pH 7 buffer.  Additional studies in phosphate buffered saline (PBS, 290 
mmol/Kg, pH 7.4) were conducted, which showed evidence of aggregation by the increase in 
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absorbance observed from 300 to 600 nm (Figure 2-21).  When PSC-RANTES was prepared in 
PBS pH 7.4 in different concentrations, solutions were only visually soluble at concentrations 
equal to or lower than 0.5 mg/mL.   
 
Effect of hydrogen peroxide 
After exposure to 3.0 or 0.8% (v/v) H2O2, no PSC-RANTES could be detected by HPLC at the 
initial time point, indicating instantaneous degradation of the protein.  Results of PSC-RANTES 
exposed to 0.02 and 0.002% H2O2 are shown in Figure 2-22.  PSC-RANTES was quickly 
degraded, and after a 5-hour period, only 10% of PSC-RANTES could be detected by HPLC 
when exposed to 0.02% H2O2.  The degradation was slower when in the presence of 0.002% 
H2O2, about 50% of PSC-RANTES remained after 5 h exposed to hydrogen peroxide.  Log of 
the concentration of PSC-RANTES was plotted against time to obtain the rate constant (Figure 
2-23).  The calculated rate constant was 0.19 h-1 for 0.002%, and 0.48 h-1 for 0.02% H2O2, 
indicating degradation over time. 
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Figure 2-22. PSC-RANTES (500 µg/mL) after exposure to H2O2 over time (h). 
(- - -) 0.02% and (___) 0.002% H2O2.  Analyzed by HPLC, n = 3. 
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Figure 2-23. Log concentration versus time (h) of PSC-RANTES exposed to H2O2. 
(- - -) 0.02% and (___) 0.002% H2O2.  Obtained from Figure 2-22 for each hydrogen peroxide 
condition. 
 
In HPLC analysis, additional peaks were observed after incubation of PSC-RANTES 
with 0.8% hydrogen peroxide and at lower concentrations.  Figure 2-24 and Figure 2-25 show the 
HPLC chromatograms for PSC-RANTES in the presence of 0.002% hydrogen peroxide at time 0 
and after 12 h. 
 
Figure 2-24. HPLC chromatogram of a PSC-RANTES (500 µg/mL) in 0.002% H2O2 
at time 0. 
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Figure 2-25. HPLC chromatogram of a PSC-RANTES (500 μg/mL) in 0.002% H2O2,  
after 12 h exposure. 
 
MALDI-TOF MS spectra of PSC-RANTES after exposure to hydrogen peroxide were 
conducted to indicate the presence of oxidative products generated by the exposure H2O2.  Figure 
2-26 shows the spectrum of PSC-RANTES after 15 h exposure to 0.8% hydrogen peroxide.  A 
higher m/z fragment (7927.97) was observed than the results obtained for PSC-RANTES in 
water (7892.20).  The difference between the two major peaks (higher intensity) is about 36, 
which indicates the incorporation of oxygen in the protein.  This oxidation can be occurring in 
one of the cysteines, methionine, or the thioproline present in PSC-RANTES.   
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 Figure 2-26. MALDI-TOF MS spectrum of PSC-RANTES (500 μg/mL) in 0.8% H2O2 
after 15 h exposure.  100% intensity = 11254 counts. 
 
Protective effect of antioxidants 
In the previous sections, it has been identified that oxidation and hydrolysis are the major 
degradation pathways for PSC-RANTES.  Considering that this protein will be administered 
vaginally in an environment that contains hydrogen peroxide, protection against oxidation is 
necessary.  A range of antioxidants from different pharmaceutical classes have been tested.  Most 
of the antioxidants studied did not show a significant protective effect against oxidation in the 
presence of hydrogen peroxide.  When analyzed by HPLC, oxidation degradation of PSC-
RANTES was faster in the presence of antioxidants than without the addition of antioxidants 
selected in this study. 
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Effect of light exposure 
Aqueous PSC-RANTES samples (500 μg/mL) stored in a photostability chamber were compared 
to control samples kept in the dark over a one week period.  No statistically significant difference 
was observed between the amounts of PSC-RANTES detected by HPLC in the samples stored in 
the dark when compared to the samples stored under light over a one week period (p > 0.1), 
indicating that PSC-RANTES is stable under light exposure. 
 
Effect of freeze-thaw cycles 
Solutions of PSC-RANTES (500 μg/mL) in water showed a 30% loss in the PSC-RANTES peak 
area after 6 freeze-thaw cycles analyzed by HPLC (Figure 2-27).  No additional bands were 
identified in the SDS-PAGE, and no changes in the CD spectra were observed for the PSC-
RANTES samples after 6 freeze-thaw cycles (Figure 2-28).  Results indicate that changes in the 
protein occur after freezing-thaw process and should be considered when utilizing samples stored 
in the freezer. 
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Figure 2-27. Effect of freeze-thaw cycles stability on PSC-RANTES (500 μg/mL). 
Analyzed by HPLC, n = 3.  
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 Figure 2-28. CD spectra of PSC-RANTES (500 μg/mL) in water after freezing-thaw cycles. 
PSC-RANTES solution before (____) and after freezing (- - -).  Average of 3 individual spectra after 
subtraction of background control (water). 
 
Effect of enzymatic activity 
PSC-RANTES was evaluated in the presence of enzymes commonly encountered in the vaginal 
fluid and cervical mucus.  PSC-RANTES was exposed to aminopeptidase, lysozyme, and 
proteinase K at concentrations of 100 units/mL, 100 units/mL, and 100,000 units/mL 
concentrations respectively.  After exposure, samples were analyzed by MALDI-TOF MS.  
Fragments observed in MALDI-TOF MS were compared to the predicted sites of degradation 
(from Figure 2-18 and Table 2-3).  No changes were observed for PSC-RANTES when exposed 
to aminopeptidase or lysozyme after a period of 1 h at 37 °C.  When PSC-RANTES was exposed 
to proteinase K under the same conditions, a complete fragmentation of the protein was observed 
using MALDI-TOF MS (Figure 2-29).  The fragment 11,181.55 (m/z) in Figure 2-29 corresponds 
to the proteinase K (Figure 2-30); other fragments are originated by degradation of PSC-
RANTES. 
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  Figure 2-29. MALDI-TOF MS spectrum of PSC-RANTES after 1 h exposure to proteinase K. 
A) PSC-RANTES after 1h exposure to proteinase K at 37 °C. 100% intensity = 4062 counts. 
B)  Expanded spectrum A to facilitate visualization of peaks. 
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 Figure 2-30. MALDI-TOF MS spectrum of Proteinase K.  
100% intensity = 372 counts. 
 
 
Table 2-4. Potential cleavage sites of PSC-RANTES in the presence of enzymes. 
Name of enzyme Number of cleavages Positions of  cleavage sites 
Asp-N endopeptidase 1 
 
5 
 
Lysozyme C 5 
 
25 33 45 55 56 
 
Proteinase K 28 
7 8 12 13 14 15 16 19 
22 24 27 28 29 30 38 
39 40 41 42 43 49 51 
57 58 61 62 65 
Calculated using Peptide Cutter software program (http://us.expasy.org) 
 
Potential cleavage sites on PSC-RANTES in the presence of the enzymes studied have 
been calculated using Peptide Cutter software program (http://us.expasy.org) an enzymatic 
activity analysis tool to predict the sites more predisposed to cleavage, and are presented in Table 
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2-4.  Due to the high number of fragments observed after exposure to enzymatic degradation 
(proteinase K), it was not possible to predict the sites of hydrolysis of the protein.  It is clear that 
PSC-RANTES is highly susceptible to degradation in the presence of proteinase K. 
 
Microbiological activity 
The effects of PSC-RANTES on normal vaginal flora were investigated (Table 2-5).  The 
lactobacilli strains selected are those most commonly present in the vaginal environment.  PSC-
RANTES did not kill or inhibit the growth of Lactobacillus crispatus or L. vaginalis; however, 
in 2 of 10 strains of L. jensenii and in 4 of 5 strains of L. iners PSC-RANTES caused a 99.99% 
kill or 4 log reduction in viability after a 30 min exposure.  The viability of N. gonorrhoeae (7 
strains), L. gasseri (1 strain), L. johnsonii (1 strain), L. acidophilus (2 strains), and G. vaginallis 
(5 strains) were not affected by PSC-RANTES. 
 
Table 2-5. Microbiological activity of PSC-RANTES (300μg/mL) in water. 
Organism L. crispatus L. iners L. jensenii G. vaginalis N. gonorrhoeae 
PSC-RANTES  
No. killed / no. 
tested 
0/ 9 4/ 5 2/ 10 0/ 5 0/ 7 
2.4 DISCUSSION AND CONCLUSIONS 
It is well known that the formulation and the delivery of proteins can be difficult due to alteration 
of the protein during the manufacturing process, during the shelf-life of the product, and after the 
protein enters the biological system (141, 142).  Topically delivered protein microbicide products 
will encounter the same obstacles.  Stability of the active protein is essential for the successful 
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development of a protein microbicide product.  Protection of the protein in a drug delivery 
system will prevent the protein microbicide from being modified before administration, and in 
biological fluids after administration, preserving and prolonging drug activity.  
According to the Alliance for Microbicide Development (143), several needs in 
microbicide formulation are considered to have a high priority.  One of these priorities is to 
perform preformulation studies to accelerate product development.  The current study addresses 
this issue by identifying and characterizing the microbicide PSC-RANTES to further understand 
its stability, which will impact formulation development and, eventually, efficacy of the product. 
The PSC-RANTES amino acid sequence is comprised of 65 amino acids and 3 chemical 
groups attached to the N-terminal sequence: nonanoyl, thioproline, and cyclohexyl glycine 
groups (Figure 2-1) (91). The estimated pI for PSC-RANTES is 9.27 
(http://ca.expasy.org/tools/protparam.html).  PSC-RANTES, an analog of RANTES, acts by 
inhibiting HIV virus fusion, through blocking the CCR5 co-receptor.  This antiviral mechanism 
makes PSC-RANTES a very attractive microbicide candidate, due to the specificity of the 
molecule and low toxicity.  Previous studies using a modified severe combined immunodeficient 
(SCID) mouse model showed that an intra-peritoneal single injection of PSC-RANTES (500 µg 
or 150 µg) protected all of the challenged mice against HIV-1 infection (96).  In a macaque 
model, topical application of PSC-RANTES demonstrated that, like other microbicide 
candidates, much more material was required to give protection than the amount expected from 
in vitro potency data (91).  The ability to protect against infection in the macaque studies was 
assessed by intravaginally delivering 4 mL of PSC-RANTES in PBS pH 7.4.  The need for such 
large amounts could be explained by poor stability of the drug in the delivery vehicle, as well as 
poor retention of the drug in the vaginal lumen.  The purpose of this study was to characterize 
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the stability of PSC-RANTES as a function of temperature, pH, ionic strength and the presence 
of hydrogen peroxide.  This preformulation study will contribute to the development of a suitable 
drug delivery system for a PSC-RANTES microbicide product. 
An HPLC and a SDS-PAGE method were developed for the quantitation and detection, 
respectively, of PSC-RANTES and its degradants.  PSC-RANTES proved to be stable in water at 
25 °C over a period of 1 week, but not at 40 °C.  Temperatures of 40 and 65 °C are accelerated 
conditions used to force the degradation of the protein, and to verify analytical method’s 
capability to indentify degradant peaks.  PSC-RANTES was quickly modified at 65 °C.  
Evaluating protein stability at increased temperatures (40 and 65 °C) is important for several 
reasons.  It facilitates an understanding of how the drug will be affected through the 
manufacturing process of the final product, during storage and transport, and ultimately in the 
body.  These studies demonstrated that increased manufacturing process temperatures may result 
in degradation of PSC-RANTES. 
The development of a successful microbicide product is dependent on the ability to 
prevent the oxidative effects of H2O2, generated in the vaginal lumen by Lactobacillus.  Forced 
degradation studies to evaluate oxidative effects are commonly conducted by exposing the 
molecule of interest to a solution of 3.0% H2O2 (144).  Initial studies with PSC-RANTES using 
3.0% H2O2, resulted in complete degradation of PSC-RANTES by HPLC immediately after 
exposure.  To evaluate the effect of hydrogen peroxide on the stability of PSC-RANTES, we 
selected three other concentrations of H2O2: 0.8, 0.02, and 0.002% (145, 146).  The 
concentrations of H2O2 were based on reports that determined the production of H2O2 by 
Lactobacillus present and calculations of concentrations Lactobacillus present in the normal 
vaginal flora (146).  The concentration of 0.8% H2O2 represents 10 times the highest estimation 
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of H2O2, and it was used for forced degradation studies.  The concentrations of 0.02%, and 
0.002% H2O2 were used to simulate biological conditions.  Oxidative studies (exposure to H2O2) 
resulted in degradation of PSC-RANTES at all concentrations tested.  MALDI-TOF MS spectra 
confirmed the results obtained by HPLC by showing higher m/z fragments when compared to 
PSC-RANTES not exposed to hydrogen peroxide.  Increase in m/z can be attributed to chemical 
reactions to the molecule, such as incorporation of oxygen.  However, the analytical methods 
used were not able to determine the mechanism of the modifications observed.  We can suggest 
that formulation development of PSC-RANTES will require the addition of an antioxidant to 
protect it against these oxidative effects.  The PSC-RANTES amino acid sequence contains four 
cysteines (Cys10, Cys11, Cys34, and Cys50) and one methionine (Met67) which are prone to 
oxidation.  In addition, the thioproline group in position two of the sequence might also be 
subjected to oxidation.  However, the binding of PSC-RANTES to CCR5 co-receptor is not 
associated with the C-terminal region of the protein (97) (40), which suggests that the oxidation 
of Met67 may not strongly affect binding.  It is likely that oxidation of thioproline will 
significantly affect binding to the target and therefore affect potency.  It has been shown that 
oxidation of PSC-RANTES results in a 10 log fold decrease in bioactivity when compared to 
PSC-RANTES before oxidation (personal communication – Oliver Hartley, Ph.D. University of 
Geneva).  Protection against oxidation was studied by evaluating the protective effects of a series 
of antioxidants.  None of the antioxidants selected were successful in protecting PSC-RANTES.  
The effects and mechanisms of several antioxidants will result in different oxidation or 
protection profiles of the protein.  Antioxidants were selected in this study to cover all classes of 
antioxidants commonly used in pharmaceutical formulations: “true” antioxidants (or phenolic 
compounds), reducing agents, and chelating agents (138).  Methionine, ascorbic acid, cysteine, 
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glutathione, and sodium metabisulfite are reducing agents and act as oxygen scavengers as they 
oxidize in preference of the protein.  Based on their mechanism of action, it was believed that 
these antioxidants would be the most suitable excipients to protect against oxidation of the 
cysteine, thioproline, and methionine in PSC-RANTES.  However, a faster oxidation was 
observed by HPLC when in the presence of antioxidants.  It has been shown that some 
antioxidants, such as ascorbic acid, can also act as a prooxidant due to the strong electron donor 
capability, which explains the observed faster oxidation profile in the presence of antioxidants 
(147, 148).  Further studies should be conducted with chelating agents to verify if removing trace 
metal ions will decrease initiation of oxidation. 
Freeze-thaw cycle stability of PSC-RANTES solutions was determined at -80 °C, and 
suggested that there was a 30% loss of PSC-RANTES after 6 cycles.  This loss indicates that 
control solutions for the study should be prepared fresh, or used frozen for no more than 3 
freezing-thaw cycles, after which no significant loss was observed. 
Presence of insoluble aggregates at pH 7 was observed at low ionic strength and high 
ionic strength, by UV-spectroscopy methods.  Changes in the absorbance baseline of the UV 
spectrum in non-absorbing regions (> 300 nm), indicates the presence of aggregates.  This 
method is only qualitative, but indicates aggregation formation (141).  Aggregates can result in 
an increase in immunogenicity, and a decrease in bioactivity (138, 149), presenting a challenge 
for formulation development.  Protein monomers can aggregate by physical association with one 
another without any changes in primary structure or by formation of a new covalent bond 
(irreversible aggregation).  Both mechanisms can generate both soluble and insoluble aggregates, 
depending on the protein, environmental conditions, and the stage of the aggregation process 
(149).  Some external factors such as temperature, pH and protein concentration may induce the 
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aggregation formation.  Results presented in this chapter have shown that PSC-RANTES forms 
insoluble aggregates at concentrations higher than 0.5 mg/mL at pH 7.  This finding will impact 
decisions made on maximum concentration to be used in a formulation, as well as the pH and 
ionic strength of the formulation, limiting the options for formulation development.  
HPLC results for PSC-RANTES in phosphate buffers showed that PSC-RANTES was 
more stable at pH 4 than at pH 7 buffer.  This loss of stability at pH 7 was confirmed by 
MALDI-TOF MS and circular dichroism, suggesting that hydrolysis may occur at this pH level.  
As mentioned in Section 2.1, potency studies of PSC-RANTES evaluated in a macaque model 
resulted in a 106-fold loss in potency for PSC-RANTES as compared with in vitro study results.  
The in vivo animal studies were conducted using a 30 mg/mL concentration of PSC-RANTES in 
PBS pH 7.4.  Our studies demonstrate that the observed loss of in vivo potency is partially due to 
its instability, lack of solubility, and aggregate formation under these conditions. 
Exposure of PSC-RANTES to a pH 12 phosphate buffer was conducted to force 
degradation by deamidation.  It resulted in loss of the peak area observed by HPLC over the 
course of 2 h.  Investigation using UV-spectroscopy, MALDI-TOF, and CD was conducted and 
confirmed degradation of the protein over time in the presence of pH 12 phosphate buffer.  Non-
enzymatic deamidation is a very common hydrolytic reaction responsible for degradation of 
peptides and proteins.  The amide group of asparagine (Asn) and glutamine (Gln) residues are 
hydrolyzed to free carboxylic acid groups: aspartic acid (Asp) and glutamic acid (Glu).  PSC-
RANTES contains four Asn residues and one Gln.  In the presence of pH 12 buffer, we 
hypothesize that those groups will change the primary amino acid sequence, potentially affecting 
protein stability and its biological activity.  HPLC chromatograms of PSC-RANTES showed the 
presence of secondary peaks in the void volume of the column.  Optimization of the method was 
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attempted to separate the degradant peaks at pH 12 from the void volume of the column, but it 
was not successful. 
In addition to chemical degradation, PSC-RANTES when administered vaginally, will 
encounter enzymes present in vaginal fluids that will potentially degrade the protein.  The 
degradation of PSC-RANTES in the presence of the three most common enzymes in vaginal 
fluid (aminopeptidase, lysozyme, and proteinase K) has been investigated in this study. 
Degradation was only observed when PSC-RANTES was exposed to proteinase K, a broad 
spectrum serine protease.  The predominant site of cleavage is the peptide bond adjacent to the 
carboxyl group of aliphatic and aromatic amino acids with blocked alpha amino groups.  Based 
on an enzymatic activity analysis performed to predict the sites more predisposed to cleavage 
using Peptide Cutter software program (http://us.expasy.org), the possible cleavage sites for 
proteinase K were established.  This software provides the query sequence with the possible 
cleavage sites mapped on it and a table of cleavage site positions.  The position of potential 
cleavage sites for the amino acid sequence of PSC-RANTES is shown in Table 2-4, and confirms 
the results obtained for PSC-RANTES by MALDI-TOF MS analysis when in the presence of 
Proteinase K, with a high number of fragments observed.   
Investigation of a potential microbicide agent must take into consideration the toxicity of 
the agent to the normal vaginal flora.  The ability of PSC-RANTES to preserve the normal 
vaginal flora was investigated.  The killing of Lactobacillus species was unexpected considering 
the mechanism of action for this drug. Hydrogen peroxide producing Lactobacilli and 
streptococci are considered essential for a healthy vaginal microflora.  The hydrogen peroxide is 
protective, and the lactic acid produced by these organisms is primarily responsible for 
maintaining the low vaginal pH which provides a native mechanism of protection against some 
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pathogens.  The results from this study suggest a potential incompatibility of PSC-RANTES with 
certain strains of normal vaginal flora.  The most common species of Lactobacillus present in the 
normal vaginal flora in the United States population are L. crispatus and L. jensenii.  Both are 
hydrogen peroxide producing Lactobacillus, which are beneficial to the normal vaginal 
microflora.  PSC-RANTES showed incompatibility with L. iners, which is a non-hydrogen 
peroxide producing strain and less beneficial to the normal flora.  This finding is similar to the 
results obtained from other microbicide proteins recently studied and represents a low concern in 
the development of a microbicide product (personal communication - Bernard Moncla, Ph.D., 
Magee-Womens Research Institute). 
This study has characterized the degradation of PSC-RANTES under various conditions, 
which is essential for the development of an effective microbicide product, and provided several 
significant findings relevant to formulation and drug delivery.  The physical instability of PSC-
RANTES observed at pH 7 suggests that any aqueous based pharmaceutical product should be 
formulated at a more acidic pH.  The identified potential for oxidation raises the need to evaluate 
protective strategies such as antioxidants for final delivery system design.  
It is essential that a microbicide product overcome physical and chemical barriers such as 
the presence of mucus and enzymatic degradation in addition to the delivery of the active 
pharmaceutical compound to the site of action.  A formulation of PSC-RANTES must include 
better protective strategies to ensure the stability of the protein.  This protection can be obtained 
by encapsulation of PSC-RANTES into nanoparticulated drug delivery systems, which will 
facilitate distribution of the microbicide agent and preserve the stability of the drug as recently 
reported (150).  However, development of such a delivery system is outside the scope of this 
dissertation, but is currently being pursued in our laboratory.  
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3.0  PREFORMULATION EVALUATION OF RC-101 
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 3.1 INTRODUCTION 
Defensins are cysteine-rich cationic antimicrobial peptides expressed by the leucocytes and 
epithelial cells of mammals.  It has been shown that α-defensins expressed by human T cells 
may prevent the development of clinical Acquired Immunodeficiency Syndrome (AIDS) (151).  
Experiments conducted showed that defensins protect cells from in vitro infection by human 
immunodeficiency virus (HIV-1).  β-defensins have shown to possess a high antiviral activity, 
inhibiting both X4 and R5 strains of HIV-1 (104).  θ-defensins have the ability to bind with high 
affinity to CD4, galactosylceramide (alternative cell surface receptor for CD4- cells), and gp120; 
and thereby confer protection against HIV-1 (106).  Retrocyclins (θ-defensins) are the 
evolutionary descendants of α-defensin genes.  Retrocyclins are circular 18-residue, tetracyclic 
peptides with three cysteine disulfides bonds.  RC-101 (GICRCICGKGICRCICGR) (Figure 
1-6), a cationic retrocyclin analog, synthesized by solid phase peptide synthesis, has shown 
activity against X4 and R5 strains of HIV-1 in vitro (102).  The mechanism occurs by preventing 
six-helix bundle formation of gp41 (a 41,000 MW glycoprotein), conferring a strong mechanism 
of protection against HIV-1 (109).  The strong net negative charge of heptad repeat 2 (HR2) and 
the net positive charge of RC-101 create a strong electrostatic attraction that promotes binding.  
In addition, ability of HIV to generate escape mutants against RC-101 is limited.  As a result, 
RC-101 has been identified as a potential microbicide candidate to prevent mucosal transmission 
of HIV-1 (102, 106). 
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A microbicide product is defined as a female controlled method, applied intravaginally to 
prevent transmission and acquisition of sexually transmitted infections, mainly HIV.  
Biopharmaceutical molecules (proteins and peptides) have demonstrated advantages over small 
molecule microbicides.  However, it is a challenge to formulate a protein or peptide into a 
microbicide product.  The product must overcome in vivo barriers that will affect efficacy of the 
product.  Changes in efficacy can be related to: 1) protein modification, mostly due to 
conformational changes; 2) chemical degradation in the drug delivery vehicle or biological 
environment; 3) proteolytic inactivation in the vaginal lumen, and/or 4) low penetration of the 
drug into the mucosal tissue (45, 134).  It is crucial to understand the potential degradation 
pathways through a complete pre-formulation study.  The preformulation study will expedite 
formulation of a successful microbicide product.   
The purpose of this research was to perform a preformulation study to characterize the 
peptide RC-101 to a sufficient extent that it can be further used in the development of a 
microbicide product.  This study evaluated selected conditions of temperature, pH, and the 
presence of hydrogen peroxide to establish rate and extent of degradation, and identify potential 
degradation pathways of RC-101.  Protective effects of excipients against oxidation were also 
investigated.  Samples were analyzed by high performance liquid chromatography (HPLC), 
circular dichroism (CD), MALDI-TOF MS, and UV-spectroscopy.   
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Retrocyclin-1 (RC-101) was synthesized by the Peptide Synthesis Facility at the University of 
Pittsburgh (Pittsburgh, PA).  Mass spectrophotometry was conducted using Electrospray Mass 
Spectroscopy (Quattro II, Fisons Inc., Valencia, CA) to confirm the molecular weight of the 
compound.  Acetonitrile (HPLC grade), trifluoroacetic acid (TFA), sodium phosphate dibasic, 
phosphoric acid 85%, sodium acetate, and acetic acid glacial were obtained from Fisher 
Scientific (Fair Lawn, NJ).  Vitamin E tocopheryl polyethylene glycol succinate (TPGS) was 
purchased from Eastman Chemical Company (Kingsport, TN).  Edetate disodium (EDTA) was 
obtained from Spectrum Chemicals (Gardena, CA).  All other materials were obtained from 
Sigma (St. Louis, MO).  De-ionized water was prepared from house-distilled water with a Milli 
Q (Millipore, Milford, MA) water system operating at 18.2 MΩ.cm. 
3.2.2 High performance liquid chromatography 
A high performance liquid chromatography (HPLC) system (Waters Corporation, Milford, MA) 
was used for the analysis of RC-101.  The HPLC system was equipped with an autoinjector 
model 717 (Waters), a quaternary pump model 600 (Waters), and an ultraviolet (UV) detector 
model 2487 (Waters).  Separation of RC-101 from degradant products was achieved using a 
Phenomenex Jupiter 5 µ C5 300 Å (4.6 x 250 mm) column (Phenomenex, Torrance, CA) 
protected by a Widepore C5 (4 x 3.0 mm) guard cartridge (Phenomenex).  The gradient consisted 
of mobile phase A (0.1% TFA in water (v/v)), and mobile phase B (0.07% TFA in acetonitrile 
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(v/v)) pumped at a flow rate of 1.0 mL/min.  Elution conditions started at A:B (80:20) and 
linearly changed to A:B (60:40) for the first 12 min, returned to the A:B (80:20) condition in 1 
min, followed by a 13 min isocratic condition at A:B (80:20) to allow equilibration of the system 
before the next sample was injected.  Retention time of RC-101 was around 10 min and the total 
run time was 26 min.  Empower PRO, Empower 2 software (Waters Corporation) was used to 
control the HPLC system.  To ensure that the method was suitable for the intended purposes of 
quantification and separation of degradants, the accuracy, precision, repeatability, Limit of 
Quantification (LOQ), and Limit of Detection (LOD) were determined in addition to other 
suitability parameters defined by the United States Pharmacopeia (135).  Forced degradation 
studies at extreme conditions of temperature, pH and oxidative potential were initially conducted 
to confirm that the HPLC system was suitable as a stability-indicating assay. 
3.2.3 Circular Dichroism Spectroscopy 
Circular dichroism (CD) was used to monitor conformational changes in the secondary structure 
of RC-101. CD measurements were performed on an AVIV Circular Dichroism 
spectrophotometer model 202 (AVIV Biomedical, Lakewood, NJ) equipped with a 0.1 cm path 
length quartz cell.  Spectra were recorded between 198 and 300 nm at 25 °C from a 500 μg/mL 
RC-101 solution in 10 mM phosphate buffer pH 3.0, 7.0, or 12.0.  Three scans were averaged 
and subtracted from buffer background over the same wavelength range.   
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3.2.4 MALDI-TOF MS 
Matrix assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometric 
(MS) experiments were performed in the positive-ion linear mode on a Voyager DE-PRO mass 
spectrometer (Applied Biosystems, Foster City, CA).  Samples were prepared by pipetting 1 μL 
of sample and 1 μL of matrix on an MS stainless steel sample probe (Applied Biosystems).  The 
matrix was prepared by dissolving α-cyano-4-hydroxycinnamic acid (CHCA) in 0.5% 
trifluoroacetic acid in acetonitrile:water (1:1 v/v).  The probe containing the sample was left to 
dry completely in air.  The spectra were calibrated using external calibration Sequazime Peptide 
Mass Standards calibration mix 1 (Applied Biosystems).  The following parameters were used: 
accelerating voltage 20 kV with delayed extraction, mass range of 500–5,000 Da, and 400 laser 
shots spectrum. 
3.2.5 UV-spectroscopy 
RC-101 solutions at concentrations of 0.125 to 2.5 mg/mL were prepared in phosphate buffer 
solutions and UV scans were performed using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies Inc, Wilmington, DE).  Scans were performed from 220 to 700 nm.  
NanoDrop software was used to control the spectrophotometer. 
3.2.6 Stability of RC-101 
For all stability studies described below, triplicate solutions of RC-101 were prepared by adding 
RC-101 at a concentration of 500 µg/mL (26.4 µM) in either water or aqueous phosphate buffer 
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solutions.  The pH of each solution was measured after solubilization of RC-101 in the vehicle 
and at the end of the experiment. All samples were used within 5 min of preparation, and 
analyzed by HPLC using the method described in section 3.2.2.  Additional analytical techniques 
(MALDI-TOF MS, UV-spectroscopy, and CD) were used to confirm results obtained by HPLC. 
 
Effect of temperature 
Thermal degradation studies were conducted at 25, 37, and 65 °C for a minimum period 
of 1 week.  RC-101 (500 µg/mL) samples were removed from each chamber 30 min prior to 
analysis by HPLC to allow the samples to equilibrate to ambient temperature.  Thermal 
degradation samples were also evaluated by MALDI-TOF MS. 
 
Effect of pH 
The effect of pH on the stability of RC-101 (500 µg/mL) was evaluated over the pH 
range from 3 to 12 using 10 mM phosphate buffer solutions.  All buffers were prepared using 
phosphate sodium to avoid interference of other salts in the solution.  Knowing that phosphate 
buffer is not a strong buffer at certain pHs, the pH values were confirmed at time 0 and at the end 
of each experiment.  Samples were analyzed by HPLC, MALDI-TOF MS, CD, and UV 
spectroscopy. 
 
Effect of ionic strength 
RC-101 solutions at concentrations ranging from 0.125 to 2.5 mg/mL were prepared in 
water and phosphate buffers (pH 4, 7, and 12) at low (50 mmol/kg) and high (500 mmol/kg) 
ionic strength to evaluate the effect of ionic strength on RC-101 stability.  Effect of high ionic 
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strength was evaluated by UV-spectroscopy analysis to determine the formation of insoluble 
aggregates. 
 
Effect of hydrogen peroxide 
The stability profile of RC-101 (500 µg/mL) under oxidative conditions was evaluated by 
exposing a solution of RC-101 to hydrogen peroxide (H2O2) at concentrations of 3.0, 0.08, 0.02, 
and 0.002% (v/v).  A minimum of five time points were taken from each of triplicate solutions 
for HPLC analysis.  Oxidative RC-101 samples were also evaluated by MALDI-TOF MS. 
 
Protective effect of antioxidants  
Solutions of RC-101 (500 µg/mL) were prepared followed by the addition of antioxidants 
commonly used in pharmaceutical products.  The antioxidants used in this study were: 
methionine (95.2 μg/mL or 250 μg/mL), cysteine (95.2 μg/mL), glutathione (90.9 μg/mL), 
vitamin E TPGS (90.9 μg/mL), ascorbic acid (1.0 mg/mL), sodium ascorbate (1.0 mg/mL), and 
EDTA (0.5 mg/mL).  Explanation on the concentration of antioxidants used was described in 
Section 2.2.7.  Briefly, the concentrations of sodium ascorbate, ascorbic acid, EDTA, and 
vitamin E TPGS were selected based on the inactive ingredient list for FDA drug approved 
products (http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm - last accessed on 
10/22/2008) and the Handbook of Pharmaceutical Excipients (136).  Concentrations of 
methionine, cysteine, and glutathione were based on literature reviews on the use of amino acids 
as competitive inhibitors of oxidation (137, 138).  RC-101 solutions prepared with EDTA were 
analyzed by HPLC for a period of 30 days after exposure with 0.002% H2O2.  All other solutions 
were analyzed by HPLC for a period of 48 h. 
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Effect of freeze-thaw cycles 
RC-101 (500 µg/mL) solutions were stored at -80 °C and allowed to freeze for at least 1 
h.  Samples were thawed immediately prior to HPLC analysis. The test was repeated 5 times, 
resulting in 5 freeze-thaw cycles.  After completion of five freeze-thaw cycles, RC-101 solutions 
were analyzed by CD. 
 
Effect of enzymatic degradation 
RC-101 (500 µg/mL) solutions in water were prepared followed by the addition of 
enzymes commonly present in human vaginal fluid. The enzymes used in this study were: 
aminopeptidase, lysozyme, and proteinase K.  Samples were tested by MALDI-TOF MS at time 
0 and after 1 h exposure at 37 °C. 
3.2.7 Statistical analysis 
HPLC data obtained from the preformulation studies were expressed as the average percentage 
of the peak area from time 0 ± standard deviation, n = 3.  Results were analyzed by one-way 
analysis of variance (ANOVA) with multiple comparisons of individual time points by using 
post hoc Bonferroni correction to detect significant differences under different conditions.  P-
values ≤ 0.05 were considered to be statistically significant, unless specified otherwise. 
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3.3 RESULTS 
High Performance Liquid Chromatography (HPLC) assay 
Linearity of the response was shown by analyzing serial dilutions of a standard solution of RC-
101 in water ranging from 10 to 500 µg/mL (0.53 to 26.4 µM).  Results for the assay 
qualification are shown in Table 3-1.  The coefficient of regression (R²) and the residual (%) 
from the observed values to the calculated standard curve were calculated.  Precision was 
determined from the standard deviation (CV) of the response areas from ten injections of a low 
concentration solution of RC-101 (10 µg/mL).  The Limit of Detection (LOD) was determined as 
three times the ratio of area standard deviation to the slope of the calibration curve (140).  Limit 
of Quantitation (LOQ) was evaluated as 10 times the area standard deviation to the slope of the 
calibration curve (140).  Repeatability was demonstrated by analysis of calibration curves on 
different days, and reproducibility was measured by analyzing calibration curves on different 
instruments by different analysts.  The results demonstrate that the method is suitable for the 
intended purposes. 
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Table 3-1. Qualification of HPLC method for RC-101 
Factor Criteria Result 
k 2<k<10 2.72 
N >4000 32501 
Rs >2 2.72 
T <1.5 0.986 
R2 >0.999 0.99973 
Residual < 10% 4.68% 
CV <1% 0.65% 
LOD  2.4 μg/mL (1.25 nM) 
LOQ  7.9 μg/mL (4.20 nM) 
 
Where k = retention factor, N = number of theoretical plates, Rs = resolution, T = tailing factor, R2 = 
coefficient of correlation, Residual = the average difference between the observed values for the 
standard and the calculated standard curve, CV = coefficient of variation of the response of 10 
injections, LOD = Limit of Detection, and LOQ = Limit of Quantification.   
 
A representative chromatogram of blank (water) and RC-101 (100 µg/mL) in water are 
shown in Figure 3-2 and Figure 3-1, respectively.  RC-101 eluted in 10 minutes. 
 
Figure 3-1. Representative HPLC chromatogram of blank sample (water). 
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 Figure 3-2. Representative HPLC chromatogram of RC-101 (100 µg/mL) in water at time 0. 
 
Stability - Effect of temperature 
The effect of temperature on the stability of RC-101 solutions (500 µg/mL in water, pH 5.7 ± 
0.3) is shown in Figure 3-3.  The graph represents the amount of RC-101 (% of the amount at 
time = 0) remaining at each time point.  Post hoc Bonferroni correction for multiple comparisons 
was applied and no statistically significance difference was observed for RC-101 stored at 25 and 
37 °C for a period of 13 days (p > 0.5).  Samples stored at 65 °C showed a significant decrease in 
the amount of RC-101 remaining over time.  However, at 24 h, the amount of RC-101 at 65 °C 
was not significantly lower than the amount observed at 25 °C (p > 0.07).  For the subsequent 
time points, the amount of RC-101 was statistically significantly lower than the amount at 25 °C 
(p < 0.04).   
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Figure 3-3. Effect of temperature on RC-101. 
RC-101 (500 µg/mL) in water stored over time at 25 °C (■), 37 °C (♦), and 65 °C (○), analyzed by 
HPLC (n=3) 
 
The log concentration versus time was plotted for each temperature condition (Figure 
3-4).  The slope of each curve was calculated to confirm the statistical results obtained from 
Figure 3-3, and to estimate the rate of degradation (rate constant, k) at each condition.  Chemical 
stability is generally expressed by rate constant to estimate rate of drug degradation.  Assuming 
first order kinetics, rate constant (k) can be calculated by the slope of the curve from a plot of log 
concentration versus time.   
Slope = -k / 2.303 
The calculated rate constant is used to predict stability for a longer time period.  Results 
show that at 25 and 37 °C, the slope of the curve was not statistically significant different than 
zero (p > 0.5); and the rate constant was zero.  This implies a stable molecule over time.  At 65 
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°C, a forced degradation temperature, the slope was -0.001 and it was statistically significant 
different than zero (p < 0.001).  The rate constant was 2.3 x 10-3 h-1, indicating degradation over 
time. 
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Figure 3-4. Log concentration of RC-101 versus time (h). 
Obtained from Figure 2-5 for each temperature condition 25 °C (■), 37 °C (♦), and 65 °C (○), 
analyzed by HPLC (n=3) 
 
To confirm the results obtained by HPLC, MALDI-TOF MS analysis were conducted 
with RC-101 (500 µg/mL) in water after 10 days incubation at room temperature, 37 °C, and 70 
°C.  The intensity (%) of the m/z fragments of RC-101 determined by MALDI-TOF MS are 
shown in Figure 3-5 for room temperature, Figure 3-6 for 37 °C, and Figure 3-7 for 70 °C.  The 
spectra show a fragment around 1890 m/z correspondent to RC-101 [M + H]+; a fragment at 948 
m/z correspondent to [M + H]2+, and the presence of a dimer (3,789.99).  No additional 
fragments were observed when compared to RC-101 in water at time 0.  The thermal degradation 
detected for RC-101 at 65 °C using HPLC assay (Figure 3-3) was not observed using MALDI-
TOF MS.  After incubation of RC-101 for 10 days at 70 °C, the spectrum did not contain any 
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additional fragments when compared with RC-101 incubated at room temperature.  Two possible 
reasons may play a role in the inability of MALDI-TOF MS spectra to display the degradation 
products.  First, if hydrolysis is occurring during thermal degradation, the molecule may lose that 
water during the ionization step of MALDI-TOF MS.  In that way, the m/z fragment of the 
hydrolyzed compound would appear in the spectrum with the same m/z ratio as RC-101.  The 
second explanation is the optimization of the method.  MALDI-TOF MS parameters have been 
optimized to detect the RC-101 ion.  Possibly, under thermal degradation, the degradation 
products are not detected because they are too small, or are ionized less efficiently than RC-101.  
The decrease in the parent peak (RC-101) observed by HPLC under thermal degradation 
suggests degradation of the peptide at higher temperatures (65 °C).  However, no indication of 
the mechanism of degradation could be concluded by MALDI-TOF MS. 
 
Figure 3-5. MALDI-TOF MS spectrum of RC-101 in water, exposed for 10 days at RT. 
100% intensity = 38291 counts 
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 Figure 3-6. MALDI-TOF MS spectrum of RC-101 in water, exposed for 10 days at 37 °C. 
100% intensity = 61027 counts 
 
 
 
Figure 3-7. MALDI-TOF MS spectrum of RC-101 in water exposed for 10 days at 70 °C. 
100% intensity = 39078 counts 
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Stability - Effect of pH 
Solutions were made at a concentration of 500 µg/mL in phosphate buffers (pH 3 to 12) and 
analyzed over time by HPLC (Figure 3-8).  The pH was confirmed before starting incubation at 
room temperature and at the end of the experiment.  The pH for each buffer solution after 
addition of RC-101 was no more than 0.5 units different than the initial buffer pH.  All solutions 
were stored in a glass container, as it was shown that no absorption to the container occurred 
during the period of time of the study.  RC-101 was stable over the pH range of 3 to 7, indicated 
by no loss of the parent peak in the HPLC.  Post hoc Bonferroni analysis for multiple 
comparisons was applied and no statistically significant decrease was observed over a period of 
10 days for the samples at pH 3, 4, and 7 (p > 0.83).  A significant decrease was observed for 
RC-101 at pH 12 phosphate buffer in the first 2 h (Figure 3-8), and degradation at this pH 
continued to occur over time.  Representative chromatogram of RC-101 exposed to phosphate 
buffer pH 4 is shown in Figure 3-9.  Loss of parent peak and generation of secondary peaks in 
the HPLC for RC-101 at pH 12 phosphate buffer were observed in the chromatograms (Figure 
3-10).    
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Figure 3-8. pH profile of RC-101 (500 µg/mL).  Concentration (µg/mL) versus time (h). 
RC-101 prepared in mM phosphate buffers pH 3, 4, 7 and 12. Analyzed by HPLC (n = 3). 
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Figure 3-9. HPLC chromatogram of RC-101 (500 µg/mL) exposed for 10 days at pH 4 buffer. 
 
 
Figure 3-10. HPLC Chromatogram of RC-101 (500 µg/mL) exposed for 48 h at pH 12 buffer. 
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The log concentration at each pH condition was plotted against time (Figure 3-11) for the 
calculation of the rate constant (k), as described in Section 3.3 (Stability - Effect of temperature).  
The rate constant for each pH value was calculated by the slope of the linear regression of the 
concentration versus time plot.  The results show that at pH 3, 4, and 7, the rate constant was not 
statistically significant different than zero (p > 0.27), indicating stability of RC-101 over this pH 
range.  However, at pH 12, biphasic degradation, defined by two rate constants, was observed.  
The rate constant values were calculated as 0.076 h-1 from time 0 to 12 h, and 0.051 h-1 from 
time 24 to 96 h.  Rate constant values at pH 12 indicate that RC-101 degrades over time at this 
pH condition. 
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Figure 3-11. pH profile of RC-101. Log Concentration versus time (h). 
Obtained from Figure 3-8 for each pH condition, analyzed by HPLC (n=3).  K1 and K2 are the rate 
constants that defined the biphasic degradation of RC-101 in pH 12 phosphate buffer. 
 
Circular Dichroism (CD) was conducted on phosphate buffer solutions of 500 μg/mL 
RC-101 at pH 3, pH 7, and pH 12 to verify changes in secondary structure.  CD spectra for each 
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pH are shown in Figure 3-12.  Under all conditions, the protein showed a random conformation, 
with a maximum absorbance at 230 nm and a minimum absorbance at 200 nm for pH 3, 205 nm 
for pH 7, and 210 nm for pH 12.  The peak shift in the wavelength and the loss of absorbance for 
pH 7 and pH 12 samples indicate a change in folding of the protein under these pH conditions. 
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Figure 3-12. CD spectra of RC-101 (500 µg/mL) under different pH conditions. 
Average of 3 individual spectra after subtraction of background control correspondent to each buffer 
solution (pH 3, 7, and 12 phosphate buffer)  
 
In addition to HPLC and CD, MALDI-TOF MS was performed to confirm stability at 
pHs 3 to 7 and degradation at pH 12 observed in the other analytical techniques.  Results for RC-
101 (500 µg/mL) exposed to pH 4 (Figure 3-13), pH 7 (Figure 3-14) and pH 12 (Figure 3-15) 
phosphate buffer for 10 days are shown.  An additional peak at 1915 m/z was observed at pH 4 
and 7, which is likely to be a sodium adduct from the buffer, a single charged specie [M + Na]+.  
Stability of RC-101 at pH 4 and 7 phosphate buffer was confirmed.  The faster degradation 
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observed at pH 12 in the HPLC and the conformational changes in the CD assay have been 
confirmed in MALDI-TOF MS, with the appearance of several smaller fragments (Figure 3-15).  
 
 
Figure 3-13. MALDI-TOF MS spectrum of RC-101 (500 µg/ml) in pH 4  
(10 mM phosphate buffer), after 10 days.  100% intensity = 44735 counts 
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 Figure 3-14. MALDI-TOF MS spectrum of RC-101(500 µg/ml)  in pH 7  
(10 mM phosphate buffer), after 10 days.  100% intensity =  30633 counts 
 
Figure 3-15. MALDI-TOF MS spectrum of RC-101(500 µg/ml) in pH 12  
(10mM phosphate buffer), after 48h.  100% intensity = 7116 counts 
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UV spectroscopy was conducted to evaluate the formation of insoluble aggregates at 
different pH buffers.  UV scans of RC-101 (500 µg/mL) in phosphate buffers pH 4, 7, and 12 
were conducted (Figure 3-16).  Similar scans were observed for RC-101 pH 4 and 7, indicating 
no formation of insoluble aggregates at these two pH buffers.  However, a small increase in the 
absorbance at RC-101 pH 12 buffer was observed in the range of 300 to 600 nm, implying the 
presence of insoluble aggregates.  No significant changes in the UV spectra were observed in all 
samples when analyzed after 1 week exposure to the buffers. 
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Figure 3-16. UV scans to determine the effect of pH and ionic strength. 
RC-101 solutions in water, pH 4, pH 7, and pH 12 buffers were analyzed by UV-spectroscopy at time 
0 to determine formation of insoluble aggregates.  A) Represent RC-101 solutions prepared in low 
ionic strength buffer (50 mmol/kg); and B) represent RC-101 solutions prepared in high ionic 
strength buffers (500 mmol/kg). 
 
Stability – Effect of ionic strength 
The effect of ionic strength on the stability of RC-101 (500 µg/mL) was evaluated by UV-
spectroscopy and results are shown in Figure 3-16.  Similar UV scans were observed for the RC-
101 solutions in high ionic strength buffers in water, pH 4 and pH 7.  However, in phosphate 
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buffer pH 12, high ionic strength, an increase in the absorbance from 300 to 600 nm was 
observed, indicating the formation of insoluble aggregates. 
 
Effect of hydrogen peroxide 
Effect of hydrogen peroxide (H2O2) on the stability of RC-101 (500 µg/mL) was evaluated in 
several concentrations of H2O2 as discussed in Section 2.4.  Briefly, forced degradation studies to 
evaluate oxidative effects are commonly conducted by exposing the molecule of interest to a 
solution of 3.0% H2O2 (144).  For a more biologically relevant level of H2O2, the concentrations 
were based on reports that determined the production of H2O2 by Lactobacillus present and 
calculations of the number of Lactobacillus present in the normal vaginal flora (146).  HPLC 
results of RC-101 (500 μg/mL) exposed to 0.002, 0.08 and 3.0% hydrogen peroxide are shown in 
Figure 3-17.  RC-101 was quickly degraded (more than 20% loss) over a 4-hour period when 
exposed to a 3.0% H2O2, which is a stressed condition used for preformulation studies.  When 
RC-101 was exposed to 0.002 and 0.08% H2O2, the loss detected by the HPLC was less than 
10% over a period of 24 h for both concentrations.  The data suggests that RC-101 is less 
susceptible to degradation by oxidative pathways than PSC-RANTES (Section 2.3). 
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Figure 3-17. Effect of H2O2 on RC-101 (500 µg/mL). Concentration (%) versus time (h). 
RC-101 exposed to 0.002, 0.08, and 3% hydrogen peroxide, stored at room temperature and analyzed 
over time by HPLC (n = 3). 
 
The log concentration at each oxidative condition was plotted against time (Figure 3-18) 
for the calculation of the rate constant (k).  The rate constant for each concentration of hydrogen 
peroxide value was calculated and the results show that the rate constant was 0.066 h-1 for 3% 
H2O2, 0.007 h-1 for 0.08%, and 0.003 h-1 for 0.002% H2O2, indicating that degradation of RC-101 
by oxidation occurs over time. 
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Figure 3-18. Effect of H2O2 on RC-101.  Log Concentration versus time (h). 
Obtained from Figure 3-17 for each concentration of hydrogen peroxide (0.002, 0.08, and 3%), 
analyzed by HPLC (n=3). 
 
HPLC chromatogram of RC-101 in the presence of 0.08% hydrogen peroxide after 120 h 
exposure is shown in Figure 3-19.  Loss of parent peak and the presence of additional peaks are 
observed and confirm the degradation by oxidation of RC-101.  
 
 100 
 Figure 3-19. Representative HPLC chromatogram of RC-101 (500 µg/mL) in 0.08% H2O2 
after 120 h exposure. 
 
MALDI-TOF MS was performed for RC-101 exposed to all three conditions of H2O2 
over time as an additional method to verify degradation pathways of RC-101.  MALDI-TOF MS 
spectra for RC-101 in 3% H2O2 for 24 h is shown in Figure 3-20.  MALDI-TOF MS spectra for 
RC-101 in 0.08% and 0.002% H2O2 for 168 h is shown in Figure 3-21 and Figure 3-22, 
respectively.  In all studies, the main peak corresponding to RC-101 (m/z = 1892) is still present 
at a maximum intensity.  However, the additional peak at m/z = 1988 is observed in all 
conditions tested and can be associated to oxidation degradation.  The difference between the m/z 
of these two peaks is 96, which can be associated to the incorporation of six atoms of oxygen.  
The disulfide bridges (R – S – S – R) in the peptide RC-101 are prone to oxidation.  It is possible 
that, in the presence of H2O2, the disulfide bridges in some of the RC-101 peptide underwent 
oxidation forming disulfide monoxide (R – SO – S – R), disulfide dioxide (R – SO2 – S – R), or 
sulfonic acid (R – SO3 – H). 
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 Figure 3-20. MALDI-TOF MS spectrum of RC-101 after 24 h exposure to 3% H2O2. 
100% intensity = 46676 counts 
 
 
 
 
Figure 3-21. MALDI-TOF MS spectrum of RC-101 after 168 h exposure to 0.08% H2O2. 
100% intensity = 34954 counts 
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 Figure 3-22. MALDI-TOF MS spectrum of RC-101 after 168 h exposure to 0.002% H2O2. 
100% intensity = 56864 counts 
 
Protective effect of excipients 
In the previous sections, it has been identified that oxidation is the major degradation pathway 
for RC-101.  Oxidation of RC-101 may disrupt the disulfide bridges, changing secondary 
structure of the peptide and affecting bioactivity.  Considering that this peptide will be 
administered vaginally in an environment that contains hydrogen peroxide, protection against 
oxidation is necessary.  A range of antioxidants from different pharmaceutical classes have been 
tested.  Most of the antioxidants studied did not show a significant protective effect against 
oxidation in the presence of hydrogen peroxide.  When analyzed by HPLC, oxidative 
degradation of RC-101 was faster in the presence of antioxidants than without them.  EDTA was 
the only antioxidant investigated that showed protection of RC-101 against oxidation after 
exposure to H2O2 (Figure 3-23).  Ethylenediaminetetraacetic acid (EDTA) is a widely used 
chelating agent, approved by the Food and Drug Administration (FDA) as a preservative for 
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pharmaceutical products.  RC-101 in the presence of EDTA was exposed to 0.002% H2O2 and 
compared to RC-101 without EDTA in HPLC analysis.  About 10% loss of RC-101 was 
observed after 30 days of exposure in the presence of EDTA, when compared to 40% loss of RC-
101 after 7 days in the absence of EDTA. 
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Figure 3-23. Effect of H2O2 in RC-101 stability in the presence and absence of EDTA.  
Concentration versus time (days). RC-101 (500 µg/mL) exposed to 0.002% H2O2 over a period of 30 
days, analyzed by HPLC (n = 3). 
 
Effect of enzymatic activity 
Further studies with RC-101 were conducted to verify potential for degradation in the presence 
of the three most common enzymes present in the vaginal fluid.  The same experimental 
conditions used for the effect of enzymatic activity in Chapter 2, Section 2.2.7 were used for RC-
101.  RC-101 was exposed to aminopeptidase (100 units/mL), lysozyme (100 units/mL), and 
proteinase K (100,000 units/mL), and results for MALDI-TOF MS experiments are shown on 
Figure 3-24, Figure 3-25, and Figure 3-26, respectively.  No significant changes compared to the 
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MALDI-TOF MS spectrum of RC-101 in water prior to enzyme exposure have been found, 
indicating stability of the peptide in the presence of all enzymes tested. 
 
 
Figure 3-24. MALDI-TOF MS spectrum of RC-101 in the presence of aminopeptidase 
at 37 °C for 1 h.  Intensity = 6536 counts. 
 
 
Figure 3-25. MALDI-TOF MS spectrum of RC-101 in the presence of lysozyme 
at 37 °C for 1 h.  Intensity = 15272 counts 
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 Figure 3-26. MALDI-TOF MS spectrum of RC-101 in the presence of proteinase K 
at 37 °C for 1 h.  Intensity = 8437 counts 
 
Effect of freeze-thaw cycles 
RC-101 in solution was not affected by freeze-thaw after 5 cycles.  Samples were analyzed after 
each cycle.  Results of analysis by HPLC showed 97.7% of RC-101 remaining in solution after 5 
cycles (Figure 3-27).  This decrease was not statistically significant (ANOVA, p > 0.18).  
However, when the freeze-thaw samples were analyzed by Circular Dichroism, a slight shift in 
the wavelength and a change in the signal were observed in the CD spectra (Figure 3-28), 
suggesting that a change in the secondary structure may occur upon freezing.  In the other hand, 
this slight change in secondary structure does not significantly affect bioactivity, as tested by Dr. 
Cole (personal communication – Alexander Cole, Ph.D., University of Central Florida). 
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Figure 3-27. Effect of freezing-thaw cycles on RC-101 (500 µg/mL) in water 
analyzed by HPLC (n = 3). 
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Figure 3-28. CD spectra of RC-101 (500 µg/mL) in water before and after freezing. 
 (___) before freeze-thaw cycles, (- - -) after freeze-thaw cycles. Average of 3 individual spectra after 
subtraction of background control (water). 
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3.4 DISCUSSION AND CONCLUSIONS 
Recently, several biopharmaceuticals (proteins and peptides) have been investigated as potential 
microbicides for prevention of HIV (134, 152-154).  However, formulation and delivery of 
biopharmaceuticals can be difficult due to degradation.  A successful formulation will protect the 
peptide against degradation during the manufacturing process, during the shelf-life of the 
product, and after the protein enters the biological system (141, 142).  According to the Alliance 
for Microbicide Development (143), several needs in microbicide formulation are considered to 
have a high priority, which includes preformulation evaluation.  Preformulation studies will 
accelerate product development of a successful microbicide product.  The current study 
addresses this issue by identifying and characterizing the microbicide RC-101 to further 
understand its stability, which will impact formulation development and, eventually, efficacy of 
the product. 
RC-101 (MW = 1890.42) (GICRCICGKGICRCICGR) is a circular cationic 18-residue 
peptide (Figure 1-6), tetracyclic peptide with three cysteine disulfides bonds (107).  The amino 
acid sequence comprises 10 polar amino acids, 4 hydrophobic residues, and 4 basic residues. 
RC-101 proved to be stable in water, by HPLC analysis, at 25 °C over a period of 13 
days, and 7 days at 37 °C, which suggests that the peptide will be stable at body temperature for 
a prolonged period of time.  The stability of RC-101 at 25 and 37 °C has been confirmed by 
MALDI-TOF MS spectra showing the m/z peak correspondent to RC-101, and no presence of 
additional peaks.  At higher temperatures (65 °C), the stability of RC-101 was compromised, 
being determined by loss of parent peak in the HPLC.  However, MALDI-TOF MS technique 
was not able to detect fragments of thermal degradation, as explained in Section 3.3, suggesting 
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that the method was not suitable for detection of the degradation peaks.  Protein stability at high 
temperatures should be considered not only to understand how the drug will be affected in the 
body, but also how the compound will behave during the manufacturing process for the final 
product, in case that high temperature is required for processing, and to extrapolate shelf-life 
predictions or enhance degradation rates.  The data showing that RC-101 is susceptible to 
degradation at 65 °C indicates that the manufacturing process of a RC-101 microbicide product 
should avoid prolonged exposure of the drug to high temperatures.  However, chemical stability 
of RC-101 under temperature conditions is superior to several other proteins studied that showed 
fast thermal degradation at temperatures higher than 40 °C (155-157). 
The peptide RC-101 was shown to be stable in phosphate buffer solutions pHs 3, 4 and 7 
using HPLC assay.  Stability at different pHs is helpful in the development of a microbicide 
product.   For instance, the stability of RC-101 in acidic pH will be important due to the drug 
being exposed to the acidic environment of the normal vaginal pH (3.5 to 5.0).  In addition, since 
the peptide is stable from pH 3 to pH 7, it expands the pH range for formulation of the 
microbicide product, and upon exposure to semen.  Stability over the pH range of 3 to 7 was 
confirmed by MALDI-TOF MS, where no additional fragments were observed.  UV 
spectroscopy results for RC-101 with high ionic strength buffers did not show any significant 
differences in stability profiles, increasing the flexibility for formulation development.  The 
secondary structure of RC-101 was also preserved in the pH range from 3 to 7, as observed by 
CD.  The spectrum obtained by CD for RC-101 in pH 3 and 7 showed a random conformation; 
similar to the spectrum obtained for the natural defensin Retrocyclin, indicating stability of the 
peptide (102). 
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The development of a successful peptide microbicide product is primarily dependent on 
the ability to prevent the oxidative effects of H2O2, present in the vaginal lumen. The stability of 
RC-101 was investigated under different levels of hydrogen peroxide.  Forced degradation 
studies to evaluate oxidative effects are commonly conducted by exposing the molecule of 
interest to a solution of 3.0% H2O2 (144).  RC-101 quickly degraded in the presence of 3.0% 
H2O2 (20% loss in 4 h); however, the degradation was much slower when compared to the 
immediate degradation observed for PSC-RANTES (Chapter 2).  In the presence of more 
biological relevant concentrations (0.002% and 0.08% H2O2), the degradation rate was slower.  
The amount of H2O2 selected was based on reported studies which determined the amount of 
hydrogen peroxide produced by Lactobacillus present in the normal vaginal flora, and estimated 
calculations based on concentrations of Lactobacillus present (145, 146).  RC-101 amino acid 
sequence contains six cysteines which are prone to oxidation; however the cysteines are present 
in their oxidized form, decreasing the likelihood of oxidative degradation.  The intramolecular 
disulfide bonds may further oxidize resulting in sulfenic acid.  The oxidation of the cysteine 
residues is a metal-ion catalyzed oxidation reaction.  In the presence of EDTA, this oxidative 
mechanism was decreased by chelation of EDTA with metal ions, eliminating the cysteine 
oxidation.  Further formulation development may include the addition of EDTA.  However, 
preliminary studies have shown that EDTA is toxic to human ectocervical tissue and normal 
vaginal microflora in concentrations of 1% or higher.  Due to this fact, this preservative should 
be further characterized regarding its potential for toxicity in vivo.   
Protection of RC-101 against oxidation may be necessary during the shelf-life of the final 
formulation and during the delivery in the vaginal lumen.  The result from the addition of EDTA 
to the RC-101 solution is indicative of a method to protect RC-101 from oxidation during shelf-
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life of the product.  The use of the preformulation data in the development of a suitable 
microbicide formulation is further discussed in Chapter 5.  In a biological environment, when the 
microbicide product is administered intravaginally, it will encounter the presence of vaginal 
fluids and cervical mucus that will not only dilute the microbicide agent, but also be a potential 
for degradation.  The enzymatic activity present may initiate degradation of the peptide, in 
addition to the normal vaginal flora that produces hydrogen peroxide which will accelerate 
oxidation of RC-101.  Our studies have shown that RC-101 is susceptible to oxidation, but in a 
very slow kinetic of degradation.  Depending on the time for binding of RC-101 to receptors and 
glycoproteins, oxidation of RC-101 after 48 h may be an irrelevant degradation pathway and 
may not affect bioactivity.  It is still unknown how long the drug should be active in the vaginal 
lumen, but it has been suggested that the virus stays in the vaginal lumen for a period of 48 h (66, 
158, 159).  If that is the case, short-term protection of RC-101 may be sufficient to overcome 
oxidative degradation pathways in the vaginal lumen and guarantee biological activity. 
Another concern during preformulation studies for peptide microbicide product 
development is the presence of enzymatic activity in the vaginal lumen.  As discussed in Chapter 
2, proteins and peptides will be prone to degradation when in contact with enzymes present in 
vaginal fluids.  The most common enzymes in vaginal fluid are aminopeptidases, proteinases, 
and lysozyme (54, 60-62).  A study was conducted to verify the potential for degradation of RC-
101 in the presence of these three enzymes.  RC-101 was shown to be much less sensitive to 
enzymatic degradation than PSC-RANTES (Chapter 2), analyzed by MALDI-TOF MS.  This 
indicates that RC-101 will be more stable when in the presence of human vaginal fluid.  Further 
experiments exposing RC-101 to human vaginal fluid and cervical mucus collected from healthy 
female volunteers were conducted and are discussed in Chapter 4.  These fluids were incubated 
 111 
with RC-101 at 37 °C and analyzed by LC-MS/MS, to verify stability of RC-101 in biological 
fluids. 
Overall, RC-101 was stable over a wide range of pH, temperature and presence of 
hydrogen peroxide.  Some degradation pathways were identified, such as thermal degradation at 
high temperature (65 °C), hydrolysis at very alkaline conditions (pH 12), and oxidation at high 
concentrations of hydrogen peroxide (3%) or prolonged time with low concentrations of H2O2, 
which can be partially protected in the presence of antioxidant EDTA.  Furthermore, enzymatic 
degradation was not observed when RC-101 was exposed to the three most significant enzymes 
with regards to vaginal delivery.  This study has characterized the degradation pathways of RC-
101 under various conditions, which is essential for the development of an effective microbicide 
product.  The major degradation pathway identified is the oxidation of RC-101, and, as discussed 
above, it may not impact bioactivity, but still needs to be further characterized to verify its 
impact on shelf-life stability.  Compared to other proteins studied (138, 141, 156, 157, 160), RC-
101 is more stable at a larger range of pH and for a prolonged time over other stressed 
conditions.  We conclude that RC-101 has the potential to become a microbicide product and the 
properties of RC-101 have been further investigated and are shown in Chapters 4, 5, and 6. 
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4.0  EVALUATION OF RC-101 STABILITY IN THE PRESENCE OF HUMAN 
VAGINAL FLUID 
 114 
 4.1 INTRODUCTION 
Vaginal fluid covers the vaginal epithelium and is composed of secretions from the cervical 
vestibular glands, plasma transudate, and endometrial and oviductal fluids.  The fluid covering 
the vaginal mucosa protects against entry of pathogens into deeper tissues.  Periodic sloughing of 
mucus and underlying cells removes adherent microbes.  Cervical mucus has similar functions, 
and in addition facilitates sperm penetration by changing its viscoelastic properties during 
ovulation.  Properties of the mucus layer can either facilitate or impede the efficacy of a drug 
product.  It is important to study the impact of vaginal fluids on vaginal microbicide product 
functionality.  When a vaginal microbicide product is applied, its presence should not disrupt the 
natural protective mechanisms associated with the mucus layer, which also provides a target for 
bioadhesive products.  In some cases, vaginal fluids may be disadvantageous.  The presence of 
physiological fluids may alter the characteristics of a vaginal product, which can reduce the 
overall efficacy of the drug substance, increase leakage, and decrease drug  residence time at the 
target tissue (161).  More importantly, enzymatic activity and the presence of hydrogen peroxide 
produced by Lactobacillus will greatly affect the stability of microbicide agents, especially 
proteins and peptides.  This enzymatic barrier in vaginal fluid has been identified as a major 
barrier to the delivery and absorption of microbicides and other drugs (63). 
The interaction of microbicide drug candidates with human vaginal fluids can result in 
chemical modification of the drug by oxidation, hydrolysis, or proteolysis, thereby decreasing its 
potential for biological activity.  In addition, dilution of the microbicide agent with vaginal fluids 
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may affect its efficacy.  Biopharmaceuticals (proteins and peptides), as discussed in Sections 1.3 
and 1.8.1, when administered intravaginally might suffer degradation by several mechanisms, 
which include action of protease enzymes present in the vagina, and oxidation by hydrogen 
peroxide produced from Lactobacillus which are a major constituent of the normal vaginal flora.   
The peptide, RC-101, a potential microbicide drug, has been shown to prevent mucosal 
transmission of HIV-1 in vitro (102, 106).  RC-101 is a strong candidate for use as a microbicide 
product because of its activity against HIV and its stability in preformulation studies shown in 
Chapter 3.  In addition, previous studies have shown that RC-101 retained full activity in the 
presence of human vaginal fluid lavages (diluted 1:20) (109). 
The purpose of this study was to investigate the potential for degradation of RC-101, 
alone and formulated, when exposed to human vaginal fluids collected from healthy 
premenopausal female volunteers.  The abundance of RC-101 was monitored by liquid 
chromatography (LC) coupled online with tandem mass spectrometry (MS/MS) at specific time 
points after incubation with human vaginal fluids.  Demographics of the volunteer population 
were collected by application of a questionnaire which included questions about age, smoking 
and drinking status, race, and gynecological history.  All volunteers were tested for Chlamydia. 
trachomatis, Neisseria gonorrhoeae, and bacterial vaginosis. 
 116 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Retrocyclin-1 (RC-101) was synthesized by the Peptide Synthesis Facility at the University of 
Pittsburgh (Pittsburgh, PA).  Urea was purchased from Spectrum Laboratory Products Inc. 
(Gardena, CA).   Polyvinyl alcohol (PVA) was obtained from Kuraray America Inc. (New York, 
NY).  Hydroxypropylmethylcellulose (HPMC) was obtained from Sigma (St. Louis, MO).  
Glycerin was obtained from Dow Chemical Company (Midland, MI).  All other chemicals were 
purchased from Fisher Scientific (Fair Lawn, NJ).  
4.2.2 Human vaginal fluid collection protocol 
Human vaginal fluid (HVF) was collected from 79 healthy volunteer, premenopausal women, 
between the ages of 19 and 45 years old, mean (± S.D.)  31.3 (± 7.6), according to approved 
Institutional Review Board (IRB) protocol #07050142.  After a phone screening (Appendix B.1), 
eligible volunteers were scheduled to participate in the research study.  Volunteers were asked to 
abstain from sexual intercourse and not to use any vaginal products for a period of 48 h prior to 
fluid collection.  After signing informed consent, volunteers were submitted to a urine pregnancy 
test using Sure-Vue® (Fisher Healthcare, Houston, TX).  If the result was positive, the subject 
was informed and excluded from the study.  If the result was negative, the subject proceeded 
with the study by answering a questionnaire.  The subject then received the Instead Softcup® 
(Instead Inc., La Jolla, CA) device and instructions on how to use it.  Instead Softcup® is a FDA 
approved device used to hold menstrual fluid during the menstrual period in replacement of a 
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tampon or pad.  Volunteers inserted the cup and waited for 30 min.  After this time period, a 
physician removed the cup, and placed it into a 50 mL conical centrifuge tube.  Human vaginal 
fluid (HVF) collected from healthy volunteer women was stored at 4 °C until used.  All samples 
were used within 4 h after collection.  HVF collected contained approximately 40% of its weight 
in sloughed epithelial cells, which were separated from the supernatant after incubation period 
with RC-101. 
After removing the Instead Softcup®, a speculum examination was performed.  Swab 
specimens of the endocervix were obtained using the Mini-tip Culturette TN collection system 
(Becton Dickinson, Sparks, MD) according to the manufacturer's guidelines.  Testing for C. 
trachomatis and N. gonorrhoeae was conducted using an amplified DNA assay based on the 
simultaneous amplification and detection of target DNA amplification primers and a fluorescent 
label detector probe (162).  Bacterial vaginosis (BV) testing was conducted by using the Gram 
stain method and assessed by the Nugent score, where score results between 0 and 3 indicate a 
normal flora, between 4 and 6 indicates an intermediate state, and between 7 and 10 indicates 
bacterial vaginosis (163).  Volunteers were notified by the physician of the test results by 
telephone within two weeks of collection, and directed to the Allegheny County Public Health 
Department (Pittsburgh, PA) for treatment and additional testing, if needed.   
4.2.3 Method development 
Preparation of RC-101 solution and film  
RC-101 100 μg/mL solutions were prepared by dissolving RC-101 in Milli Q water.  RC-101 
and placebo films were prepared by the method described in Chapter 5.  Briefly, a quick-dissolve 
vaginal film formulation containing RC-101 was prepared by casting a polymeric film solution 
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into an 8-well-plate (dimensions: 26.7 x 33.3 mm/well).  A polymeric film solution was prepared 
by adding Milli Q water, PVA, and Hydroxypropylmethylcellulose (HPMC).  Next, the solution 
was heated at 95 °C for 20 min for complete dissolution of the polymers.  After cooling, glycerin 
and RC-101 were added.  Film solution (2.4 g) containing RC-101 was poured into each well of 
the 8-well plate.  The plate was placed into a vacuum oven at 30 ± 2 °C for 20 ± 4 h.  All dried 
films were removed from the plates and stored at room temperature in PET/Aluminum foil 
pouches (Amcor Flexibles Healthcare Inc, Mundelein, IL) until further analysis.  Placebo films 
were prepared in the same way without the addition of RC-101.  Each RC-101 film contained 
100 μg of RC-101.  For analytical purposes, films (RC-101 and placebo) were dissolved in 1 mL 
of Milli Q water before addition to HVF. 
 
Preparation of RC-101 + HVF sample 
The Instead Softcup® containing HVF and the conical tube were centrifuged for 10 min at 5,000 
rpm.  HVF was then removed from the cup and the pH of each HVF sample was measured with 
Fisher Alkacid pH filter strips (Fisher Scientific).  All samples collected on a specific day were 
pooled to be used for the research studies.  If the pH of the individual samples was higher than 5, 
which is indicative of the presence of bacterial vaginosis (BV), the sample was not included in 
the pool but it was stored at –80 °C for separate analysis.  If the sample contained blood, it was 
immediately discarded. 
Samples were prepared as described in Table 4-1, and are detailed as follows.  Samples 
A, control blank samples, were prepared by combining HVF with water.  Samples B, RC-101 
solution test, were prepared by combining RC-101 solution (100 µg/mL in water) with HVF.  
Samples C, RC-101 solution control, were prepared by combining RC-101 solution (100 µg/mL 
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in water) with water.  Samples D, RC-101 film test, were prepared by dissolving RC-101 100 
µg/film in 1 mL of water and then combining with HVF.  Samples E, RC-101 100 µg/film 
control, were prepared by dissolving one film in 1 mL of water and then combining with water.  
Samples F, placebo film test, were prepared by dissolving one placebo film in 1 mL of water and 
then combining with HVF; however, due to the limited amount of HVF, this sample was not 
prepared.  Samples G, placebo film control, were prepared by dissolving one placebo film in 1 
mL of water and then combining with water.  All samples (RC-101 solution, RC-101 film or 
placebo film) were combined with vehicle (HVF or water) in a ratio of 1:1.  Because of its high 
viscosity, HVF was measured by weight and not by volume.  All solutions were prepared fresh 
and incubated with HVF (or water) at 37 °C for specific periods of time (0, 2, 6, 12, 24, 48, and 
72 h), unless specified otherwise. 
To evaluate the influence of freezing the fluid prior to the analysis, the last pool of HVF 
was divided into two samples: one used fresh (at the time of collection), and the other one stored 
at -80 °C for a 3-month period.  After that time period, HVF was thawed and processed for blank 
and RC-101 solution only, as described in Table 4-1.  For control blank samples, frozen HVF 
was combined with water (Sample AF).  For RC-101 solution with frozen HVF, RC-101 (100 
µg/mL in water) was combined with HVF frozen (Sample BF).  All solutions were prepared fresh 
and incubated with HVF (or water) at 37 °C for specific periods of time (0, 2, and 48 h). 
HVF samples collected with a high pH value indicative of BV were stored at -80 °C as 
previously mentioned.  After confirmation of BV on those fluid samples by Gram stain score, the 
fluid samples (HVF BV+) were thawed, pooled, and processed as described in Table 4-1.  For 
control blank samples, HVF BV+ was combined with water (Sample ABV+).  For RC-101 
solution with HVF BV+, RC-101 (100 µg/mL in water) was combined with HVF BV+ (Sample 
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BBV+).  All solutions were prepared fresh and incubated with HVF (or water) at 37 °C for 
specific periods of time (0, 2, 6, 24, and 48 h). 
Table 4-1. Summary of RC-101, in solution and formulated, samples combined with HVF. 
 
Sample 
Code 
 
Sample  
Description 
 
 
HVF 
RC-101 
(100 μg/mL) 
SOLUTION 
 
 
Water 
RC-101  
100 μg/ 
FILM* 
 
Placebo 
FILM* 
A Blank HVF 100 mg ----- 100 mg ----- ----- 
B RC-101 solution  
combined with 
HVF 
100 mg 100 mg ----- ----- ----- 
C RC-101 solution 
control 
----- 100 mg 100 mg ----- ----- 
D RC-101 film  
combined with 
HVF 
100 mg ----- ----- 100 mg ----- 
E RC-101 film 
control 
----- ----- 100 mg 100 mg ----- 
F Placebo film  
combined with 
HVF  
Not 
performed 
  
----- ----- ----- ----- 
G Placebo film 
control 
----- ----- 100 mg ----- 100 mg 
AF Blank HVF frozen 100 mg ----- 100 mg ----- ----- 
BF RC-101 solution  
with frozen HVF  
100 mg 100 mg ----- ----- ----- 
ABV+ Blank HVF BV 
positive 
100 mg ----- 100 mg ----- ----- 
B BV+ RC-101 solution  
with HVF  BV+ 
100 mg 100 mg ----- ----- ----- 
Amounts correspond to one time point.  
*RC-101 film and placebo film were initially dissolved in 1 mL of water prior to addition to HVF.  Amounts 
in the films columns correspond to the solution of the film in 1 mL of water.  
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Sample processing 
At each time point, the sample was removed from the incubation chamber and centrifuged for 10 
min at 10,000 rpm, at 4 °C to separate the supernatant from cell pellet.  Supernatant (100 μL) 
was added to microcentrifuge filters Ultracel YM-10 Microcon MWCO 10,000 (Millipore 
Corporation, Bedford, MA), which were pre-washed with Milli Q water to eliminate any trace of 
propylene glycol from the filters.  Samples were centrifuged twice for 15 min at 8,500 rpm, at 4 
°C.  The filtrate was collected and frozen at –80 °C until further analysis.  A solution of 3 M urea 
was added to the cell pellet (1:1 w/w) obtained from the first centrifugation, to lyse the cells.  
This mixture was vortexed three times for 30 sec, and then centrifuged for 10 min at 10,000 rpm, 
at 4 °C.  The supernatant from the cell lysate was then added to microcentrifuge filters Ultracel 
YM-10 Microcon MWCO 10,000 pre-washed with Milli Q water.  Samples were centrifuged 
twice for 15 min at 8,500 rpm, at 4 °C.  The filtrate was collected and frozen at –80 °C until 
analysis.  The peptide RC-101 has been shown to be stable in 3 M urea for at least 24 h.   
Samples were thawed and added to PepCleanTM C-18 spin columns (Pierce 
Biotechnology Inc., Rockford, IL) for desalting, after column conditioning with 
acetonitrile:water (50:50) and equilibration with 0.1% trifluoroacetic acid.  The column was 
washed three times with 0.1% trifluoroacetic acid, and RC-101 was eluted with acetonitrile:water 
(60:40) in 0.1% trifluoroacetic acid.  Samples were dried in a speed vacuum CentriVap 
concentrator (LabConco Corp., Kansas City, MO) and resuspended with 200 µL of Milli Q water 
for LC-MS/MS analysis.  Each sample described in Table 4-1 originated two sets of samples: 
one labeled as supernatant and the second one labeled as cells.  LC-MS/MS chromatogram in the 
results (Section 4.3) show separated chromatograms for supernatant and cells. 
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4.2.4 Nanoflow LC Selected Reaction Monitoring Mass Spectrometry 
Integrated electrospray ionization (ESI)-capillary reversed-phase columns (75 μm inner diameter 
x 360 μm outer diameter x 100 mm length) packed with 5 μm 300 Å pore size Jupiter C18 
reversed-phase stationary phase (Phenomenex, Torrance, CA) were prepared, as previously 
described (164).  Solvent flow was supplied by a nanoflow HPLC system (Ultimate 3000, 
Dionex Corporation, Sunnyvale, CA).  Each sample (3 µL) was loaded onto the column through 
a 5 µL loop at a flow rate of 0.5 µL/min in 98:2 mobile phase A (0.1% formic acid in water, v/v) 
and mobile phase B (0.1% formic acid in acetonitrile, v/v) for 30 min.  The step-wise linear 
gradient was delivered at 250 nL/min as follows: 2 to 40% mobile phase B over 40 min, 
followed by 40 to 98% mobile phase B over 30 min.  High voltage contact for ESI was provided 
through a metal union connecting the microcapillary column to the pump.  The RC-101 peptide 
abundance was measured by selected reaction monitoring (SRM) using a triple quadrupole MS 
(TSQ Quantum Ultra, Thermo Fisher Scientific Inc., San Jose, CA).  While operating in SRM 
mode, Q1 and Q3 resolutions were set to 0.7 atomic mass unit (amu), and the collision induced 
dissociation (CID) gas pressure was 1.5 mTorr with a collision energy (CE) of 18 volts.  Each 
SRM scan width was set to 0.002 m/z units and the scan rate was 0.020 sec.  Data were analyzed 
by construction of mass chromatograms for each SRM transition separately, and peak areas were 
manually tabulated.   
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4.3 RESULTS 
Demographics of the volunteers enrolled in the study 
To this date, 117 volunteers have been screened over the phone (for phone screening script see 
Appendix B.1), and 83 volunteers have signed the consent form and were enrolled in the study. 
However, 4 participants withdrew from the study prior to sample collection.  Information 
collected from these 4 volunteers was not used in the study.   
A total of 79 human vaginal fluid collections were made from premenopausal women.  
Since the main objective of this study was to evaluate the stability of RC-101 in the presence of 
HVF, some of the volunteers gave more than one sample in different days, but always one 
sample only per day.  All volunteers reported to be not pregnant at the date of the fluid 
collection, and this information was confirmed by urine pregnancy test.  None of the participants 
were using a vaginal ring or Intra Uterine Device (IUD) as contraceptive.  None of the volunteers 
tested positive for either C. trachomatis or N. gonorrhoeae.  The mean age of the volunteers that 
completed the study was 31 ± 8 years; the age distribution is displayed in Figure 4-1.  The 
average pH (n = 62) was 4.5 ± 0.6, the pH distribution is shown in Figure 4-2.  The majority of 
the volunteers were Caucasian; and the race distribution is shown in Figure 4-3.  A large 
percentage of the volunteers (49.4%) did not use any type of contraceptive (Figure 4-4); and 
when used, condoms were the most often contraceptive method used.  The day of the menstrual 
cycle on which the samples were collected, was calculated based on the information reported in 
the questionnaire by the volunteer about the first day of their last menstrual period (Figure 4-5).  
The bacterial vaginosis (BV) score for each individual is presented in Figure 4-6.  All other 
information obtained from the questionnaire was complied and is presented in Table 4-2.  
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Figure 4-1. Age distribution frequency of volunteers enrolled in the study. 
based on the answers provided in the questionnaire. 
 
 
Figure 4-2. Distribution frequency of individual pH values determined for each fluid sample 
collected for the studies.   
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Figure 4-3. Distribution (%) of the volunteers by race. 
Based on the answers provided in the questionnaire. 
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Figure 4-4. Distribution (%) of the volunteers by contraceptive method used. 
Based on the answers provided in the questionnaire. 
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Figure 4-5. Day of the menstrual cycle at the collection day.  
Calculated for each volunteer based on the answers provided in the questionnaire. 
 
 
 
Figure 4-6. Distribution of Bacterial Vaginosis (BV) Nugent score. 
Determined by Gram stain testing for each individual sample collected. 
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Table 4-2. Compiled data from answers provided in the questionnaire for each volunteer. 
 
Characteristic No (%) 
Last alcohol consumption 
    Within 2 days 
    Between 2 and 7 days 
    More than 7 days prior 
    Never 
    Did not answer the question 
 
 
10 (12.7) 
25 (31.6) 
37 (46.8) 
  4   (5.1) 
  3   (3.8) 
Smoking status 
    Never 
    Smoking 
    Quit less than 1 year ago 
    Quit more than 1 year ago 
 
 
39 (49.4) 
15 (19.0) 
  2   (2.5) 
23 (29.1) 
Sexually active 
    Yes 
    No 
 
61 (77.2) 
18 (22.8) 
 
Last sexual intercourse 
    Between 2 and 5 days prior 
    6 or more days prior 
    Not sexually active or did not answer the question 
 
 
23 (29.1) 
40 (50.6) 
16 (20.3) 
Age of the first menstrual period 
    8 – 10 
    11 – 13 
    14 – 16 
 
 
10 (12.7) 
53 (67.1) 
16 (20.2) 
 
Duration of the period 
    1 – 3 
    4 – 5 
    6 – 7 
    Continuous pill or Depo-Provera 
 
 
18 (22.8) 
49 (62.0) 
  9 (11.4) 
  3   (3.8) 
 
Duration between periods 
    15 – 20 
    21 – 26 
    27 – 32 
    33 – 35 
    Continuous pill or Depo-Provera 
 
  5  (6.3) 
12 (15.2) 
56 (70.9) 
  1   (1.3) 
  5   (6.3) 
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Characteristic (Continuation) No (%) 
Currently using vaginal products 
    Yes (more than 2 days prior) 
    No 
 
  3   (3.8)  
76 (96.2) 
 
Gynecological problems 
    None 
    Ovarian cysts or polycystic ovary 
    Uterine Fibroid 
    Did not answer the question 
 
 
73 (93.6) 
  4   (5.1) 
  1   (1.3) 
  1   (1.3) 
Gynecological procedures 
    None 
    Removed one ovary 
    Tubal ligation 
    Did not answer the question 
 
 
72 (91.1) 
  2   (2.6) 
  2   (2.6) 
  3   (3.8) 
Previous pregnancies 
    Never 
    Once 
    Twice 
    3 or more 
     
 
50 (63.3) 
  6   (7.6) 
16 (20.3) 
  7   (8.9) 
Medical conditions 
   No 
   Yes* 
 
61 (77.2) 
18 (22.8) 
 
Current medications 
    None 
    OTC** 
    Prescription drugs*** 
 
42 (53.2) 
27 (34.2) 
16 (20.2) 
 
 
*Medical conditions reported: anemia, anxiety, bipolar-disorder, blood clot, depression, high cholesterol, 
hypertension, and pain. 
**OTC drugs reported: acetaminophen, allergy medicine, fish oil, ibuprofen, multivitamin and mineral 
supplements, naproxen sodium, and nasal spray. 
***Prescription drugs reported: amlodipine, atenolol, atorvastatin, almotriptan malate, bupropion, 
escitalopram, metformin, sertraline. simvastatin, trazodone, varenicline (Chantix), and warfarin. 
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Initial samples collected from healthy volunteers were used for method development.  
Several challenges were encountered during analytical method development.  The presence of 
interfering peaks from the fluid eluting at the same time in the HPLC with the RC-101 peak 
made it impossible for analysis using HPLC assay.  Several approaches for sample purification 
prior to HPLC analysis were evaluated using different conditions for solid phase extraction, ion 
exchange microcentrifuge columns, and molecular weigh microcentrifuge filters (data not 
shown).  After development of the method for LC-MS/MS, samples from volunteers were pooled 
on the day of collection generating 3 pools (Pool 1, 2 and 3) for normal HVF, and one pool (BV 
pool) for HVF positive for BV.  Samples were used as detailed in Table 4-1.  All the other data 
obtained from the questionnaire was compiled for each pool and is presented in Table 4-3. 
 
Table 4-3. Compiled data from answers provided in the questionnaire  
for each volunteer enrolled in the study, per sample pool.  
Characteristic Pool 1 Pool 2 Pool 3 BV Pool 
Age 
    Mean ± SD 
 
 
28.7 ± 6.7 
 
30.6 ± 8.9 
 
33.2 ± 7.8 
 
35.2 ± 5.2 
pH 4.1 ± 0.3 4.3 ± 0.3 4.1 ± 0.4 
 
5.8 ± 0.6 
BV score 
    Between 0 and 3 
    Between 4 and 6 
    Between 7 and 10 
 
 
3 (75.0) 
1 (25.0) 
0 
 
5 (71.4) 
2 (28.6) 
0 
 
3 (50.0) 
1 (16.7) 
2 (33.3) 
 
 
0 
1 (25.0) 
3 (75.0) 
Race 
    African American 
    Asian 
    Caucasian 
    Hispanic 
    Other 
 
0 
0 
4 (100.0) 
0 
0 
 
1 (14.3) 
1 (14.3) 
4 (57.1) 
1 (14.3) 
0 
 
0 
1 (16.7) 
5 (83.3) 
0 
0 
 
4 (100.0) 
0 
0 
0 
0 
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Characteristic (continuation) Pool 1 Pool 2 Pool 3 BV Pool 
Last alcohol consumption 
    Within 2 days 
    Between 2 and 7 days 
    More than 7 days prior 
    Never 
 
 
1 (25.0) 
1 (25.0) 
2 (50.0) 
0 
 
 
1 (14.3) 
3 (42.9) 
2 (28.5) 
1 (14.3) 
 
0 
0 
5 (83.3) 
1 (16.7) 
 
0 
1 (25.0) 
2 (50.0) 
1 (25.0) 
Smoking status 
    Never 
    Smoking 
    Quit less than 1 year ago 
    Quit more than 1 year ago 
 
 
0 
1 (25.0) 
1 (25.0) 
2 (50.0) 
 
4 (57.1) 
0 
0 
3 (42.9) 
 
3 (50.0) 
0 
0 
3 (50.0) 
 
3 (75.0) 
1 (25.0) 
0 
0 
Sexually active 
    Yes 
    No 
 
4 (100.0) 
0 
 
4 (57.1) 
3 (42.9) 
 
5 (83.3) 
1 (16.7) 
 
 
4 (100.0) 
0 
Last sexual intercourse 
    Between 2 and 5 days prior 
    6 or more days prior 
    Not sexually active 
 
 
1 (25.0) 
3 (75.0) 
0 
 
1 (14.2) 
3 (42.8) 
3 (42.8) 
 
2 (33.3) 
3 (50.0) 
1 (16.7) 
 
2 (50.0) 
2 (50.0) 
0 
 
Age of the first menstrual period 
    8 – 10 
    11 – 13 
    14 – 16 
 
 
1 (25.0) 
3 (75.0) 
0 
 
1 (14.3) 
5 (71.4) 
1 (14.3) 
 
1 (16.7) 
5 (83.3) 
0 
 
1 (25.0) 
2 (50.0) 
1 (25.0) 
Duration of the period 
    1 – 3 
    4 – 5 
    6 – 7 
    Continuous pill or Depo-Provera 
 
0 
3 (75.0) 
1 (25.0) 
0 
 
2 (28.6) 
4 (57.1) 
1 (14.3) 
0 
 
1 (16.7) 
4 (66.7) 
1 (16.6) 
0 
 
0 
3 (75.0) 
0 
1 (25.0) 
 
Duration between periods 
    15 – 20 
    21 – 26 
    27 – 32 
    33 – 35 
    Continuous pill or Depo-Provera 
 
 
 
 
0 
0 
4 (100.0) 
0 
0 
 
2 (28.6) 
0 
4 (57.1) 
0 
1 (14.3) 
 
1 (16.6) 
0 
4 (66.7) 
1 (16.7) 
0 
 
1 (25.0) 
0 
2 (50.0) 
0 
1 (25.0) 
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Characteristic (continuation) Pool 1 Pool 2 Pool 3 BV Pool 
Currently using vaginal products 
    Yes (more than 2 days prior) 
    No 
 
 
0 
4 (100.0) 
 
0 
7 (100.0) 
 
0 
6 (100.0) 
 
0 
4 (100.0) 
Gynecological problems 
    None 
    Ovarian cysts or polycystic ovary 
 
4 (100.0) 
0 
 
7 (100.0) 
0 
 
5 (83.3) 
1 (16.7) 
 
 
4 (100.0) 
0 
Gynecological procedures 
    None 
    Tubal ligation 
    Did not answer the question 
 
4 (100.0) 
0 
0 
 
6 (85.7) 
0 
1 (14.3) 
 
5 (83.3) 
0 
1 (16.7) 
 
2 (50.0) 
2 (50.0) 
0 
 
Previous pregnancies 
    Never 
    Once 
    Twice  
    Thrice    
 
3 (75.0) 
0 
1 (25.0) 
0 
 
 
6 (85.7) 
0 
1 (14.3) 
0 
 
4 (66.7) 
0 
2 (33.3) 
0 
 
0 
1 (25.0) 
1 (25.0) 
2 (50.0) 
 
Medical conditions 
   No 
   Yes* 
 
 
4 (100.0) 
0 
 
7 (100.0) 
0 
 
6 (100.0) 
0 
 
3 (75.0) 
1 (25.0) 
Current medications 
    None 
    OTC** 
    Prescription drugs*** 
 
2 (50.0) 
2 (50.0) 
0 
 
4 (57.1) 
2 (28.6) 
1 (14.3) 
 
4 (66.7) 
1 (16.7) 
1 (16.7) 
 
 
4 (100.0) 
0 
0 
* Medical condition reported: hypertension 
**OTC drugs reported: acetaminophen, allergy medicine, fish oil, ibuprofen, multivitamin and mineral 
supplements, naproxen sodium, and nasal spray. 
***Prescription drugs reported: amlodipine, atenolol, atorvastatin, almotriptan malate, bupropion, 
escitalopram, metformin, sertraline. simvastatin, trazodone, varenicline (Chantix), and warfarin. 
 
The distribution of the day of the menstrual cycle for pools 1, 2, 3, and BV pool are 
shown in Figure 4-7, Figure 4-8, Figure 4-9, and Figure 4-10, respectively.  Pool 1 and 3 showed 
that the majority of women were in the secretory phase of their menstrual cycle, while pool 2 and 
BV pool were mostly in the proliferative phase. 
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Figure 4-7. Distribution frequency (%) of the day of the menstrual cycle for Pool 1. 
 
 
 
Figure 4-8. Distribution frequency (%) of the day of the menstrual cycle for Pool 2. 
 133 
 
Figure 4-9. Distribution frequency (%) of the day of the menstrual cycle for Pool 3. 
 
 
Figure 4-10. Distribution frequency (%) of the day of the menstrual cycle for BV pool. 
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Nanoflow Liquid Chromatography Selected Reaction Monitoring (SRM) Mass Spectrometry 
RC-101 peptide abundance was measured by selected reaction monitoring (SRM).  Initially, 
confirmation of the peptide detection was obtained on a high resolution Orbitrap mass 
spectrometer (Thermo Scientific). The initial base peak chromatogram with a representative 
mass spectrum of the [M + 4H]4+ RC-101 molecular ion is shown in Figure 4-11. 
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Figure 4-11. LC-MS/MS of RC-101 (1 µg/mL) solution in water. 
 
After the incubation period of RC-101 combined with HVF, each sample (described in 
Table 4-1) was removed from the incubation chamber and processed for LC-MS/MS analysis as 
described in Section 4.2.4.  For each condition analyzed, supernatant and cells, the LC-MS/MS 
chromatogram was obtained.  Representative LC-MS/MS chromatograms at time 0 are shown 
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for Sample A supernatant (blank HVF), Sample B supernatant (RC-101 solution + HVF), 
Sample C supernatant (RC-101 solution control), and Sample D (RC-101 film + HVF) in Figure 
4-12, Figure 4-13, Figure 4-14, and Figure 4-15, respectively.  RC-101 was detected at a 
retention time of 20.8 to 22.8 min.  Variation in retention time is attributed to the use of a 
capillary column and pre-column.  Sample A (HVF control) showed the presence of several 
peaks; however, no interference peaks were detected, indicating that the method was suitable for 
detection of RC-101.  For all other chromatograms, the m/z was confirmed for RC-101 detection.  
Representative LC-MS/MS chromatograms at time 0 are shown for Sample E supernatant (RC-
101 film control), and Sample G (Placebo film control) in Figure 4-16 and Figure 4-17, 
respectively.  No interference peaks were detected in the placebo film.  
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Figure 4-12. Sample A (blank HVF control) representative LC-MS/MS chromatogram 
of supernatant solution, at time 0.  
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Sample B (RC-101 solution + HVF) –
supernatant
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Figure 4-13. Sample B (RC-101 solution + HVF) representative LC-MS/MS chromatogram 
of supernatant solution at time 0. 
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Figure 4-14. Sample C (RC-101 control) representative LC-MS/MS chromatogram 
of solution at time 0. 
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Figure 4-15. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of supernatant solution at time 0. 
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Figure 4-16. Sample E (RC-101 film control) representative LC-MS/MS chromatogram 
of solution at time0.  
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Figure 4-17. Sample G (Placebo film control) representative LC-MS/MS chromatogram 
of solution at time 0. 
 
Representative chromatograms of solutions obtained from cell lysate for the initial time 
point (time 0) as well as the chromatograms at the end point of the experiment for all conditions 
tested are shown in Appendix C.  The area from the RC-101 peak was obtained for each time 
point and plotted in Figure 4-18 for the Sample B (RC-101 + HVF).  The area represents the total 
area of the peak for RC-101 obtained from the supernatant and cells samples.  Each pool 
represents the fluid from one day of collection.  Since the LC-MS/MS method developed is not a 
quantitative method, the amount of RC-101 was not obtained.  Overall, RC-101 was detected for 
48 h in two pools tested and up to 72 h in another pool tested.  To better illustrate the detection of 
RC-101 over time, representative LC-MS/MS chromatograms for Sample B supernatant solution 
are shown in Figure 4-19, Figure 4-20, and Figure 4-21, for 24, 48, and 72 h after exposure to 
HVF at 37 °C. 
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Figure 4-18. Area of RC-101 (supernatant + cells) obtained from Samples B. 
(RC-101 solution + HVF) for each pooled samples, at each time point. Average area of three 
injections + S.D.  
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Figure 4-19. Sample B (RC-101 + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 24 h incubation. 
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Figure 4-20. Sample B (RC-101 + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 48 h incubation. 
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Figure 4-21. Sample B (RC-101 + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 72 h incubation. 
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Detection of RC-101 was also observed when the RC-101 film was incubated over time 
with HVF.  The area from the RC-101 peak was obtained for each time point and plotted in 
Figure 4-22 for the Sample D (RC-101 film + HVF).  The area represents the total area of the 
peak for RC-101 obtained from the supernatant and cells samples.  Each pool represents the fluid 
from one day of collection.  As previously mentioned, LC-MS/MS method developed is not a 
quantitative method, so the amount of RC-101 was not obtained.  Overall, RC-101 from a film 
formulation was detected for 48 h in one pool tested and up to 72 h in another pool tested.  To 
better illustrate the detection of RC-101 over time, representative LC-MS/MS chromatograms for 
Sample D supernatant solution are shown in Figure 4-23, Figure 4-24, and Figure 4-25, for 24, 
48, and 72 h after exposure to HVF at 37 °C. 
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Figure 4-22. Area of RC-101 (supernatant + cells) obtained from Samples D. 
(RC-101 film + HVF) for each pooled samples, at each time point. Average area of three injections + 
S.D.  
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Figure 4-23. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 24 h incubation. 
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Figure 4-24. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 48 h incubation. 
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Figure 4-25. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of supernatant solution after 72 h incubation. 
 
The incubation period of two pooled samples (Pool 1 and Pool 3) differ from Pool 2.  The 
total incubation period of Pool 2 was 72 h, instead of 48 h as conducted for Pools 1 and 3, due to 
scheduling conflicts with volunteers and sample analysis.  Detection of RC-101 by LC-MS/MS 
was observed in duplicated pools for up to 48 h and in one pool for 72 h, indicating the stability 
of the peptide for at least 48 h.  Formulation of RC-101 into the film still maintained the stability 
of RC-101 over the same time period.  Overall, RC-101 was detected after exposure to HVF at 
least for 48 h, and no difference was observed for RC-101 in a solution or a film formulation. 
To verify if the freezing process would interfere with the stability of RC-101 in the fluid, 
frozen HVF was used for incubation with RC-101 solution (Sample BF).  Representative LC-
MS/MS chromatograms are shown in Figure 4-26 for the sample BF (RC-101 solution + HVF 
frozen) after 48 h exposure to HVF at 37 °C.  It was expected that RC-101 would be detected at a 
higher concentration when using frozen HVF, due to the decrease in enzymatic activity of the 
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fluid upon freezing.  Since the LC-MS/MS method is not quantitative, it was not possible to 
determine this difference in concentration. Figure 4-26 shows that RC-101 is detected in frozen 
HVF, suggesting that no detectable differences were observed in the peptide after incubation 
with frozen fluid.  The total area (supernatant + cells) of each sample was calculated and 
compared to the RC-101 using fresh HVF.  Frozen HVF combined with RC-101 solution utilized 
in the study (Sample BF) showed a slight difference in the stability of RC-101.  However this 
variability is within the variability observed in the LC-MS/MS method and may be an artifact of 
the analysis rather than a difference in the fresh versus frozen fluid.  The results show that RC-
101 was detected up to 48 h when frozen HVF was used.  
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Figure 4-26. Sample BF (RC-101 film + frozen HVF) representative LC-MS/MS 
chromatogram of supernatant solution after 48 h incubation. 
 
Stability of RC-101 over time was also investigated in bacterial vaginosis (BV) fluid 
obtained from volunteers (HVF BV+).  These samples were collected and stored at -80 °C, prior 
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to incubation with RC-101.  When RC-101 was combined with HVF BV+ Pool (samples BBV+), 
RC-101 was undetectable in the LC-MS/MS analysis at any time point studied, demonstrating 
that RC-101 was not stable in those fluids.  Representative LC-MS/MS chromatograms of 
supernatant solution from Sample ABV+ (blank HVF BV+), and sample BBV+ (RC-101 solution + 
HVF BV+) at time 0 are shown in Figure 4-27 and Figure 4-28, respectively.  No RC-101 was 
detected at any time point in the Samples BBV+ in either supernatant or cells.  Since this study 
was only conducted in one pool of BV samples, more studies are recommended to evaluate a 
larger pool of HVF BV+ samples to confirm this finding. 
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Figure 4-27. Sample ABV+ (blank HVF BV+ control) representative LC-MS/MS  
chromatogram of supernatant solution at time 0. 
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Figure 4-28. Sample BBV+ (RC-101 + HVF BV+) representative LC-MS/MS  
chromatogram of supernatant solution at time 0. 
 
Table 4-4.  Summarized results for detection of RC-101 by LC-MS/MS 
 Time (h) 
Sample Code Sample Description 0 2 6 12 24 48 72* 
A Blank HVF - - - - - - - 
B RC-101 solution combined with HVF + + + + + + + 
C RC-101 solution control + + + + + + + 
D RC-101 film combined with HVF + + + + + + + 
E RC-101 film control + + + + + + + 
G Placebo film control - - - - - - - 
AF Blank HVF frozen - - - - - - NA
BF RC-101 solution with frozen HVF + + + + + + NA
ABV+ Blank HVF BV positive - - - - - - NA
B BV+ RC-101 solution with HVF  BV+ - - - - - - NA
( - ) represents absence of RC-101 peak; ( + ) represents presence of RC-101 peak detected by LC-MS/MS. 
*only one pool of sample analyzed up to 72 h.  NA = not analyzed samples at this time point. 
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Overall, RC-101 detection by LC-MS/MS is summarized in Table 4-4, showing the 
detection of RC-101 after incubation with HVF for each time point. 
4.4 DISCUSSION AND CONCLUSIONS 
Few studies have investigated the interaction of simulated vaginal fluid and cervical mucus with 
microbicide candidates (161, 165-168).  In those studies, the physical and chemical properties of 
the vaginal microbicide product, as well as the bioactivity of the microbicide drug have been 
investigated.  However, only a few studies report the interaction of human and animal vaginal 
fluids with microbicide agents (109, 153, 169).  In addition, most of those studies use lavages or 
otherwise extensively diluted fluid, decreasing the concentration of enzymes present, and thereby 
underestimating the potential for degradation due to enzymatic activity.   
Several reports that involve the collection of human vaginal fluid and cervical mucus 
have been published (170-178).  The collection methods varied and reflected the objective of 
each respective study, and included: rotating a Dacron-tipped plastic applicator into the posterior 
vaginal fornix for 15 sec (171), holding sterile double-tipped swab into the posterior vaginal 
fornix for 20 sec until saturation (173), inserting a 4 mL syringe and rinsing with 0.9% sodium 
chloride (174), aspirating fluid from the endocervix with a long tuberculin syringe for tentative 
collection of pure cervical mucus (175), applying a Rovumeter vaginal aspirator in the posterior 
fornix (176), inserting a sterile gauze vaginally for 1 h (177), and inserting a menstrual collection 
device (Instead Softcup®) (178).  From the methods available in the literature, Instead Softcup® 
appeared to be the device most suitable for our study purpose.  In the study reported (178), 
among 27 samples, an average of 0.5 g of secretions (ranging from 0.1 to 1.5 g) was collected.  
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The Instead Softcup® enables a rapid and convenient collection of large volumes of undiluted 
cervicovaginal secretions. 
To understand the impact of vaginal fluids on the stability of RC-101, fresh human 
vaginal fluid was collected and the interaction between fluid and peptide was investigated.  An 
appropriate method to collect human vaginal fluid (HVF) was identified.  The vaginal 
microbicide product will encounter both vaginal fluid and cervical mucus.  Because it is difficult 
to collect those fluids separately, a method for the collection of both fluids combined was 
selected.  In these studies, HVF was collected by using an Instead Softcup®. 
Several factors such as menstrual status, oral contraceptive use, and age will affect the 
amount and characteristics of vaginal fluids.  A questionnaire was applied to all participant 
volunteers to characterize the demographics of the population, including: day of the menstrual 
cycle, drinking status, and smoking status.  Increase in estrogen levels is associated with increase 
in the amount of vaginal fluid and cervical mucus.  During ovulation, the mucus volume 
increases 10 to 20-fold, becomes less viscous, and has a higher oligosaccharide content.  Some 
studies have also reported an increase in the enzymatic activity during ovulation (48, 50, 179).  
However, Andersch-Bjorkman et al. studied the protein pattern of cervical mucosal secretions 
over the menstrual cycle and no correlative protein pattern was found (175).   Oral contraceptives 
(OC) may also play a role in the vaginal mucosa and fluid status.  However, a study examined 
thirty women before and after the use of oral contraceptive (for 2 months) to verify the effect of 
OC in the vaginal discharge, epithelium and flora (180).  It was found that OC did not change the 
gross colposcopic or histologic appearance of the vaginal epithelium or characteristics of vaginal 
or cervical discharge.  Vaginal flora essentially remained unchanged after 2 months of OC use 
(180).  Information about OC use was collected for our studies; however, due to the number of 
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volunteers used and the necessity to pool samples together to obtain a significant volume for the 
analysis, we were unable to make any conclusions regarding the OC use and the stability of RC-
101 in the fluids.  
Volunteers were not allowed to participate if they had had sexual intercourse in less than 
48 h before the time for collection.  This is a regular practice in collection of human vaginal fluid 
to avoid any contamination with semen in the fluids.  Macaluso et al. reported the identification 
of a marker in vaginal fluid, prostate-specific antigen (PSA), to determine condom failure (181).  
It was shown that in 24 h, mean PSA values were close to baseline levels, and in 48 h, no PSA 
was detected, suggesting that in 48 h there is no presence of semen in the vaginal fluid (181).   
Drinking and smoking may affect the amount of vaginal fluid and its characteristics.  
Mendelson et al. found that acute ingestion of vodka punch (0.7 g/kg ethanol) raised circulating 
estradiol levels by more than 50% in women in the follicular phase.  However, no significant 
changes in estrogen were observed when the same amount of alcohol was given in the luteal 
phase (182).  Increase in estrogen is associated with increase in the amount of vaginal fluid and 
cervical mucus.  In another study, Reichman et al. studied 30 premenopausal women randomized 
to receive either 30 g of alcohol or placebo beverage, nightly for 3 months.  After the chronic 
alcohol consumption, midcycle estradiol levels increased by 28%, plasma estrone by 21%, and 
urinary estradiol by 32% (183).   
The influence of smoking status on vaginal fluid has been investigated, and some 
epidemiologic studies suggest that female smokers have lower endogenous estrogen than 
nonsmokers (184-186).  It has also been suggested that the irritant and carcinogenic chemicals in 
cigarette smoke are toxic to normal vaginal flora.  These chemicals inhibit the synthesis of 
cytoprotective eicosanoids and alter the immune defense mechanism of vagina (186).  In 
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addition, smoking was found to induce accelerated exfoliation of cervicovaginal epithelial cells 
(184).  In our study, the sample size was insufficient to correlate any differences in vaginal fluids 
with behavioral status (drinking and smoking).  However, any future larger studies should take 
these factors into consideration.  
Enzymatic activity of vaginal fluids has still not been fully characterized.  
Aminopeptidases are the most abundant type of enzyme present in human vaginal mucosa, and a 
major contributor to protein and peptide degradation.  The aminopeptidase activity is located 
mainly in the cytoplasm, and the concentration/activity in the vaginal mucosa ranges from 0.5 to 
1.4 µmol substrate hydrolyzed/min/mg protein (187).  The identification and quantification of 
enzymes present are not very well established but lysozyme has also been identified in human 
cervical mucus (60).  Other enzymes, including aminopeptidases, are present in both vaginal and 
cervical secretions and their activity may also vary with the menstrual cycle (61, 62).  Recently, 
with the advances in proteomic analysis, determination of proteins and enzymes present in 
human cervical-vaginal fluids have been conducted.  In one study, most of the proteins identified 
in vaginal fluid were plasma components, such as: albumin, transferrin, apolipoprotein I, 
calgranulins A and B, and alpha-1-acid glycoprotein 1 (174).  Other studies have found similar 
results (171, 173, 174, 177, 188).  In the preformulation studies conducted in Chapter 3, Section 
3.3, we have shown that RC-101 was stable after incubation for 1 h at 37 °C to aminopeptidase, 
lysozyme, and proteinase K, providing an indication of stability of the peptide for a short time 
period in biological fluids. 
One of the caveats of all the studies for identification and quantification of enzymatic 
activity in HVF is that it was necessary to freeze the fluid collected before beginning analysis.  
The impact of the freezing process leads to a change in the enzymatic activity of the fluid, 
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contributing to the data obtained from these studies.  To evaluate the impact of freezing on the 
degradation pattern of RC-101, fluid pooled from one day of collection was analyzed prior and 
after freezing process.  Results suggest that RC-101 possess the same stability in HVF after 
freezing process as in fresh HVF.  No indication that freezing process alters the enzymatic 
activity of the HVF was obtained from this study.  However, it is recommended that further 
studies with fresh versus frozen fluid be evaluated in replicates to confirm this result.  
This is the first study in the microbicide field to evaluate a microbicide candidate using 
fresh HVF.  RC-101 was detected by LC-MS/MS assay at least 48 h after incubation with HVF 
at 37 °C.  In one of the pooled samples studied, RC-101 was detected up to 72 h after incubation 
with HVF.  No difference was observed between RC-101 in solution and RC-101 formulated 
into a film.  Both incubation samples showed the presence of RC-101 for at least 48 h, indicating 
presence of the peptide for this time period in HVF.  The results obtained in this study will 
promote a better understanding of the impact of human vaginal fluid on the microbicide product 
development and efficacy.  It is still uncertain how long a microbicide drug should be active in 
the vaginal lumen.  However, it has been suggested that the HIV stays active in the vaginal 
lumen for a period of 48 h (66, 158, 159).  This implies that any microbicide drug delivered in 
the vaginal lumen should be stable for at least this time period.  Other important points are the 
time required for HIV to bind to the receptors in the host cell and the time to infect immune host 
cells.  It has been observed by Gallo et al. (189) and Dimitrov et al. (190) that conformational 
changes observed between gp41 and CD4 takes around 15 to 20 min.  Another study by Hu et al. 
(158) have shown that SIV enters the vaginal mucosa within 60 min of intravaginal exposure, 
infecting primarily intraepithelial dendritic cells.  It is known that RC-101 binds with high 
affinity to glycoproteins preventing six-helix bundle formation of gp41 in a reversible process 
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(107).  If RC-101 can be detected in HVF for at least 48 h, it is suggested that RC-101 will be 
available for binding to gp120 during that time period, conferring protection against HIV.  The 
prolonged stability of RC-101 in HVF indicates that this molecule is a promising candidate to be 
delivered vaginally and survive the enzymatic activity present in the normal vaginal fluid.  
However, further studies in vivo are recommended to confirm the results obtained.  Another 
advantage of the stability of RC-101 for at least 48 h in HVF is the dose regimen selected for the 
microbicide.  The stability suggests that the final RC-101 microbicide product could be applied 
once every two days or once a day, without being coital-dependent.  This would increase patient 
adherence to the product, and would be more favorable to a successful product.  As a future 
recommendation, the RC-101 detected after incubation with HVF should be tested for bioactivity 
against HIV.  This bioactivity test is already planned to be conducted in the laboratory of Dr. 
Cole (University of Central Florida).  
The impact of HVF positive for bacterial vaginosis (BV) has also been investigated.  It 
has been shown that RC-101 was completely unstable in fluid positive for BV evidenced by the 
undetectable levels of RC-101 after exposure to HVF positive for BV at all time points.  Some 
studies have evaluated the difference between normal HVF and HVF positive for BV, and a 
difference in the enzymatic activity between a normal fluid and a BV positive fluid has been 
demonstrated (145, 191, 192).  BV is characterized by a reduction in vaginal colonization by 
Lactobacillus and an overgrowth of anaerobic gram-negative bacteria.  Intensive production of 
hydrolytic enzymes in BV may lead to a decreased mucosal barrier in the vaginal and cervical 
mucosa.  Glycosidases and proteases, produced by anaerobic gram-negative bacteria, are 
associated to the degradation of mucins in the HVF (192).  In addition to those enzymes, it has 
been shown that an increase in lactate dehydrogenase activity (191), and glycosulfatase (193) in 
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HVF is associated with BV patients.  The higher enzymatic activity found in BV can explain the 
immediate degradation of RC-101 in the presence of HVF positive for BV.  This finding is 
extremely important as a future study for the development of biopharmaceuticals and other 
molecules as microbicides.  Bacterial vaginosis is a highly prevalent condition, affecting almost 
one third of women between the ages of 14 and 49 years old in the United States, according to 
the 2001 - 2004 National Health and Nutrition Examination Survey (194).  Considering the high 
prevalence of BV, further studies should investigate the effects of HVF positive for BV on the 
stability of microbicide drug candidates. 
Overall, this study has shown that RC-101 is present in HVF for at least 48 h.  
Formulation of RC-101 into a film maintains the stability of RC-101 in HVF for the same time 
period, freezing may not affect the study of RC-101 stability, and HVF positive for BV will 
considerably affect the stability of RC-101.  As a continuation of this study, the in vitro activity 
of RC-101 against HIV-1 after exposure to HVF will be conducted to verify if activity is 
maintained.  The important findings from this project have shown that RC-101 is a promising 
microbicide candidate.  Further studies for RC-101 formulation development, permeability and 
tissue localization in human and monkey reproductive tracts were conducted and are discussed in 
Chapters 5 and 6. 
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5.0  RC-101 FORMULATION IN A QUICK-DISSOLVE POLYMERIC FILM 
 156 
 5.1 INTRODUCTION 
As discussed in Chapter 1, current therapeutic strategies to prevent transmission of HIV have not 
been completely successful.  Considering that many women are unable to negotiate condom use 
with their partners and are more susceptible to HIV, strategies to prevent heterosexual 
transmission of HIV must include female-controlled methods (11, 25).  One approach is the 
development of a vaginal topical microbicide product to be used before intercourse to prevent 
transmission and acquisition of HIV. 
RC-101 is a circular 18-residue peptide microbicide candidate. Throughout this 
dissertation work, it has been shown that RC-101 is stable under most of the conditions evaluated 
in the preformulation studies conducted (Chapter 3) and is stable in the presence of human 
vaginal fluid for a period of at least 48 h (Chapter 4), making this peptide a viable candidate as a 
topical vaginal microbicide.  Further development of RC-101 as a vaginal microbicide product 
requires its formulation into a viable dosage form that is suitable for the intended route of 
administration, acceptable to the patient, and able to maintain the stability of the peptide in the 
product during its shelf-life and in the biological environment.    
Most of the vaginal microbicides in development are formulated as hydrogels (120, 195).  
More recently, new dosage forms have been considered such as vaginal rings, tablets, ovules, 
and polymeric films (122-125).  The choice of dosage form is directly dependent on the physical 
and chemical characteristics of the microbicide drug, on patient acceptability, and on maintaining 
drug efficacy and targeting (123). 
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The successful formulation of biopharmaceuticals (proteins and peptides) is often 
challenging.  Due to their high susceptibility to degradation, protective strategies applied in their 
formulation may prevent peptide degradation and, consequently, preserve the activity of the 
product during its shelf-life and in the biological environment.  Semi-solids are the most 
frequently used vaginal dosage form.  However, a semi-solid product would not be suitable as a 
dosage form for RC-101.  If an aqueous semi-solid dosage form is developed, it would expose 
RC-101 to a significant amount of water accelerating the degradation of the peptide.  In Chapter 
3, it has been shown that the major degradation pathway of RC-101 is oxidation, which can be 
facilitated in the presence of water.  In addition, it was shown that the peptide is stable for 2 
weeks over a range of pH from 3 to 7.  This short-term stability indicates that RC-101 is stable; 
however, long-term stability storage in the final product formulation still needs to be evaluated.  
As an alternative, a non-aqueous based semi-solid product could be formulated.  However, the 
product would have very low patient acceptability and difficult miscibility in the fluids 
encountered in the vaginal lumen.   
Based on the characteristics of RC-101, an alternative dosage form was investigated.  
Polymeric films contain lower water content when compared to traditional gel formulations, and 
can provide rapid release of the drug from the delivery system in contact with cervicovaginal 
fluids.  In addition, polymeric films have several advantages: convenience for women to use 
without the need of an applicator, lower cost per dose, absence of messiness relative to current 
vaginal gel products, and increased stability of the drug. 
In this study, RC-101 was formulated into a quick dissolve polymeric film. Film 
assessment, ex vivo safety and in vitro efficacy studies using human ectocervical tissue, and in 
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vivo non-human primate safety studies were conducted.  Film characterization and stability were 
also assessed. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Retrocyclin-1 (RC-101) was synthesized by the Peptide Synthesis Facility at the University of 
Pittsburgh (Pittsburgh, PA).  Polyvinyl alcohol (PVA) was obtained from Kuraray America Inc. 
(New York, NY).  Glycerin was purchased from Dow Chemical Company (Midland, MI).  
Hydroxypropylmethylcellulose (HPMC) 6 cps was purchased from Sigma (St. Louis, MO).  
Ethylene diamine tetraacetic acid disodium salt (EDTA) was purchased from Spectrum 
Laboratory Inc. (Gardena, CA).  All other materials were obtained from Fisher Scientific (Fair 
Lawn, NJ) unless specified otherwise. 
5.2.2 Quantitative assay for RC-101 in film product 
An HPLC system (Waters Corporation, Milford, MA) was used for the analysis of RC-101 in the 
formulation as described in Section 3.2.2.  Briefly, the HPLC Waters system was equipped with 
an autosampler model 717 (Waters), a quaternary pump model 600 (Waters), and an ultraviolet 
(UV) detector model 2487 (Waters).  Separation of the RC-101 was achieved by using a Jupiter 
5 µ C5 column 4.6 x 250 mm, 300 Å (Phenomenex, Torrance, CA) protected by a guard 
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cartridge Widepore C5 4 x 3.0 mm (Phenomenex).  Empower PRO, Empower 2 software 
(Waters Corporation) was used to control the HPLC system.  
5.2.3 Formulation development 
RC-101 polymeric vaginal film manufacturing 
A quick dissolve polymeric vaginal film formulation containing RC-101 was developed.  
Vaginal films were prepared by casting a polymeric film solution into an 8-well-plate 
(dimensions: 27.5 x 33.5 mm/well).  Three film formulations were prepared; an initial film 
formulation (RC_F+LA) containing 0.8% (w/w) lactic acid to maintain an acidic pH to simulate 
the conditions found in the vaginal environment; a second formulation without lactic acid 
(RC_F); and a final optimized formulation (RC_F+EDTA) containing 0.05% (w/w) EDTA in 
an effort to protect RC-101 against oxidation.  Incorporation of EDTA in the RC-101 film was 
based on the results found in the preformulation studies.  It has been shown in Chapter 3 (Section 
3.3), that only 10% loss of RC-101 in 30 days is observed when in solution containing EDTA in 
the presence of hydrogen peroxide as compared to a 40% loss of RC-101 in 6 days without 
addition of EDTA. 
All three formulations contained a basic polymeric solution base prepared as described.  
The polymeric film solution base was prepared by adding 40 ml of Milli Q water into a beaker.  
PVA (3.0 g) was slowly added to water with mixing, using a magnetic stir bar; followed by the 
addition of 60 mg of HPMC.  The solution was heated for 20 min at 95 °C for complete 
dissolution of the polymers.  After cooling the solution to room temperature under mixing, 1.5 g 
of glycerin was added.  For RC_F+LA, 0.8% lactic acid was added and the films were prepared 
at a dose of 100 µg RC-101/film.  The second formulation, without lactic acid, was prepared at 
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two dose levels: 100 µg/film (RC_F100) and 2000 µg/film (RC_F2000).  The optimized 
formulation (RC_F+EDTA) was prepared by adding 0.05% EDTA, and RC-101 at a dose of 
100 µg RC-101/film.  The completed formulation solution (2.4 g) containing RC-101 was poured 
into each well of the 8-well plate.  The plate was placed into a vacuum oven at 30 ± 2 °C for 20 ± 
4 h for drying.  After this period of time, the films were removed from the plate.  Placebo films 
were prepared without the addition of RC-101.  All films were removed from the plates, 
weighed, and stored in PET/Aluminum foil pouches (Amcor Flexibles Healthcare Inc, 
Mundelein, IL) until further analysis. 
5.2.4 Formulation assessment 
5.2.4.1 Physical and chemical characterization 
Dimensions of the film (thickness, length and width) were determined using a digital micrometer 
caliper (Fisher Scientific, Fair Lawn, NJ).   
Disintegration was determined by placing the film into 3 mL of Milli Q water in a 
crystallization dish (50 x 35 mm).  The crystallization dish was rotated on an orbital shaker 
Rotomix Type 48200 (Thermolyne, Dubuque, IA) at 90 rpm, at room temperature, and the time 
to visual disintegration of the film was recorded. 
Determination of water content of the film was obtained by Karl Fisher titration using a 
758 KFD Titrino Metrohm (Brinkmann Instruments Inc., Westbury, NY).  Films were initially 
dissolved in 3 ml of dimethyl sulfoxide (DMSO) for a period of 20 h.  An aliquot (0.5 mL) of the 
dissolved film solution was weighed and added to the Karl Fisher titration vessel for moisture 
determination.  The water content of the DMSO was determined as a blank and the result was 
subtracted from the sample’s results.  Water content was expressed in percent (w/w).  
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Tensile strength of the films was evaluated using a texture analyzer TA.XT2 (Texture 
Technologies, Scarsdale, NY).  Films were held between two clamps positioned at a distance of 
4.85 mm.  During measurement, the films were pulled by the top clamp at a rate of 3 mm/sec 
until break point.  The force at the break point was recorded.  Tensile strength was calculated as:  
Tensile strength (N/mm2) = breaking force (N)/ cross-sectional area of sample (mm2) 
Stability studies were conducted to evaluate RC-101 content throughout the 
manufacturing process and storage.  Storage conditions used were: room temperature (25 ± 2 °C/ 
60 ± 5 % relative humidity (RH) and 40 ± 2 °C/ 75 ± 5% RH).  At each time point, films (n = 3) 
were removed from the packaging container, cut into six pieces, and dissolved into 0.5 mL of 
Milli Q water.  Each solution was analyzed in duplicate by the HPLC-UV method described in 
Section 5.2.2.  Results were expressed as percent (%) of RC-101 compared to amount of RC-101 
added per film.  
5.2.4.2 Efficacy studies 
In vitro efficacy studies using TZM-bl cells 
Each excipient of the film formulation as well as the film products were tested for bioactivity 
against HIV-1.  Experiments were conducted in the laboratory of Alexander Cole, Ph.D. 
(University of Central Florida, Orlando, FL).  Excipients were prepared and dissolved in 1 mL of 
water to obtain the final concentration equivalent to that contained in one film dissolved in 1 mL 
of water.  Each sample was further diluted with growth medium (GM) at the ratios of 1:10, 1:20, 
and 1:40 (v:v).  Activity of RC-101 against HIV-1BaL was determined using TZM-bl reporter 
cells and quantified for luciferase expression as previously described (196).  Briefly, cells 
(5000/well; 96-well plates) were treated with 50 µL of either plain GM or GM containing the 
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samples.  To each well, 50 µL of GM containing HIV-1BaL (2 ng of p24/ml) was added.  
Supernatants were then removed, and cells were lysed with 100 µL of 1x Glo Lysis Buffer 
(Promega Corporation, Madison, WI). Luciferase activity was measured using Bright Glo 
luciferase assay buffer (Promega).  Protection from infection was measured as the percentage of 
reduction in luciferase activity, relative light units (RLU), compared with the HIV-1BaL-infected 
control (vehicle only, no peptide).  To confirm that the observed reductions in luciferase activity 
were not due to toxic effects of RC-101 on the cells, the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assays were performed on identically treated TZM-bl cells.  
For placebo and RC-101 2000 µg films (RC_F2000), films were dissolved in 1 mL of GM and 
then processed as described above. 
 
Ex vivo efficacy studies using human ectocervical tissue 
Ex vivo efficacy studies were performed in the laboratory of Phalguni Gupta, Ph.D. (University 
of Pittsburgh, Pittsburgh, PA).  Human ectocervical tissues were obtained from premenopausal 
women undergoing hysterectomy.  The ex vivo efficacy studies were set up using an organ 
culture system previously described (67, 197).  Briefly, cells (5 x 105) were placed directly in the 
bottom chamber of the Transwell system (Corning Inc, Corning, NY).  A Transwell with agarose 
only in the top chamber served as a negative control, while Transwell with the membrane only 
served as a positive control.  To study the transmission of virus, a defined amount of pre-titered 
cell-free HIV-1 was added to the top chambers of the tissue and control wells and incubated at 
37 °C for 3 to 4 days.  After incubation, the top chamber of the well was removed and culture of 
CD8- depleted cells in the bottom chamber was continued for an additional 10 days.  Viral 
growth was monitored by measuring HIV-1 p24 antigen levels in the culture supernatant in the 
bottom chamber of the tissue well.  A 3-fold or greater increase in HIV-1 p24 during the 2-week 
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period was taken as positive virus infection of the CD8- depleted cells.  Suppression of viral 
transmission was measured by monitoring viral infectivity of transmitted HIV-1 in the bottom 
well, determined at day 14 of culture by measuring HIV-1 p24 in the culture supernatant of the 
bottom well. 
5.2.4.3 Ex vivo and in vivo safety and toxicity studies 
Excised macaque reproductive tract 
Reproductive tracts from sexually mature female Macaca nemestrina were obtained from a 
colony of animals at the Washington National Primate Research Center.  Prior approval for use 
of monkeys in this protocol was obtained from the Institutional Animal Care and Use Committee 
at the University of Washington.  Animals were handled humanely, and experiments were 
performed within the National Institutes of Health’s laboratory animal use guidelines.  Animals 
were sacrificed and the whole reproductive tract was removed and transported to Magee-
Womens Research Institute (Pittsburgh, PA) in ice within 24 h.  Upon arrival, the tissue was 
warmed to 37 °C and immediately used for the experiments.  
 
Ex vivo safety studies in full monkey reproductive tract tissue 
Safety of placebo films and RC-101 (100 µg) films were evaluated in full excised monkey 
reproductive tract.  The protocol was designed to simulate the experimental conditions used in an 
in vivo setting.  During an in vivo experiment, the animals are sedated and stay in a horizontal 
position for about 30 min.  For that reason, freshly excised monkey reproductive tissue was 
maintained in a horizontal orientation for the first 30 min after insertion of the film.  After that 
time, the tissue was oriented vertically for another 90 min.  Excised monkey reproductive tract 
was warmed to 37 °C, and placed in a 15 mm Petri dish containing 2 mL of Milli Q water.  The 
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film product was inserted into the vaginal cavity with a glass rod.  Full reproductive tract tissue 
was incubated for a total period of 2 h at 37 °C.  The tissue was then removed from the incubator 
and washed (4 mL of water, 10 times) by inserting a 5 mL syringe in the vaginal opening.  A 
cytobrush was inserted and gently rotated 6 times into the cervical os.  The cytobrush was then 
placed in 4 mL of water and vortexed.  The tissue was cut open and 6 mm (n = 3) biopsy samples 
were collected from each part of the tissue (lower vagina, middle vagina, upper vagina, 
transformation zone, endocervix, ectocervix, and uterus), and stained for histology. 
 
Excised human ectocervical tissue 
Freshly excised human ectocervical tissue was obtained from the Tissue Procurement Facility at 
Magee-Womens Hospital (Pittsburgh, PA), according to approved IRB protocol #0503103.  
Tissue was obtained from premenopausal women undergoing hysterectomy for benign 
conditions.  No specimens were used when there was evidence of tissue abnormality that could 
influence the state of the mucosa.  All tissue specimens were obtained within 1 h of surgical 
excision, and held at 4 °C in Dulbecco’s Modification of Eagles Medium (DMEM) (Mediatech 
Inc, Herndon, VA) during transfer from surgery to the laboratory.  Tissue samples were retained 
for histological evaluation for comparison before and after the experiment. 
 
Ex vivo safety studies in human tissue 
Ex vivo safety studies were conducted using a Franz-cell system, a two-compartment system 
consisting of an upper chamber (donor compartment) and a lower chamber (receptor 
compartment).  The Franz-cells were water-jacketed and the temperature was maintained at 37 
°C throughout the experiment via a circulating water bath.  DMEM was used in the receptor 
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chamber, continuously stirred by a magnetic stir bar.  Human ectocervical tissue was sandwiched 
between the two compartments with the epithelial side facing the donor solution.  The tissue was 
equilibrated with DMEM in the donor compartment for 5 min prior to the initiation of the safety 
study.  After the equilibration period, DMEM was removed from the donor compartment and 
replaced with 100 µL of vaginal fluid simulant (VFS) (198) and a 6 mm punch biopsy of a RC-
101 containing film (RC_F+LA, RC_F100, or RC_F+EDTA).  After a 2 h period, tissue 
samples were removed and processed for histological evaluations. 
 
Histological evaluations 
Histological evaluations were conducted on all tissue specimens tested.  Retained tissue from 
each test specimen was fixed for histology and processed to compare with post-experimental 
histology.  Tissue was fixed in Clark’s solution (ethanol-acetic acid (75:25)) for 24 h, transferred 
to ethanol and incubated for 24 h, and subsequently embedded in paraffin.  Tissue sections of 5 
µm were cut and stained with hematoxylin and eosin (H & E).  Histology was conducted to 
evaluate gross alterations in tissue morphology caused by exposure to the film product. 
 
In vivo safety evaluation 
Safety evaluations in animals were conducted by the laboratory of Dorothy Patton, Ph.D. 
(University of Washington, Seattle, WA).  A total of five sexually mature female Macaca 
nemestrina were obtained from a colony of animals at the Washington National Primate 
Research Center.  Prior approval for use of monkeys in this protocol was obtained from the 
Institutional Animal Care and Use Committee at the University of Washington.  Animals were 
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handled humanely, and experiments were performed within the National Institutes of Health’s 
laboratory animal use guidelines.   
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Figure 5-1. Study design for in vivo safety protocol. 
Application of RC-101 2 mg film in 5 animals, wash-out period of two weeks, application of placebo 
film.  Four consecutive (one per day) applications of film for each animal. Cytobrush was conducted 
only on day 5. Final assessments (cytobrush, pH, colposcopy, microbiology) conducted on day 8. 
 
Films were applied to the animals following the experimental design shown in Figure 
5-1.  Films of RC-101 2000 µg/film (RC_F2000) were assessed for safety with multiple vaginal 
applications and compared to a placebo film.  Each animal controls for itself by completing both 
arms of the study (first RC-101 and then placebo film).  Two experimental runs, each lasting 8 
days and evaluating five animals per arm, were conducted with a 2-week recovery time 
scheduled between runs.  Each animal received one film/day for a period of 4 days.  On study 
days 1 to 4, colposcopy assessments, swabs for vaginal pH, and microflora were obtained.  
Immediately following specimen collections, an intravaginal application of 1 film (RC-101 or 
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placebo) was administered to each animal.  Colposcopy, and vaginal swabs for pH assessment 
were collected 30 min after film application.  Colposcopy was conducted every day after 30 min 
of application and before the next day application.  On study days 5 and 8, colposcopy, and 
swabs for vaginal pH, and microflora were collected to document recovery.  Standardized 
colposcopic assessments were conducted by a team of three cross-trained individuals.  In order to 
document the appearance of the cervicovaginal tissues prior to potential tissue perturbation 
caused by sampling, colposcopy took place immediately after speculum placement before any 
swab collections.  Vaginal pH was determined by rolling a swab of vaginal secretions onto a pH 
indicator strip with a resolution of 0.5 pH unit.  A second vaginal swab was collected and 
immersed in a transport tube (Port-a-Cul; Becton Dickinson Microbiology Systems, 
Cockeysville, MD) for quantitative microbiologic characterization. Microbiologic 
characterization was conducted in the laboratory of Sharon Hillier, Ph.D. (Magee-Womens 
Research Institute, Pittsburgh, PA).   
5.2.5 Statistical analysis 
HPLC data obtained from the stability studies were expressed as the average percentage of the 
RC-101 concentration ± standard deviation (n = 3).  Results were analyzed by one-way analysis 
of variance (ANOVA) with comparisons of individual time points to time 0 by using Dunnett 
correction to detect significant differences. P-values ≤ 0.05 were considered to be statistically 
significant, unless specified otherwise.  Bioactivity data was expressed as average percentage 
suppression of the virus (n = 2). 
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5.3 RESULTS 
Formulation assessment 
The appearance of all films (placebo, RC_F+LA, RC_F100 and RC_F2000) was clear, without 
bubbles, flexible, no sharp edges, and with a smooth surface.  A summary of results of the film 
assessment tests for placebo and RC_F100 are presented in Table 5-1.   
 
Table 5-1. Summary of physical and chemical assessment of film formulation 
TEST Placebo film RC_F100 
Dimensions (mm) 27.5 x 33.5 27.5 x 33.5 
Thickness (mm) 0.192 ± 0.003 0.208 ± 0.005 
Weight (mg) 238.2 ± 9.3 240.2 ± 3.7 
Disintegration (min)     3.1 ± 0.5     4.8 ± 1.1 
Water content (%)        0.30 ± 0.04        0.46 ± 0.06 
Tensile strength (N/mm2)     5.22 ± 1.88      6.38 ± 1.30 
Amount RC-101 (%) N/A      96.2 ± 3.8 
 
The stability of RC-101 content in the films, determined by HPLC, when stored at 25 °C 
and at 40 °C/ 75% RH was evaluated by HPLC analysis.  Figure 5-2, Figure 5-3, and Figure 5-4 
show the RC-101 content (%) (average ± standard deviation) results of the stability study 
conducted for RC_F+LA, RC_F100, and RC_F+EDTA films, respectively.  In RC_F+LA and 
RC_F100, when stored at 40 °C/75% RH, RC-101 quickly degraded within the first month.  In 
the films containing lactic acid (RC_F+LA), 15% loss was observed after 90 days when stored 
at room temperature; and 50% loss of RC-101 was observed after 30 days when stored at 40 °C/ 
75% RH.  No RC-101 was detected in the films stored for more than 30 days at 40 °C/75% RH 
(Figure 5-2).  In the film formulation without lactic acid (RC_F100), 25% loss was observed 
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after 90 days when stored at room temperature; and 40% loss of RC-101 was observed after 30 
days stored at 40 °C/ 75% RH.  No RC-101 was detected in the films stored for more than 30 
days at 40 °C/ 75% RH (Figure 5-3).  Addition of EDTA to the RC-101 films (RC_F+EDTA) 
did not show a significant improvement in the stability of the drug, contradicting the results 
obtained in the preformulation studies. In the film formulation containing EDTA 
(RC_F+EDTA), 35% loss was observed after 45 days when stored at room temperature; and 
33% loss of RC-101 was observed after 30 days stored at 40 °C/ 75% RH.  No RC-101 was 
detected in the films stored at analysis at 90 days at 40 °C/ 75% RH (Figure 5-4).  It should be 
noted that although loss of parent peak (RC-101) occurred over time, no secondary peaks were 
generated in the HPLC.  Preliminary studies have shown that the bioactivity of RC-101 films 
after storage for 6 months, retain their activity against HIV-1 in vitro in more than 90% 
suppression of the virus (personal communication – Dr. Alexander Cole, University of Central 
Florida).  This result indicates that loss of RC-101 can be attributed to a mechanism of 
degradation different than oxidation or thermal degradation, and does not affect bioactivity.  
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Figure 5-2. Stability of RC-101 100 µg film containing 0.8% lactic acid (RC_F+LA). 
Analyzed by HPLC, n = 3, mean ± S.D. (■) 25 °C and (   ) 40 °C/ 75% RH.  No RC-101 was detected 
at 60 and 90 days stored at 40 °C/ 75% RH. *p < 0.002, Dunnett analysis for multiple comparisons.  
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Figure 5-3. Stability of RC-101 100 µg films (RC_F100). 
Analyzed by HPLC, n = 3, mean ± S.D. (■) 25 °C and (   ) 40 °C/ 75% RH.  No RC-101 was detected 
at 90 or 180 days stored at 40 °C/ 75% RH.  *p < 0.001, Dunnett analysis for multiple comparisons. 
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Figure 5-4. Stability of RC-101 100 µg films + EDTA (RC_F+EDTA). 
Analyzed by HPLC, n = 3, mean ± S.D. (■) 25 °C and (   ) 40 °C/ 75% RH.  No RC-101 was detected 
at 90 days stored at 40 °C/ 75% RH.  *p < 0.05, **p < 0.001, Dunnett analysis for multiple 
comparisons.  
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In vitro efficacy evaluations 
The toxicity and bioactivity of each excipient used in the film formulation was tested against 
TZM-bl cells.  MTT results are expressed as percentage viability (%) and are shown in Figure 
5-5 for each excipient used in the film formulation.  Figure 5-5 represents the average of two 
MTT determinations (n = 2).  Duplicates did not differ by more than 20%.  A media control 
(growth medium) was used for those studies.  Most of the excipients showed no difference in 
viability when compared to the blank vehicle (water) used to dissolve the excipients.  However, 
lactic acid showed toxicity as identified by the MTT assay, when compared to control (viability 
less than 30%). 
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Figure 5-5. MTT results for each excipient used in the film formulation. 
3 dilutions (1:10, 1:20, and 1:40), n = 2 for each dilution were tested. 
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The in vitro bioactivity of each excipient, demonstrated by the percent of HIV-1 
suppression is shown in Figure 5-6.  PVA and lactic acid showed activity against HIV, by 
showing HIV-1 suppression higher than 70% for PVA, and higher than 95% for lactic acid for 
the initial dilution.  Figure 5-6 represents the average of two bioactivity determinations (n = 2).  
Duplicates did not differ more than 10%.  Bioactivity observed for lactic acid, evidenced by the 
high HIV suppression, is most likely due its toxicity to the cells used in the test.  As shown in 
Figure 5-5, viability of cells after exposure to lactic acid is lower than 30%.  For this reason, 
lactic acid was removed from the formulation. 
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Figure 5-6. Suppression of HIV-1 (%) for each excipient used in the film formulation. 
3 dilutions (1:10, 1:20, and 1:40) were tested, n = 2 for each dilution.  
 
RC_F2000 and placebo films were tested for bioactivity using an in vitro and an ex vivo 
method.  For the in vitro method, RC_F2000 and placebo films were tested against HIV-1 using 
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the TZM-bl cell model to verify efficacy of these two formulations.  RC_F2000 films were 
further used in safety studies in vivo, as described in Section 5.3 (In vivo safety studies).  Results 
of HIV suppression (%) are shown in Figure 5-7.  A second graph was plotted using the log of 
the final RC-101 concentration (µM) of each dilution versus the suppression of HIV (%) (Figure 
5-8).  The IC90 and IC50 were determined from Figure 5-8 as the concentration that suppressed 
90% and 50% of HIV-1, respectively.  Log calculations estimated an IC90 of 5.0 µM, and an IC50 
of 2.2 µM.  Calculations of IC90 and IC50 are commonly used in determination of efficacious 
concentrations of a compound. 
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Figure 5-7. Suppression (%) of HIV-1 using TZM-bl cell in vitro model 
for RC_F2000 (RC-101 2000 µg/film) and placebo film.  Dilution factor represents how many times 
the sample was diluted in growth medium. 
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Figure 5-8. Suppression (%) of HIV-1 versus log RC-101 concentration (µM). 
RC_F2000 using TZM-bl cell in vitro model.  Continuous line shows IC90 at 90% HIV-1 suppression.  
Dotted line shows the IC50 at 50% HIV-1 suppression.  
 
RC_F2000 films were tested using the ex vivo explant model of human ectocervical 
tissue, and the results are shown in Figure 5-9.  Activity of RC_F2000 was observed up to a 20 
fold dilution of the films.  RC_F2000 films upon dilution of 100 times still demonstrated some 
effectiveness against HIV-1.  However, the suppression after 100 times dilution was around 
60%, which is below the minimal suppression required to be considered active against HIV-1 
when using this ex vivo explant method (89, 161).  A second graph was constructed by plotting 
the suppression of HIV-1 (%) versus the log of the final RC-101 concentration (µM) of each 
dilution (Figure 5-10).  Since the suppression values were greater than 60%, it was not possible 
to estimate the IC50.  In this case, only IC90 was calculated and it was estimated to be 57.5 µM.  
The IC90 result for RC_F2000 film using ex vivo model represents a 10 fold increase over the 
RC_F2000 film tested using an in vitro model (IC90 = 5.0 µM).  A decrease in IC90 observed 
between the models is expected.  In a cell-based assay (in vitro), target receptors for RC-101 are 
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readily available, requiring a lower concentration of the peptide for the same inhibition effect.  In 
contrast, in the ex vivo model, RC-101 must penetrate the tissue to attach to CD4+ cells in 
addition to being available to attach to the glycoproteins in the virus, requiring a higher 
concentration to achieve the same virus inhibition of 90%. 
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Figure 5-9. Suppression (%) of HIV-1 using human ectocervical tissue ex vivo model 
for determination of activity of RC_F2000 and placebo film. 
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Figure 5-10. Suppression (%) of HIV-1 versus log RC-101 concentration (µM). 
RC_F2000 using an ex vivo ectocervical tissue model.  Red line represents the IC90 at 90% 
suppression.  
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Ex vivo safety studies in human tissue 
Results presented in the efficacy section show that RC-101 is effective against HIV using in vitro 
and ex vivo models.  The next step is to determine if the formulated films are safe for female 
reproductive tract tissues.  RC-101 films were exposed to human ectocervical tissue using a 
Franz-cell model.  After 2 h exposure, tissues were removed and stained for histological 
evaluations.  Hematoxylin and eosin (H & E) staining conducted for tissues exposed to placebo 
film with lactic acid, or RC_F100, or RC_F+EDTA are shown in Figure 5-11, Figure 5-12, and 
Figure 5-13, respectively.  No gross changes in morphology were observed for all three samples 
when compared to the pre-exposure tissue or DMEM exposure, indicating that the RC-101 
formulations and placebo are safe to human ectocervical tissue.  Most importantly, when aliquots 
of the receptor phase of the Franz-cell system were analyzed by HPLC, no RC-101 was detected.  
This finding indicates that systemic uptake of RC-101 is not likely to occur.  Further experiments 
conducted with RC-101 films with human and monkey reproductive tissues to verify 
permeability of RC-101 through these tissues are detailed and discussed in Chapter 6. 
 
Figure 5-11. Histology results for Placebo film with lactic acid.  
Pre exposure tissue, post exposure (2 h) to DMEM, and post exposure (2 h) to placebo film containing 
0.8% lactic acid. 
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Figure 5-12. Histology results for RC_F100. 
Pre exposure tissue, post exposure (2 h) to DMEM, and post exposure (2 h) to RC_F100 film. 
 
 
Pre exposure     DMEM    RC_F+EDTA  
Figure 5-13. Histology results for RC_F+EDTA  
Pre exposure tissue, post exposure (2 h) to DMEM, and post exposure (2 h) to RC_F+EDTA film. 
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Ex vivo safety studies in full monkey reproductive tract  
Safety studies for RC-101 films were conducted in the Macaca nemestrina ex vivo model using 
full excised reproductive tract.  Figure 5-14 (a) shows the full reproductive tract of the excised 
monkey tissue.  Figure 5-14 (b) shows the histology (H & E staining) of the biopsies obtained 
from the monkey tissue after exposure to the RC_F+LA.  No gross morphological changes were 
observed throughout the whole reproductive tract after exposure to the films, suggesting that RC-
101 and placebo formulations are safe to full monkey reproductive tract. 
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 Figure 5-14. Safety studies in excised Macaca nemestrina reproductive tract tissue. 
(a) Picture of a full reproductive tract of Macaca nemestrina before experiment was conducted. 
(b) Histological evaluations of excised Macaca nemestrina reproductive tract tissue after exposure for 
2 h with RC_F+LA. Stained with H & E.  
 
In vivo safety studies 
Evaluation of RC-101 films in an in vivo animal model was conducted using a film containing 
RC-101 at a concentration of 2 mg/film. The higher dose of RC-101 in the films used in this 
study was selected for two reasons.  First, evaluation of safety of a product in vivo should be 
conducted at a higher dose to best verify the toxic effects, if any, of the product.  Second, the 
RC-101 dose selected to be used in in vitro studies may not reflect the final dose of the product 
that will be selected when used in vivo.   It is known that doses required for efficacy in vivo are 5 
to 10 times higher than doses required for efficacy in vitro.  For biopharmaceuticals, this increase 
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in dose can reach levels of 102 to 106 fold.  In our studies, the dose selected for RC-101 film 
safety study in vitro was 1000 times higher than the IC50 of RC-101 in vitro (196). 
In vivo safety evaluations were conducted as described in Figure 5-1, and Section 5.2.4.3.  
Colposcopy, pH and vaginal microflora determinations were the parameters used to evaluate 
safety of RC-101 films.  The colposcopy of the cervix of representative animals before film 
insertion (RC_F2000 or placebo film), at time 0, 30 min, and 24 h after the film insertion is 
shown in Figure 5-15.  Complete disintegration of the film was observed.  No visual changes 
were seen in the cervix following film exposure, indicating safety of the RC_F2000 film in in 
vivo animal models.  This procedure was repeated after each film application (total of 4 films) 
and no visual changes were observed in any of the colposcopic evaluations. 
 
 
Figure 5-15. Colposcopy results for placebo and RC-101 2mg/film (RC_F2000). 
Images from colposcopy examination of cervical and vaginal mucosa of non-human primates prior to 
insertion of films (placebo or RC_F2000), at time 0 after insertion, 30 min and 24 h after insertion.  
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Vaginal pH was monitored 30 min after film application and at days 5 and 8 after the last 
film application for continuous follow-up.  No significant changes in pH were observed after 
application of RC-101 film or placebo; the pH remained within the normal range of vaginal pH. 
Vaginal microflora examined showed detection of hydrogen peroxide-producing 
Lactobacilli, other Lactobacilli species, hydrogen peroxide Viridians, and black anaerobic gram 
negative rods.  Identification of the species was not performed.  A small decrease in lactobacillus 
was observed on days 2 and 3 of the study; however, full recovery to baseline levels was 
detected in the follow-up assessments.  Staphylococcus aureus was detected in 3 animals after 
exposure to RC-101 films, and in one animal after exposure to placebo films.  Microbiological 
evaluation of vaginal microflora after application of RC-101 and placebo films (days 1 to 4, 5 
and 8) revealed that no significant changes were observed in the flora composition evaluated 
prior to film application. 
5.4 DISCUSSION AND CONCLUSIONS 
Film formulation for vaginal drug delivery has several advantages over alternative formulations.  
When compared to semi-solid gels, film products are easy to apply, quickly release the drug, and 
can improve the stability of drugs that are sensitive to water.  In contrast, conventional vaginal 
gel dosage forms are often associated with limitations of poor retention in the vaginal lumen, 
leakage, and messiness.  In addition, there may be incompatibilities of peptide drugs with some 
conventional dosage forms.  Based on the advantages of vaginal films as a drug delivery system 
for microbicides, films were selected as the final dosage form of RC-101. 
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RC-101 was formulated into a quick dissolving polyvinyl alcohol (PVA) film.  PVA is a 
polymer prepared from polyvinyl acetate, primarily used in topical pharmaceutical formulations.  
It is generally regarded as a nontoxic material and it is approved by the Food and Drug 
Administration (FDA) for vaginal use.   
RC-101 film formulation was optimized to obtain the most suitable formulation that 
would assure RC-101 stability during the shelf-life.  Initial film formulations (RC_F+LA) 
contained 0.8% lactic acid in an attempt to maintain an acidic pH and thereby to simulate the 
conditions found in a vaginal environment.  There is a certain limitation for a polymeric film 
dosage form to maintain the vaginal pH.  In contrast to vaginal gels, the distribution and final 
volume of a film is dependent on the vaginal fluids present in the vaginal lumen.  Initial 
development of a vaginal film included lactic acid to maintain the acidic pH in the vagina; 
however no tests were conducted to confirm this idea.  Evaluation of stability of RC-101 in the 
film upon storage at 25 °C and 40 °C/ 75% RH showed loss of RC-101 content over time, 
indicating a short-term stability of this formulation.  Despite the fact that the film formulation 
was safe to be used in human ectocervical tissue, films proved to be toxic when used with TZM-
bl cells for determination of bioactivity.  When decomposition of the gel was conducted and 
individual excipients were analyzed, it was found that lactic acid was the component that was 
cytotoxic.  Lactic acid was removed from the formulation to avoid any toxicity to the cells 
during evaluation of in vitro activity against HIV-1.  Since RC-101 was shown to be stable over 
a range of pH 3 to 7 (Chapter 3), there were no detrimental effects on drug stability in the 
formulation without lactic acid.  The second formulation prepared without lactic acid 
(RC_F100) also demonstrated short-term stability of RC-101 over time, at 25 °C and at 40 °C/ 
75% RH.  A third formulation was prepared with the addition of EDTA as a chelating agent to 
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delay the oxidation process of RC-101.  As shown in the preformulation studies (Chapter 3), RC-
101 was stable for 30 days in the presence of hydrogen peroxide when EDTA was added to the 
solution.  EDTA is a common pharmaceutical excipient that sequesters metal ions with its 
carboxylate and amine groups.  Metal ions act as a catalyzer for cysteine oxidation, which are 
present in the peptide RC-101.  Films prepared in this study contained a concentration of 0.05% 
EDTA and displayed no toxicity when exposed to human ectocervical tissue using single 
exposure in an ex vivo model.  However, no chronic exposure to human ectocervical tissue was 
investigated and depending on the dose regimen for this product (coital-dependence), chronic 
exposure to the films should be evaluated.  Preliminary studies in our laboratory have shown that 
EDTA is toxic to the human ectocervical tissue in vitro and may affect normal vaginal flora at a 
concentration of 0.1% in solution. 
Films prepared with EDTA (RC_F+EDTA) did not show a significant improvement on 
stability results, as evidenced by a loss of RC-101 observed by HPLC over time.  About 30% 
loss of RC-101 was observed after films were stored for 45 days at room temperature, similar to 
what was observed in the films without EDTA.  The loss of RC-101 observed over time must be 
further investigated.  In the HPLC analysis of all three film formulations, no additional peaks 
have been observed that would indicate the mechanism of degradation of RC-101.  The HPLC 
method developed in Chapter 3 and used for stability studies in this chapter, is a stability 
indicating assay for RC-101 degradation by oxidative pathways and thermal degradation.  
Interestingly, preliminary studies have shown that the bioactivity of RC-101 films after storage 
for 6 months is maintained.  RC-101 films provided more than 90% suppression of the HIV-1 in 
vitro (personal communication – Dr. Alexander Cole, University of Central Florida).  This result 
indicates that disappearance of the RC-101 HPLC peak can be attributed to a mechanism of 
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degradation different than oxidation or thermal degradation, that does not affect bioactivity.  RC-
101 may be aggregating with the PVA polymer, decreasing detection of the parent peak by 
HPLC.  Further investigations of RC-101 stability in films are being conducted to: 1) confirm 
bioactivity of RC-101 films against HIV-1 over time to understand if modification of the drug 
compromises bioactivity; 2) evaluate interaction of RC-101 with other polymers to verify 
compatibility; and 3) identify other analytical methods that will facilitate extraction of RC-101 
from the polymer. 
In vitro HIV-1 efficacy studies have been used extensively to screen microbicide 
candidates.  Most of the in vitro methods published are cell-based assays to determine the 
suppression of HIV-1 by an investigational compound (15, 89, 199).  In our studies, we have 
investigated the efficacy of RC-101 films against HIV using an in vitro cell assay and an ex vivo 
model.  Results for in vitro assays show an IC90 of 5.0 µM, and an IC50 of 2.2 µM.  In one study 
reported to evaluate inhibitory concentration of RC-101 tested against 27 primary isolates of 
HIV-1, it was shown that the IC50 was less than 1.25 µg/mL (0.66 µM) (107).  Our results 
suggest that formulation of RC-101 into films required a concentration three times higher than 
RC-101 in solution for a 50% viral inhibition.  This increase in the IC50 may be attributed to the 
lower availability of RC-101 in the formulation as compared to solutions. 
More recently, ex vivo explant models using human ectocervical tissue (67, 81)  have 
been investigated to assess efficacy of microbicide candidates.  In a study by Cole et al., it was 
demonstrated that RC-101 (10 µM) prevented HIV-1 infection by more than 90%, in a 
biologically relevant explant model using cervicovaginal engineered epithelial tissue (109).  In 
our studies, RC-101 formulated into film evaluated in an ex vivo model displayed an IC90 of 57.5 
µM.  Results suggest that formulation of RC-101 into films required a concentration about 5 
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times higher than RC-101 in solution for 90% viral inhibition.  Again, the increase in the IC90 
may be attributed to the lower availability of RC-101 in the formulation when compared to 
solutions. 
An important objective of pharmaceutical drug development is to correlate in vitro with 
in vivo results.  Experiments conducted in this study have yielded the effective concentrations of 
RC-101 in the formulation to inactivate 90% of HIV-1 in an in vitro and in an ex vivo model.  
Values obtained in the ex vivo model were 10 fold greater than what was observed in the in vitro 
model.  An increase in inhibitory concentrations going from the in vitro to the ex vivo model is 
expected.  In the drug development process, efficacy and toxicity studies are conducted starting 
with less complex systems and progressing to systems of greater complexity, finally ending with 
human studies.  In vitro assays are used as a screening tool for new pharmaceutical compounds, 
followed by studies in small animals, larger animals, and ultimately clinical trials in humans.  Ex 
vivo models represent a higher degree of complexity than cell-based assays, but do not represent 
an ideal in vivo situation.  In microbicide development, ex vivo studies represent an alternative to 
investigate protection against HIV, and provide an additional screening tool.  A cell-based assay 
is constituted of a monolayer of cells and does not represent the squamous epithelial structure of 
ectocervical and vaginal mucosa.  Specifically for RC-101, in a cell-based assay (in vitro), target 
receptors for RC-101 are readily available.  RC-101 binds to gp120 of HIV and CD4 receptors in 
immune cells.  In contrast, in the ex vivo model, RC-101 must penetrate tissue before it can 
attach to the majority of CD4 receptors on immune cells, requiring a higher concentration to 
achieve the same virus inhibition of 90%.  In addition, non-specific binding of RC-101 to other 
proteins or to biological matrices in an ex vivo experiment may decrease the efficacy of the 
peptide.  As presented in Chapter 4, when RC-101 is combined with human vaginal fluids, the 
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peptide is found to be present in the supernatant of the fluid and also in the epithelial cells 
sloughed from the vaginal walls.  The binding of RC-101 to epithelial cells can decrease amount 
of RC-101 available to bind to glycoproteins.  On the other hand, the binding to epithelial cells 
may serve as a depot for RC-101 to be released later, prolonging the anti-HIV activity.  In 
addition, it can offer protection from HIV infection for epithelial cells, in case the theories that 
HIV can infect epithelial cells are correct, as discussed in Section 1.5.  Investigation of a 
microbicide candidate alone also results in different efficacy data when compared to a 
microbicide formulation.  Non-specific binding of RC-101 to the polymers of the formulation 
may require a higher concentration to achieve the same IC90.  Further studies should be 
conducted to evaluate the efficacy of RC-101 in animals.  An animal efficacy study is being 
planned and will provide valuable information for estimation of the in vivo dose. 
Evaluation of tissue (vaginal and cervical mucosa) damage caused by product exposure is 
part of the pre-clinical development of any successful vaginal formulation.  Preclinical activity 
and toxicity data are typically generated very early in the drug development process.  According 
to the FDA, this information then serves as the basis for a preliminary risk/benefit assessment to 
determine product suitability for Phase I/II clinical testing.  It is also recommended that 
toxicology studies be conducted in at least two animal species (one of which a non-rodent) and 
should use the intended route of exposure (i.e., vaginal administration), to assess acute, sub 
chronic and chronic toxicity.  The rabbit is typically the non-rodent species of choice for vaginal 
irritation studies (200-202) because of the similarity of the rabbit and human menstrual cycle and 
tissue morphology (41).  However, this model failed to predict the vaginal toxicity caused by 
nonoxynol-9 in humans (203, 204), which moved the microbicide field towards the development 
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of new models to assess toxicity.  Other animals studied are mice (205-207), and non-human 
primates (208). 
Before the use of animal models, an in vitro or ex vivo model is necessary to assess the 
safety of a formulation.  Excised human vaginal and ectocervical tissue has been extensively 
used in our laboratory to assess the changes in morphology after exposure to the vaginal 
microbicide solution or the final product formulation.  In the research presented in this chapter, 
none of the film formulations induced gross changes in morphology in human ectocervical 
tissue, indicating the relative safety of the formulation to human tissue. 
The pig-tailed macaque, Macaca nemestrina, has been used as a model for human 
vaginal and cervical physiology, safety, and for study of transmission of sexually transmitted 
infections.  Recently, this model has been applied to evaluate topical vaginal and rectal 
microbicides (209, 210).  It has been demonstrated that the vaginal microflora found in the M. 
nemestrina is very similar to the vaginal flora in humans (210).  However, some limitations to 
the model apply.  In contrast to the human vagina, the pig-tailed macaque has a smaller vaginal 
depth (4 cm), and a cervical diameter of 1.5 cm (209).  Human vagina has a depth of 7 cm, and a 
cervical diameter of 3.25 cm.  Another limitation of this model is the vaginal pH range, which is 
4.0 to 8.5 in the macaque compared to 3.5 to 5.0 in humans (209).  Even with these limitations, 
the macaque model is still the closest model to humans available for safety studies.  When the 
animal safety protocol for RC-101 films was being developed, a pilot study to determine the 
appropriate size of the film was conducted.  Placebo films were prepared in three different sizes 
and sent to Dr. Patton (University of Washington) for evaluation in monkeys.  Films were 
inserted vaginally and disintegration time was determined.  Small films were very difficult to 
manipulate and started to form a gel prior to complete insertion.  In this study it was shown that 
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the smallest sized film (7 x 11 mm) dissolved in 30 min, the medium sized film (11 x 16 mm) 
dissolved in 45 min and the largest sized film (21 x 32 mm) dissolved in 60 min.  Even though 
the largest film took the longest to dissolve, films continued to be formulated at the largest size, 
because of the difficulty in manipulating smaller film sizes in the macaque model. 
Our in vivo studies conducted in the M. nemestrina demonstrated that RC-101 films at a 
dose of 2000 µg/ film are safe when applied daily for 4 consecutive days.  There was no 
evidence of changes in pH, microbiology, and colposcopy when comparing either untreated 
animals with placebo films or films containing RC-101.  Since the early 1990s in the 
development of vaginal products, colposcopy is the established method to assess vaginal 
irritation and detect epithelial changes that may increase the likelihood of HIV or acquisition of 
other sexually transmitted diseases assessing (211).   
In this Chapter, we have described RC-101 formulation development, efficacy from a cell 
based assay to an ex vivo model, and safety from an ex vivo model to an animal study.  Major 
results show that RC-101 was successfully formulated in a quick-dissolve polymeric film.  This 
film demonstrated to be efficacious and safe in an in vitro method used.  The safety of RC-101 
films in animals after multiple exposures to a high concentration RC-101 film further validates 
this peptide as a promising microbicide.  Stability of RC-101 films over time still requires further 
investigation prior to completion of the formulation development.  While efficacy studies in 
animals still needs to be conducted, important findings from this research provide a significant 
contribution to the further development of RC-101 into a successful microbicide product.  In 
addition, the rational process of microbicide development presented here may be considered as a 
template to be used for the systematic development of other microbicide molecules.  
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Investigation of penetration of RC-101 in human and monkey female reproductive tracts are 
presented in Chapter 6. 
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6.0  PERMEABILITY AND TISSUE LOCALIZATION OF RC-101 
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 6.1 INTRODUCTION 
More than 25 years have passed since the discovery of the human immunodeficiency virus 
(HIV), and the numbers of infected people have reached pandemic levels.  A feminization of the 
epidemic has been observed, which is attributed to the difficulty for women to negotiate condom 
use and the higher transmission and infection rate from male to female relative to female to male 
(11).  Considering that many men are often unwilling to use condom and women are more 
susceptible to HIV, strategies to prevent heterosexual transmission of HIV must include female-
controlled methods (25).  
In this scenario, the idea of a topical microbicide product appears to be one of the best 
options for HIV prevention.  A microbicide product would be applied vaginally or rectally before 
intercourse, to prevent transmission and acquisition of HIV (26-28).  During male to female 
transmission, virus in semen penetrates the stratified squamous epithelium of the vagina and 
ectocervix or the columnar epithelium of the endocervix to infect immune cells within and below 
the epithelium (79, 80).  It is still uncertain if the virus must cross the epithelium or if the 
Langerhans cells (LC) will reach out for the virus.  However, studies have indicated that HIV is 
present in the epithelial mucosa and penetrates the mucosa in a gradient distribution (212). 
RC-101 is among several microbicide drugs that have been investigated.  It is a circular, 
18-residue peptide, with three cysteine disulfide bonds.  Activity of RC-101 against HIV in vitro 
has been shown against X4 and R5 strains of HIV-1 (102), making this peptide a potential 
microbicide agent to prevent mucosal transmission of HIV-1 (102, 106).  The mechanism of 
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action of RC-101 against HIV occurs by high affinity binding to CD4, galactosylceramide 
(alternative cell surface receptor for CD4- cells), and gp120.  RC-101 operates by preventing six-
helix bundle formation of gp41, thereby conferring protection against HIV-1 (106).   
The dual mechanism of action observed for RC-101 (binding to the glycoprotein of the 
virus and binding to the receptor of the host cell) offers a strong incentive to develop RC-101 as 
a topical vaginal microbicide product.  In order to take advantage of this dual mechanism, RC-
101 must be targeted to both the epithelium and vaginal lumen. 
Important findings described throughout this dissertation work have validated RC-101 as 
a promising microbicide candidate, encouraging further investigation of the molecule.  
Preformulation studies (Chapter 3), compatibility with human vaginal fluids (Chapter 4), and 
formulation and safety (Chapter 5) of RC-101 were investigated.  The key observations indicate 
that RC-101 is stable in biological fluids, possess activity against HIV, and is safe.  In this 
chapter we further investigate the ability of RC-101 to penetrate into human ectocervical and 
endometrial tissue and monkey vaginal and endometrial tissue.  The purposes of this study were 
to first investigate the permeability of human and monkey female reproductive tract tissues to 
RC-101 using an ex vivo system to characterize systemic absorption.  And second, to analyze the 
distribution of RC-101 in human and monkey reproductive tracts tissue to verify targeting to 
immune cells when delivered in a solution or a formulated state.  Quantification of RC-101 in 
solutions was conducted by HPLC and immuno-dotblot.  Detection of RC-101 in human and 
animal tissue was accomplished by immunohistochemistry, an immunostaining method, using a 
polyclonal antibody of RC-101.  
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6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Retrocyclin-1 (RC-101) was synthesized by the Peptide Synthesis Facility at the University of 
Pittsburgh (Pittsburgh, PA).  Polyvinyl alcohol (PVA) was obtained from Kuraray America Inc. 
(New York, NY).  Glycerin was purchased from Dow Chemical Company (Midland, MI).  
Hydroxypropylmethylcellulose (HPMC) 6 cps was purchased from Sigma (St. Louis, MO).  All 
other materials were obtained from Fisher Scientific (Fair Lawn, NJ) unless specified otherwise.   
6.2.2 Quantification and detection of RC-101 
Quantification by High Performance Liquid Chromatography (HPLC)  
An HPLC system (Waters Corporation, Milford, MA) was used for the analysis of RC-101 in the 
formulation as previously described (Section 3.2.2).  Briefly, the HPLC system was equipped 
with an autosampler model 717 (Waters), a quaternary pump model 600 (Waters), and an 
ultraviolet (UV) detector model 2487 (Waters).  Chromatographic separation of RC-101 was 
achieved by using a Jupiter 5 µ C5 column 4.6 x 250 mm, 300 Å (Phenomenex, Torrance, CA) 
protected by a guard cartridge Widepore C5 4 x 3.0 mm (Phenomenex).  Empower PRO, 
Empower 2 software (Waters) was used to control the HPLC system.  
 
RC-101 quantification by quantitative immuno-dotblot  
Aliquots from permeability studies were frozen at -80 °C and sent to the laboratory of Alexander 
Cole, Ph.D. (University of Central Florida, Orlando, FL).  Samples were processed as previously 
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described by Cole et al. (109).  Briefly, a known volume of each sample was dried using a 
ThermoSavant speed vacuum (ThermoSavant, Waltham, MA), and resuspended to the original 
volume in 0.1% acetic acid.  Extracts (4 µl/dot) were dotted onto a polyvinylidene fluoride 
(Immobilon-P) membrane.  Results were expressed as a percent of the RC-101 in the donor 
compartment at the start of the experiment. 
 
RC-101 detection by immunohistochemistry  
Detection of RC-101 in the tissue was conducted as previously described by Cole et al. (109).  
Briefly, unstained tissue sections were deparaffinized, washed in tris-buffered saline (TBS), and 
incubated overnight with anti-RC-101 or preimmune serum, each diluted in TBS containing 1% 
gelatin, 0.05% Tween 20 and 0.01% thimerosal (TBS-T).  Following three 20 min washes in 
TBS-T, an alkaline phosphatase-conjugated secondary antibody was applied at 1:2000 dilution 
and the sections were left overnight at room temperature.  The next day, the slides were washed 
three times for 20 min in TBS-T, developed with Fast Red (Sigma, St. Louis, MO), and 
counterstained with Harris hematoxylin. 
6.2.3 Permeability and tissue localization protocol 
6.2.3.1 Excised human tissue and monkey tissue 
Human cervical and endometrium tissue 
Freshly excised human ectocervical and endometrium tissue were obtained from the Tissue 
Procurement Facility at Magee-Womens Hospital (Pittsburgh, PA), according to approved IRB 
protocol #0503103.  Tissue was obtained from 18 premenopausal women, 30 to 50 years old, 
undergoing hysterectomy for benign conditions.  No specimens were used when there was 
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evidence of tissue abnormality that might have influenced the state of the mucosa.  All tissue 
specimens were obtained within 1 h of surgical excision, and held at 4 °C in Dulbecco’s 
Modification of Eagles Medium (DMEM) (Mediatech Inc, Herndon, VA) during transfer from 
surgery to the laboratory. 
 
Excised macaque reproductive tract 
Reproductive tracts from sexually mature female Macaca nemestrina were obtained from a 
colony at the Washington National Primate Research Center (Seattle, WA) as previously 
described in Chapter 5.  Animals were euthanized and the whole reproductive tract was removed 
and transported to Magee-Womens Research Institute (Pittsburgh, PA) in ice within 24 h.  Upon 
arrival, the tissue was warmed to 37 °C and immediately used for the experiments.  
6.2.3.2 Experimental set up 
RC-101 film and solution samples 
A quick-dissolving polymeric vaginal film formulation containing RC-101 was used in these 
studies and compared to unformulated RC-101 in a solution of 100 mM phosphate buffered 
saline (PBS), pH 7.4.  RC-101 and placebo films were formulated as described in Chapter 5.  
Briefly, vaginal films were prepared by casting a polymeric film solution containing PVA, 
glycerin, and HPMC.  Two formulations have been used for the permeability studies and tissue 
localization tests: an initial film formulation (RC_F+LA) containing 0.8% of lactic acid to 
maintain an acidic pH to simulate the conditions found in a vaginal environment; and a second 
formulation without lactic acid (RC_F100).  Both films were prepared at a dose of 100 µg RC-
101 per film.  Placebo films were prepared identically without the addition of RC-101.  All films 
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were removed from the plates, weighed, and stored in PET/Aluminum foil pouches (Amcor 
Flexibles Healthcare Inc, Mundelein, IL) until further analysis.  Prior to the experiments, each 
film was dissolved in 1 mL of PBS, pH 7.4.  RC-101 100 µg/mL solution in phosphate buffered 
saline (PBS), pH 7.4 was used as a control (RC_SOL). 
 
RC-101 tissue localization in excised full monkey reproductive tract tissue 
RC_F+LA (n = 2) was evaluated in whole excised monkey reproductive tract as described in 
Chapter 5.  Briefly, the excised monkey reproductive tract was warmed to 37 °C, and placed in a 
15 mm Petri dish containing 2 mL of Milli Q water.  The film product was inserted into the 
vaginal cavity using a glass rod.  The reproductive tract was kept in a horizontal orientation for 
the first 30 min after insertion of the film.  After that time, the tissue was oriented vertically for 
another 90 min.  The protocol was designed to simulate the experimental conditions used in an in 
vivo setting as described in Section 5.2.4.3.  The tissue was then removed from the incubator and 
rinsed (4 mL of water, 10 times) by inserting a 5 mL syringe in the vaginal opening.  Lavage 
samples were collected, centrifuged at 10,000 rpm for 10 min, and the supernatant was separated 
for further analysis by HPLC and immuno-dotblot.  A cytobrush was inserted and gently rotated 
6 times into the cervical os.  The cytobrush was then placed in 4 mL of water and vortexed.  The 
tissue was cut open and 6 mm diameter (n = 3) biopsy samples were collected from each part of 
the tissue (lower vagina, middle vagina, upper vagina, transformation zone, cervix, and uterus), 
and stained for histology.  Tissue biopsy samples were fixed using two procedures: one specific 
for evaluation of histological changes and the second one for RC-101 localization.  Histological 
changes were evaluated by Hematoxylin and Eosin (H & E) staining following the procedure 
described in Chapter 5.  Tissue fixation for localization of RC-101 was conducted by placing the 
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tissue in 4% paraformaldehyde solution and storing at 4 °C overnight.  Tissue was then 
transferred to a solution of 75% (v/v) ethanol for 24 h, and subsequently embedded in paraffin.  
Immunohistochemistry (RC-101 localization) analyses were performed as described in section 
6.2.2. 
 
Permeability studies and tissue localization using Franz-cell apparatus 
Permeability studies were conducted using a Franz-cell system previously described for the 
safety studies in Chapter 5, with a few modifications.  For permeability studies, 4.5 mL 
phosphate buffered saline (PBS) pH 7.4 solution was used in the receptor chamber, which was 
continuously stirred by a magnetic stir bar.  Permeability studies were conducted using excised 
monkey reproductive tract (vaginal and endometrium tissue), and excised human (ectocervical 
and endometrium) tissue.  In the Franz-cell system, the tissue is sandwiched between the two 
compartments with the epithelial side facing the donor solution, with the apical side of the tissue 
exposed to the solution to be tested.  The tissue was equilibrated with PBS in the donor 
compartment for 5 min prior to the initiation of the permeability study.  After the equilibration 
period, the PBS solution was removed from the donor compartment and replaced with 400 μl of 
either RC-101 100 µg/mL solution in PBS (RC_SOL) or RC-101 100 µg/film (RC_F+LA or 
RC_F100) dissolved in 1 mL of PBS.  An aliquot of 50 µL was removed from the donor 
compartment at time 0 for quantitative analysis of RC-101.  Aliquots of 200 μl were removed 
from the receptor compartment at various time intervals for a total period of 6 h.  Aliquots were 
replaced with 200 µL PBS (pH 7.4) to maintain sink conditions.  All solutions (donor and 
receptor) were analyzed by HPLC for quantification of RC-101.  Since the limit of quantification 
for RC-101 in the HPLC assay is 7.9 µg/mL, the amount of RC-101 in the receptor phase would 
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be below the limit of quantification in the receptor compartment, but it is still above the limit of 
detection of the method.  Therefore, any leaks in the tissue would be identified by the HPLC 
method.  For quantification purposes, all receptor solutions were additionally analyzed by 
immuno-dotblot.  The limit of detection for the immuno-dotblot method is 0.25 µg/mL (109).  
Tissue samples after the experiment were processed and stained with H & E, embedded in 
paraffin, and cut into slides to be sent to Alexander Cole, Ph.D. (University of Central Florida) 
for staining with anti-RC-101, to determine RC-101 tissue localization as described in Section 
6.2.2. 
6.2.4 Statistical analysis 
Data obtained from the permeability studies were expressed as concentration of RC-101 in 
µg/mL (mean ± S.D.).  Results were analyzed with Mann-Whitney test for comparisons of each 
condition investigated in the permeability studies, without corrections for multiple comparisons.  
P-values ≤ 0.05 were considered to be statistically significant, unless specified otherwise.   
6.3 RESULTS 
RC-101 tissue localization in excised monkey reproductive tract  
Full excised monkey reproductive tract studies were conducted using tissues from two animals 
exposed to RC_F+LA (RC-101 100 µg/film with lactic acid).  Lavage samples obtained after a 2 
h exposure to RC-101 film were centrifuged and supernatant was separated from the cells.  
Supernatant lavage samples were analyzed by HPLC for quantification of RC-101; however, no 
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RC-101 was detected in any lavage sample analyzed.  The same samples (supernatant and cells) 
were sent for testing by immuno-dotblot.  Results are presented (Table 6-1) as the percent of RC-
101 recovered from the original amount of RC-101 introduced in the monkey reproductive tract, 
for supernatant, cells, and total amount.  A low concentration of RC-101 was detected in the 
recovered lavage.  RC-101 was found in the epithelial cells sloughed from the vaginal walls 
during lavage and in the supernatant.  In tissue 1, about 80% of the amount of RC-101 found was 
present in the cells.  In tissue 2, about 40% of RC-101 was present in the cells.   
 
Table 6-1. RC-101 in lavage samples expressed as percentage of the amount introduced.   
Description Supernatant RC-101 (%) Cells – RC-101 (%) Total RC-101 (%)
Tissue # 1  1.91 8.14 10.04 
Tissue # 2 1.94 1.57    3.51 
Immuno-dotblot analysis of the first lavage samples obtained from full monkey reproductive tract  
exposed to RC_F+LA. 
 
After exposure for 2 h with RC-101 vaginal film (RC_F+LA), full reproductive tract 
tissue was cut and biopsies were used for determination of RC-101 localization in the tissue.  
RC-101 staining for each tissue is shown in Figure 6-1.  The figure shows the staining by H & E 
to demonstrate that there were no gross morphological changes that would provide evidence of 
damage to the epithelial layer, the tissue pre-immuno staining, and after the RC-101 staining 
(green fluorescent).  In the tissue from both animals, the staining (green fluorescent) shows that 
RC-101 is present throughout the entire reproductive tract and is more concentrated in the cervix, 
and middle and upper vagina.  When RC-101 films are placed vaginally in the full reproductive 
tract, the films are placed near the cervix and covered the upper and middle vaginal wall.  
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Physical localization of the film explains the higher presence of RC-101 in the cervix, middle 
and upper vagina.  Evidence of localization of RC-101 in the tissue can be shown by the 
presence of RC-101 in the epithelial layer suggesting its penetration into the mucosa.   
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Figure 6-1. RC-101 tissue localization in excised monkey whole reproductive tract. 
H & E staining, pre-immune and after anti-RC-101 immunohistochemistry staining of excised 
Macaca nemestrina reproductive tract tissue after exposure for 2 h with RC-101 100 µg/ film 
(RC_F+LA).  Pre-immune staining and anti-RC-101 staining show the overlayed images of FITC 
(green fluorescence) and DIC (differential interference contrast).  A) Monkey tissue 1, and B) 
Monkey tissue 2.  
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Permeability studies and tissue localization using the Franz-cell apparatus 
After finding evidence that showed localization of RC-101 in the full reproductive tract and 
suggestion of RC-101 penetration into the epithelial mucosa, further investigations using excised 
monkey and human tissue were conducted.  To evaluate permeability and tissue localization of 
RC-101 in these tissues, a Franz-cell system was utilized. 
Monkey vaginal (VG) and endometrium (UT) tissue were exposed to RC 100 µg/mL 
solution (RC_SOL), RC-101 100 µg/film with lactic acid (RC_F+LA), and RC-101 100 µg/film 
without lactic acid (RC_F).  The concentration of RC-101 in the receptor compartment was 
analyzed by both HPLC and immuno-dotblot.  No RC-101 was detected in the receptor solution 
at any time point by HPLC assay.  However, immuno-dotblot results showed no more than 10% 
of RC-101 was detected in the receptor compartment at the end of the experiment, indicating that 
low permeability of RC-101 through the tissue occurred.  The solution from the donor 
compartment was analyzed by HPLC at time 0 and at the end of the experiment.  The 
concentration (µg/ml) of RC-101 in the donor compartment at the end of the experiment (6 h) 
was determined and plotted for each tissue obtained (each subject) and for each exposure 
condition (RC_SOL, RC_F+LA, and RC_F).  Results for monkey tissues are shown in Figure 
6-2.  Closed symbols represent monkey vaginal tissue and open symbols represent monkey 
endometrium tissue.  Circled symbols represent tissue obtained from one animal that presented a 
high level of parakeratosis and extensive inflammation, with some ulceration of the tissue.  Due 
to the small number of tissues analyzed, no statistical calculations were conducted.  Results from 
the permeability study presented in Figure 6-2, suggest that RC-101 penetrates the tissue as 
evidenced by the decrease in the amount of RC-101 detected in the donor compartment at the 
end of the experiment.  In some tissues, no decrease in the donor compartment was observed.  To 
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normalize the data, and eliminate variability in the thickness of the tissue caused by hand-
microtome, a graph with diffusion of RC-101 in monkey reproductive tissues was calculated and 
plotted (Figure 6-3). 
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Figure 6-2. RC-101 permeability in monkey female reproductive tract tissue 
using the Franz-cell system for 6 h.  Circled symbols represent tissue obtained from one animal that 
exhibited a high level of parakeratosis and extensive inflammation, with some ulceration of the tissue.  
Closed symbols represent monkey vaginal tissue (VG). Open symbols represent monkey 
endometrium tissue (UT).  
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Figure 6-3. RC-101 diffusion (µg/mm2/h) into monkey female reproductive tract tissue 
using the Franz-cell system for 6 h.  Closed symbols represent monkey vaginal tissue (VG).  Open 
symbols represent monkey endometrium tissue (UT).  
 
 
With the evidence presented that RC-101 penetrates into monkey tissue, a more extended 
study was performed using human ectocervical and endometrium tissue in a Franz-cell system.  
Human ectocervical (CX) and endometrium (UT) tissue were exposed to RC 100 µg/mL solution 
(RC_SOL), RC-101 100 µg/film with lactic acid (RC_F+LA), or RC-101 100 µg/film without 
lactic acid (RC_F).  The concentration of RC-101 in the receptor compartment was analyzed 
over time; however, no RC-101 was detected in the receptor solution by HPLC assay at any time 
point.  When immuno-dotblot was used, no more than 10% was detected in the receptor 
compartment at the end of the experiment, indicating that low permeability of RC-101 through 
the tissue occurred.  The solution from the donor compartment was analyzed by HPLC at time 0 
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and at the end of the experiment.  The concentration (µg/ml) of RC-101 in the donor 
compartment at the end of the experiment (6 h) was determined and plotted for each tissue 
obtained (each subject) and for each exposure condition (RC_SOL, RC_F+LA, or RC_F).  
Results for human tissues are shown in Figure 6-4.  Closed symbols represent human 
ectocervical tissue and open symbols represent human endometrium tissue.  Results from the 
permeability study conducted presented in Figure 6-4 suggest that RC-101 penetrates into the 
tissue as evidenced by the decrease in the amount of RC-101 detected in the donor compartment 
at the end of the experiment for most of the tissue samples studied.   
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Figure 6-4. RC-101 concentration (µg/mL) in the donor compartment in human tissues 
using the Franz-cell system, after 6 h incubation. Closed symbols represent human ectocervical tissue 
(CX).  Open symbols represent human endometrium tissue (UT).  Bars represent the median for each 
condition. 
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In an attempt to understand the variability observed for each condition, the pathology 
reports were evaluated and patient demographic data identified by means of an honest broker.  
No pathological conditions could be correlated with the differences in the results obtained for 
permeability studies.  As a representative example, some demographic data was identified and 
shown in Figure 6-5, Figure 6-6, and Figure 6-7.  The phase of the menstrual cycle is shown in 
Figure 6-5, where the circles represent women in the secretory phase of their menstrual cycle.  
Women between the ages of 45 and 50 years old (circled data) are identified in Figure 6-6, and 
race is represented in Figure 6-7, where the circled data represents African American women.  
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Figure 6-5. Evaluation of menstrual cycle phase for RC-101 concentrations (µg/mL) 
in the donor compartment in human tissues using the Franz-cell system, after 6 h incubation. Closed 
symbols represent human ectocervical tissue (CX).  Open symbols represent human endometrium 
tissue (UT).  Circles represent women during the secretory phase of their menstrual cycle.  
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Figure 6-6. Evaluation of age for the RC-101 concentrations (µg/mL) 
in the donor compartment in human tissues using the Franz-cell system, after 6 h incubation. Closed 
symbols represent human ectocervical tissue (CX).  Open symbols represent human endometrium 
tissue (UT).  Circles represent women in the ages between 45 and 50 years old.  
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Figure 6-7. Evaluation of race for the RC-101 concentrations (µg/mL) 
in the donor compartment in human tissues using the Franz-cell system, after 6 h incubation. Closed 
symbols represent human ectocervical tissue (CX).  Open symbols represent human endometrium 
tissue (UT).  Circles represent African American women. 
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No correlation was observed between the results obtained from permeability studies and 
any of the demographic variables analyzed.  Overall, there is a statistically significant difference 
in the concentration of RC-101 obtained in the donor compartment between RC_SOL and 
RC_F when used in human ectocervical tissue (Mann-Whitney, p = 0.02), and no statistically 
significant difference between RC_SOL and RC_F when used in human endometrium tissue (p 
= 0.36).  When the same samples were statistically compared to evaluate the difference in the 
type of tissue, it was observed that a significant statistically difference was observed between 
ectocervical and endometrium tissue for RC_SOL (p = 0.02), and no statistical difference was 
observed for RC_F (p = 0.12).  Two major findings are important in these studies.  First, both 
tissue types (ectocervical and endometrium) showed penetration of RC-101 by evidence of 
decrease in the donor compartment concentration of RC-101.  Second, no difference in 
penetration was observed between RC-101 solution (RC_SOL) and RC-101 film (RC_F).   
However, a difference was observed when the permeability results were corrected for the 
thickness of the tissue as discussed below. 
To diminish the tissue thickness variability due to the experimental method used to 
isolate the epithelial layer, calculations of the diffusion of RC-101 through the tissue were made.  
In these calculations, the amount of RC-101 that diffused into a cross-sectional area of the tissue 
over time was plotted for each subject and each condition.  Results are shown in Figure 6-8.  A 
statistically significant difference (p < 0.05, Mann-Whitney test) was observed in all conditions 
showing that there is a difference between RC_SOL and RC_F, and a difference between tissue 
types (ectocervical and endometrium).  There is a lower diffusion of RC-101 through the 
endometrium when compared to human ectocervical tissue. 
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Figure 6-8. RC-101 diffusion (µg/mm2/h) in human female reproductive tract tissue 
using the Franz-cell system. Closed symbols represent human ectocervical tissue (CX).  Open 
symbols represent human endometrium tissue (UT).  Bars represent the median for each condition.  
P values were calculated using Mann-Whitney test. 
 
After permeability studies were conducted for RC-101 in the Franz-cell system, tissues 
were processed and stained for localization of RC-101 by immunostaining with a polyclonal RC-
101 antibody.  Results for the monkey vaginal and endometrium tissues are shown in Figure 6-9 
A and Figure 6-9 B, respectively.  Both figures show three pictures of each tissue.  In the first 
picture, the staining by hematoxylin and eosin (H & E) demonstrates that there were no gross 
morphological changes after exposure to the sample that would evidence damage to the epithelial 
layer.  The second picture shows the negative control for the RC-101 immunostaining, the tissue 
pre-immune staining (PRE).  And the third picture shows the tissue after the RC-101 staining 
(green fluorescent) (POST).  RC-101 in monkey tissue was mostly detected in the upper 
epithelial layer of the mucosa.  No differences were observed between tissues exposed to 
RC_SOL or RC_F+LA. 
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Figure 6-9. RC-101 tissue localization in monkey tissue.  
Exposure of RC-101 solution and film to monkey vaginal and endometrium tissue. Hematoxylin and 
Eosin (H & E) staining of tissue post experiments; pre-immune staining (PRE); and after anti-RC-
101 staining after exposure (POST) to RC-101 solution (RC_SOL) or RC-101 film with lactic acid 
(RC_F+LA).  A) vaginal tissue; B) endometrium tissue.  
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Localization of RC-101 for human ectocervical tissue in the proliferative and secretory 
phase of the menstrual cycle are shown in Figure 6-10 A and Figure 6-10 B, respectively.  
Localization of RC-101 for human endometrium tissue in the proliferative and secretory phase of 
the menstrual cycle are shown in Figure 6-11 A and Figure 6-11 B, respectively.  Both figures 
show three pictures of each of the tissues in the same way as was presented for the monkey 
tissue.  In the first picture, the staining by hematoxylin and eosin (H & E) demonstrates that there 
were no gross morphological changes after exposure to the sample, providing no evidence of 
damage to the epithelial layer.  The second picture shows the negative control for the RC-101 
staining, the tissue pre-immune staining (PRE).  And the third picture shows the tissue after the 
RC-101 staining (green fluorescent) (POST).  RC-101 was mostly detected in the upper 
epithelial layer of the human ectocervical and endometrium mucosa.  No differences were 
observed in tissues exposed to RC_SOL (RC-101 solution), RC_F+LA (RC-101 film with lactic 
acid) or RC_F (RC-101 film).  Similar results were obtained in the other replicates.  Only one 
tissue showed a slight penetration of RC-101 into the deeper layers of the epithelial mucosa.  
Data obtained from the RC-101 localization studies in monkey and human excised tissues 
indicate that RC-101 localizes in the upper epithelial layers of the mucosa.   
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Figure 6-10. RC-101 tissue localization in human ectocervical tissue.  
Exposure of RC-101 solution and film to human ectocervical tissue. Hematoxylin and Eosin (H & E) 
staining of tissue post experiments; pre-immune staining (PRE); and after anti-RC-101 staining after 
exposure (POST) to RC-101 solution (RC_SOL), RC-101 film with lactic acid (RC_F+LA), or RC-
101 film (RC_F).  A) proliferative phase; B) secretory phase.  
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Figure 6-11. RC-101 tissue localization in human endometrium tissue.  
Exposure of RC-101 solution and film to human endometrium tissue. Hematoxylin and Eosin (H & 
E) staining of tissue post experiments; pre-immune staining (PRE); and after anti-RC-101 staining 
after exposure (POST) to RC-101 solution (RC_SOL), RC-101 film with lactic acid (RC_F+LA), or 
RC-101 film (RC_F).  A) proliferative phase; B) secretory phase.  
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6.4 DISCUSSION AND CONCLUSIONS 
Topical vaginal microbicides are intended to prevent transmission of HIV and other sexually 
transmitted infections (STIs).  The development of RC-101 into a vaginal microbicide film has 
been shown to be a promising HIV prevention method, as studied using in vitro and ex vivo 
models.  This study focuses on the permeability and penetration of RC-101 into excised human 
and monkey reproductive tract as a means of offering a more targeted protection against HIV.  
This is the first study in the microbicide field performed to evaluate the presence of a 
microbicide candidate in full animal reproductive tract tissue as well as in excised human and 
monkey tissue. 
During male to female transmission, virus in semen will penetrate the stratified squamous 
epithelium of the vagina and ectocervix or the columnar epithelium of the endocervix to infect 
target immune cells (macrophages, T cells, and dendritic cells), within and below the epithelium 
(79, 80).  The majority of these cells are located in the subepithelial layers of vaginal and 
cervical mucosa.  However, studies have confirmed the presence of Langerhans cells (LCs) in 
the epithelial mucosa (72, 81), and the ability of these cells to take up HIV-1.  This uptake by 
LCs can extend near to, or into the mucosal lumen (85). 
The mechanism of action of each microbicide agent will define the appropriate vaginal 
drug delivery system for those products.  If a microbicide agent acts by blocking the receptor or 
co-receptor in the target host cells, it is imperative that the delivery system is able to deliver the 
drug to the site of action.  Conversely, a microbicide agent that disrupts the viral membrane 
before attachment of the virus to the host cell can be delivered to the vaginal lumen without 
deeper penetration in the vaginal mucosa.  Defining the specific site of action for a microbicide 
that targets immune cells has been the research focus of several groups (83, 212, 213).  Studies 
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suggest that immune cells are more concentrated in the basal layers, but are present throughout 
the whole epithelial tissue (69-71, 83, 212, 213).  As described in Section 1.3, normal cervical 
stratified squamous epithelium consists of several layers of epithelial cells.  The layers can be 
subdivided into four different classes according to the stage of maturation: basal, parabasal, 
intermediate, and superficial.  The presence of target cells throughout the whole epithelial 
mucosa makes it a challenge to effectively target the drug.  Drug delivery systems should enable 
access to a broad distribution of target cells for the development of an effective and successful 
microbicide product.  
In addition to several studies regarding the localization of immune cells, research groups 
have been focusing on understanding the mechanism of sexual transmission of HIV. As 
described in Section 1.5, several mechanisms have been proposed such as: direct infection of 
epithelial cells, transcytosis through epithelial cells, epithelial transmigration, uptake by intra-
epithelial Langerhans cells, and circumvention of the epithelial barrier.  However it is still 
uncertain if these mechanisms fully explain the HIV-1 transmission in vivo.  Two schools of 
thought in the microbicide research field co-exist, explaining one of the HIV mechanisms of 
transmission.  One of these schools suggest that HIV-1 could directly infect epithelial cells, 
through binding to alternative receptors of CD4 (82, 83), such as galactosylceramide.  The other 
one has shown that HIV-1 is unable to infect epithelial cell lines, due to the lack of CD4 receptor 
and co-receptors in epithelial cells, even when galactosylceramide was detected (66, 84).  
However, it has also been suggested that epithelial cells can transfer HIV to activated immune 
cells, and may contribute to sexual transmission of HIV-1 (66).  Both theories play a role and 
add to the complex matrix of HIV prevention strategies and to the identification of site of action 
and targets for microbicides. 
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Distribution of the vaginal microbicide product throughout the vaginal and cervical 
tissues may offer better protection against HIV.  For semi-solid gel formulations, distribution of 
the vaginal gel may add additional mechanisms of protection against HIV by coating the mucosa 
and forming a mechanical barrier to the virus, and protecting against disruption of the epithelial 
mucosa by increasing lubrication.  A few studies have assessed the distribution of microbicide 
product in the vaginal lumen in in vivo models (11, 121, 208).  However, no study has analyzed 
the distribution of the drug in the tissue, either in an in vitro or an in vivo model.  For semi-solid 
microbicides, spreadability of the gel product has been characterized by imaging the distribution 
of the product in the vaginal lumen (11, 121, 208).  Polymeric vaginal films, such as the one 
developed for RC-101, are more dependent in the presence of vaginal fluids to disintegrate the 
film and distribute its drug contents throughout the vaginal canal.  The quick dissolve film 
developed for RC-101 (Chapter 5) will rapidly release the drug upon disintegration of the film, to 
be readily bioactive. 
 Independent of the dosage form chosen, localization of the microbicide drug at the site of 
action is required for an efficacious microbicide product.  According to the mechanism of action 
of RC-101, penetration of RC-101 into the tissue will provide an advantage to improve efficacy 
of the final microbicide product.  We have conducted a RC-101 localization study using full 
excised reproductive tract monkey tissue.  RC-101 films were vaginally inserted into excised full 
female monkey reproductive tract and immunostaining conducted after 2 h exposure to the film.  
Results have shown that RC-101 penetrated into the epithelial mucosa.  Presence of RC-101 was 
evident throughout all epithelial layers, including submucosal and basal layers, as detected by 
immunostaining of RC-101.  This result suggests that RC-101 penetrates the epithelial mucosa, 
being available for target immune cells.  However, full excised tissues are obtained after 
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monkeys are euthanized, then the whole reproductive tract is removed, placed in media, and 
shipped on ice to our laboratory, taking up to 24 h to arrive.  Upon arrival, the tissue is warmed 
to 37 °C and immediately used for the experiments.  When a tissue is removed from the whole 
animal, it is immediately deprived of its physiological supportive and protective mechanisms.  
There is no supply of nutrients to the cells, no removal of waste products, and no maintenance of 
pH and osmotic pressure.  Due to this fact, caution should be taken when interpreting these 
results.  Future studies should include evaluation of RC-101 distribution in an in vivo animal 
model. 
A number of experimental models for permeability studies have been reported in the 
literature (214-217).  A simple in vitro method extensively used for intestinal permeability study 
utilizes Caco-2 cells.  This method is easy to perform in large numbers.  However, in this model 
there is a low paracellular permeability present and a lack of absorption barriers such as a mucus 
layer (214).  More specific to vaginal and cervical permeability, studies using cultured human 
vaginal-cervical epithelial cells have been described (217-219).  These methods utilizes human 
endocervical and ectocervical cell lines cultured on filters.  The major disadvantage of using cell-
based assays for permeability studies of vaginal and cervical tissues is that cell models are found 
in monolayers, which does not represent the multilayer squamous epithelium of vaginal and 
ectocervical tissues.  More complex models, such as the Ussing chamber (220) and Franz-cell 
(221), have been investigated using excised human or animal tissues.  The Ussing chamber 
consists of two half-chambers connected to electrodes, which measure the short-circuit current as 
an indicator of the transport taking place across an epithelium.  The Franz-cell system also 
consists of two half-chambers.  In both systems, the tissue is sandwiched between the two 
compartments, the whole apparatus is kept at 37 °C, and there is a possibility of sampling both 
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compartments over time.  The Ussing chamber system allows for the monitoring of electrical 
resistance during the experiment and supplies oxygen in the donor compartment.  In our studies, 
the Franz-cell system represented an advantage due to the fact that we could evaluate multiple 
pieces of tissue at the same time, and better investigate inter- and intra-patient variability. 
Permeability of RC-101 was investigated using excised monkey and human tissues with a 
Franz-cell system.  Monkey vaginal and endometrium tissues were exposed to RC-101 in 
solution and RC-101 in film formulation.  None of the conditions tested showed significant 
concentrations of RC-101 in the receptor phase (less than 10% detected by immuno-dotblot), 
suggesting that systemic uptake of RC-101 will not be significant.  Donor solutions from the 
Franz-cell were analyzed by HPLC to determine the amount of RC-101 that penetrated into the 
tissue during the exposure period.  In the studies conducted for excised monkey tissue, 
penetration of RC-101 occurred for tissues exposed to RC-101 in solution (RC_SOL), RC-101 
in film with lactic acid (RC_F+LA), or RC-101 film (RC_F).  This penetration was observed for 
both tissue types: monkey vaginal and endometrium tissues.  Due to the small number of tissues 
available for these studies, no statistical calculations were made.   
Permeability of RC-101 into human excised ectocervical and endometrial tissue was also 
investigated using a Franz-cell system.  The tissues were exposed to RC-101 in solution, or in 
film formulation.  Similar to the results obtained in monkey tissue, none of the conditions tested 
showed significant concentration of RC-101 in the receptor phase (less than 10% detected by 
immuno-dotblot), suggesting that systemic uptake of RC-101 will not be significant.  Donor 
solutions from the Franz-cell at time 0 and at the end of the experiment were analyzed by HPLC 
to determine the amount of RC-101 that penetrated the tissue.  In the studies conducted for 
excised human tissue, penetration of RC-101 occurred in tissues exposed to RC-101 in solution 
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(RC_SOL), RC-101 in film with lactic acid (RC_F+LA), or RC-101 film (RC_F).  Median 
values of RC-101 concentration in the donor compartment at the end of the experiment for 
human ectocervical tissue were 38.2, 59.6, and 36.8 µg/mL, for RC_SOL, RC_F+LA, and 
RC_F, respectively.  Compared to the initial concentration of RC-101 (100 µg/mL) introduced 
to the Franz cell in the beginning of the experiment, permeability studies suggest that more than 
60% of RC-101 penetrates into the tissue when RC_SOL, or RC_F is used, while more than 
40% of RC-101 penetrates when RC_F+LA is used. 
The RC-101 film formulation currently being pursued in the laboratory is the RC_F.  
Calculation of the median concentration of RC-101 in the donor compartment following 
exposure to RC_F shows that 63.2 μg/mL was lost from the donor compartment during the 
exposure period.  Assuming that this concentration penetrated into the tissue and given the fact 
that the IC90 for the RC_F2000 film described in Section 5.3 using an ex vivo model was 
estimated to be 57.5 µM (108.6 μg/mL), the results suggest that about 60% of the RC-101 
necessary to suppress 90% of HIV is within the tissue.  This concentration of RC-101 would be 
available to bind to CD4.  The remaining 40% of RC-101 would remain in the vaginal lumen 
where it would be available to bind to glycoproteins of the virus, taking advantage of the dual 
mechanism of action of RC-101. 
The variability observed in the individual values obtained for RC-101 concentration was 
investigated.  No known demographic variables such as age, race, menstrual cycle or any other 
pathological condition observed in the histological sections of the tissue pre- and post-
experiment could explain the variability.  We have evaluated some of the characteristics of the 
tissue utilized in the study in order to understand the variability observed.  However, each 
characteristic (race, age, and menstrual phase) analyzed by itself could not be correlated to the 
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varied results of RC-101 concentration obtained.  The discrepancy in the results can be attributed 
to inter- and intra-patient variability, which is an intrinsic characteristic of vaginal and 
ectocervical tissues.  Despite the variability observed, the major finding in this study is that 
penetration of RC-101 occurred over a 6-hour period in all 18 tissue samples analyzed including 
both tissue types (ectocervical and endometrium).  This penetration is evidenced by the decrease 
in the donor compartment RC-101 concentration and the positive staining for RC-101 in the 
mucosal tissue.  
In addition to patient variability, some experimental artifacts can contribute to the 
difference observed in the concentration values.  Human tissues utilized in the Franz-cell system 
originate from fresh human tissue from women undergoing hysterectomy.  This tissue is 
sectioned by the use of a hand-microtome, causing inconsistency in the thickness of the slices 
obtained.  The thickness of the each section is measured prior to the experiment.  To minimize 
the variability in the thickness encountered, permeability results were calculated as diffusion 
coefficient by calculating the amount of RC-101 (µg) per cross-section area of the tissue (mm2) 
per time (h).  Evaluation of diffusion coefficients obtained did not result in a reduction of the 
observed variability. 
Correcting for differences in overall tissue thickness may not reduce variability due to the 
fact that differences in the number of epithelial layers may occur.  One study has reported a 
difference in the number of cell layers according to the menstrual cycle (222).  To evaluate the 
number of cell layers and epithelial immune cells, vaginal biopsies obtained from premenopausal 
women during 3 phases of the normal menstrual cycle (menstrual period, preovulatory, and 
postovulatory) were utilized.  The mean number of epithelial cell layers underwent a small but 
statistically significant decrease from menstrual period to post ovulatory period, which can 
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contribute to the different drug permeability profiles being obtained.  However, no significant 
changes were observed in the number of Langerhans cell, macrophage, CD4 or CD8 lymphocyte, 
and neutrophil cell populations during the three phases of the cycle (222), indicating that 
penetration of microbicide drugs into the tissue must occur to be able to protect against infection.  
This penetration is important in those microbicide drugs whose site of action requires targeting 
of the immune cells. 
Because the transmission mechanism of HIV is not completely elucidated, it is important 
that the microbicide candidate be present throughout the epithelial mucosa with the objective of 
targeting the immune cells that would be available to the virus.  Localization of RC-101 in the 
epithelial tissue after exposure to RC_SOL or RC_F+LA was evaluated after 6 h exposure 
using the Franz-cell system.  When monkey excised vaginal and endometrium tissue was 
analyzed, immunostaining of RC-101 showed that the peptide is present in the upper epithelial 
layer of the tissue.  No differences were observed in the penetration pattern of RC-101 in 
formulation or in a solution, or in different tissue types studied (vaginal and endometrium).  
Immunostaining of RC-101 after 2 h exposure to RC-101 film (RC_F+LA) into a full monkey 
reproductive tract showed that RC-101 penetrates into the epithelial mucosa, being evident 
throughout all epithelial layers, including submucosal and basal layers.  Differences observed in 
the excised tissue versus the excised full reproductive tract can be explained by the complexity 
of each model used.  In the same line of thought as the in vitro to an ex vivo model discussed in 
Section 5.4, the full reproductive tract represents a more complex system than the excised tissue 
in a Franz-cell system.  Therefore, the results suggest that when the RC-101 product is applied in 
vivo, a deeper penetration of the drug may be observed.  However, the limitations of the method 
should be taken into consideration, especially the fact that the full reproductive tract tissue had 
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been excised 24 h prior to the experiments conducted.  Localization of RC-101 in the epithelial 
tissue was also observed when human ectocervical and endometrium tissue were investigated.  
Immunostaining of RC-101 showed that the peptide is present in the upper epithelial layer after 
exposure to RC_SOL, RC_F+LA or RC_F using the Franz-cell system.  
In this Chapter, permeability and tissue localization of RC-101 were investigated using 
human and monkey tissue.  Major findings from this study have shown that RC-101 formulated 
into a film, when inserted vaginally into an excised full monkey reproductive tract, results in the 
detection of RC-101 throughout all epithelial layers, including submucosal and basal layers.  
This result suggests that RC-101 will be present within the epithelial layer after administration of 
the film product, targeting the area rich in immune cells, offering protection against HIV.  For 
future studies, we recommend investigating the potential of RC-101 to protect against HIV-1 
after penetration into the tissue.  Such studies can be conducted by challenging the tissues 
obtained from the full reproductive tract after exposure to the films, using the ex vivo model 
described in Section 5.2.4.2.  Excised human and monkey studies using the Franz-cell system, 
also showed penetration of RC-101 into the tissue, evidenced by the decrease in the RC-101 
donor concentration following tissue exposure to drug and detection of RC-101 by 
immunostaining in the upper epithelial layer.  Again, we recommend as a future study to 
investigate the potential of RC-101 to protect against HIV-1 after penetration into the tissue in 
these experiments.  Furthermore, to confirm the deeper penetration of RC-101 in the full excised 
reproductive tract, in vivo exposure to RC-101 should be conducted in animals such as monkeys.  
Biopsies of the vaginal mucosa should be obtained after exposure to the films, followed by 
challenging with the virus to verify if the peptide is still bioactive. 
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7.0  MAJOR FINDINGS AND FUTURE DIRECTIONS 
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7.1 INTRODUCTION 
The alarming pandemic levels of HIV and the lack of efficient prevention methods are 
contributing to the development of new strategies to prevent the spread of the virus.  The idea of 
developing a microbicide product emerged in the 1990’s mainly in response to the increasing 
number of HIV infections in women.  The work presented contributes significantly to the 
microbicide research field, focusing on product development, preformulation strategies, stability 
in the biological environment, and drug targeting.  We investigated two biopharmaceutical 
(protein/peptide) microbicide candidates: PSC-RANTES, a chemokine analog of RANTES; and 
RC-101, a circular θ-defensin analog. 
In this dissertation project, we hypothesized that the use of a drug delivery system would 
protect a biopharmaceutical (protein or peptide) microbicide candidate against degradation 
before administration, and in biological fluids after administration, while maintaining drug 
activity. We further hypothesized that the interaction of biopharmaceutical microbicide 
candidates with human vaginal fluids could result in chemical modification of the drug.  Our 
hypothesis was addressed by three specific aims that evaluated the degradation pathways for two 
microbicide drug candidates (PSC-RANTES and RC-101) (Chapters 2 and 3), assessed the 
stability of the most promising of the two (RC-101) in human vaginal fluid (Chapter 4), and 
designed a formulation for targeting of this microbicide drug candidate (Chapters 5 and 6). 
The purpose of this final chapter is to present a summary of the major findings, with their 
implications and limitations, describe possible further development as a microbicide product, and 
discuss the contributions of the approaches we have followed to the development of other 
molecules as microbicide products. 
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7.2 SUMMARY OF MAJOR FINDINGS, IMPLICATIONS, AND LIMITATIONS 
7.2.1 PSC-RANTES and RC-101 preformulation studies 
The proposed study started with two potential biopharmaceutical microbicide candidates: PSC-
RANTES and RC-101.  Preformulation studies were conducted for both molecules in which their 
stabilities were characterized under various conditions including: temperature, pH, ionic 
strength, and presence of oxidizing agents.  These studies are essential for the development of an 
effective microbicide product, providing information critical to the successful formulation and 
effective delivery of a drug.   
PSC-RANTES, (N-α-(nonanoyl)-des-Ser1-[L-thioproline2, L-α-cyclohexyl-glycine3] 
RANTES), is chemically identical to the naturally occurring RANTES except for the substitution 
of a nonanoyl moiety, a thioproline, and a cyclohexyl glycine for the first three N-terminal amino 
acids of the endogenous protein.  PSC-RANTES exhibits in vitro antiviral activity, for some 
HIV-1 isolates in the picomolar range (97).  However, when challenged with HIV-1/SIV 
chimeric virus (SHIV), the PSC-RANTES concentration required for in vivo activity (1 mM) for 
vaginal transmission in Rhesus macaques was 106-fold greater than that needed in vitro (91).  
Reduced potency observed in vivo may be attributed to: 1) protein modification due to 
conformational changes, including aggregation; 2) protein modification due to covalent chemical 
changes; 3) proteolytic inactivation in the vaginal lumen, 4) low penetration of the drug into the 
mucosal tissue, and/or 5) drug binding (134).  Preformulation studies revealed that: PSC-
RANTES is unstable at pH 7 immediately upon exposure to the buffer; has short term stability at 
acidic pHs; forms insoluble aggregates under low and high ionic strength buffers; is prone to 
thermal and oxidative degradation; degrades in the presence of proteinase K; and may affect the 
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viability of normal, protective, vaginal flora.  The physical and chemical instability of PSC-
RANTES indicates that this microbicide candidate would not be stable in a traditional 
microbicide product formulation.  For this reason, the molecule PSC-RANTES was not pursued 
for further development in this dissertation project.  Protection of PSC-RANTES may be 
achieved by encapsulation of PSC-RANTES into nanoparticulated drug delivery systems, which 
would facilitate distribution of the microbicide agent and preserve the stability of the drug, as 
recently reported (150).  This approach was not a part of this dissertation project; however, it is 
currently being pursued in our laboratory. 
RC-101 is a retrocyclin analog θ-defensin peptide that contains 18 residues, is tetracyclic, 
and has three cystein disulfide bonds.  Retrocyclins have the ability to bind with high affinity to 
CD4, galactosylceramide (alternative cell surface receptor for CD4- cells), and gp120; and 
thereby confers protection against HIV-1 (106).  RC-101 possesses a single amino acid 
substitution from an arginine (R) to a lysine (K) on one of the β turns, which increases its 
potency.  RC-101 operates by preventing six-helix bundle formation of gp41 (a 41,000 MW 
glycoprotein), and, thus far, is a promising antiretroviral drug.  The dual mechanism of 
protection of RC-101 (binding to glycoprotein in the virus, as well as to receptors on the host 
cell) offers a significant advantage for a HIV prevention drug.  In addition, based on the cyclic 
structure of the peptide and the presence of disulfide bonds, stability of RC-101 is expected to be 
higher than that of linear proteins (223).  The majority of proteins are synthesized as a linear 
chain of aminoacids, with flexible ends that are targeted by peptidases, reducing the binding to 
receptors that mediate biological activity.  Cyclic peptides, especially the ones containing 
disulfide bridges, have a more rigid structure and are less prone to deactivation by peptidases.  
Despite the predicted relative stability of the peptide, the results obtained from our 
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preformulation studies surpassed the expectations.  RC-101 was stable over a range of pHs (3 to 
7), stable at room and body temperatures, and did not form insoluble aggregates at pH 3 to 7 at 
low and high ionic strength.  The only pathway of degradation identified was oxidation in the 
presence of hydrogen peroxide, but this degradation was decreased in the presence of EDTA, 
which functions as an antioxidant by chelating metal ions.  In addition, RC-101 was stable in the 
presence of enzymes commonly present in human vaginal fluid and cervical mucus, suggesting 
that RC-101 has the potential to become a successful microbicide product.  Based on the 
excellent results obtained in the preformulation studies for RC-101, it was a logical step to 
further develop this peptide into a microbicide product. 
7.2.2 Interaction of RC-101 with human vaginal fluid 
After verification of RC-101 stability under several conditions in preformulation studies 
(chemical and physical stability), analyses were conducted to verify its stability in a biological 
environment.  To understand the impact of vaginal fluids on the stability of RC-101, fresh human 
vaginal fluid (HVF) was collected from healthy volunteers and the effect of the fluid on the 
peptide was investigated.  This is the first study in the microbicide field to evaluate a microbicide 
candidate using fresh non-diluted HVF.  We have shown that RC-101 is detected in human 
vaginal fluid for at least 48 h after exposure at 37 °C, indicating stability of the molecule in this 
biological fluid over time.  In addition, formulation of RC-101 in a film delivery system 
maintained the stability of RC-101 in HVF for the same time period. 
Another important finding resulted from studying the impact of HVF positive for 
bacterial vaginosis (BV) on RC-101 stability.  It was shown that RC-101 was unstable in fluid 
positive for BV evidenced by the undetectable levels of RC-101 after exposure to HVF positive 
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for BV at all time points.  The higher enzymatic activity reported in HVF positive for BV could 
explain the immediate degradation of RC-101.  Given the fact that bacterial vaginosis is a highly 
prevalent condition (one third of women between the ages of 14 and 49 years old in the United 
States (194)), the efficacy of a microbicide product in the population may be greatly affected by 
the presence of BV.  This finding is extremely important and should lead to a change in the way 
biopharmaceuticals and other molecules are developed as microbicides.  In the future, the 
development of microbicides should include an evaluation of the effects of HVF positive for BV 
on the stability of microbicide candidates, as we have done with RC-101. 
A considerable limitation of the LC-MS/MS method used for RC-101 detection is that the 
method was qualitative and not quantitative.  This study showed the presence of RC-101 in HVF 
for at least 48 h, but absolute amounts of RC-101 could not be determined.  The synthesis of a 
RC-101 stable isotope would be necessary for the quantitative determination of RC-101.  
However, due to funding limitations, we were unable to synthesize an isotopic peptide.  Another 
approach to obtain a quantitative determination for RC-101 using LC-MS/MS is to construct a 
standard curve using RC-101.  This approach was not followed due to the fact that RC-101 
ionizes poorly when alone in solution, giving values with low reproducibility.  Further 
development of a quantitative method is recommended to quantify the loss, if any, of RC-101 
over time. 
The RC-101 detection for at least 48 h in HVF gives a great indication of the stability of 
the molecule in this fluid, suggesting that it will maintain bioactivity.  However, further studies 
should be conducted to evaluate if the RC-101 detected after exposure to HVF is still active 
against HIV.  These studies are already being planned in collaboration with Dr. Alexander Cole 
(University of Central Florida).  Based on the cyclic structure of RC-101, preformulation studies, 
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and LC-MS/MS detection in HVF, we hypothesize that RC-101 stability is preserved, 
maintaining bioactivity.  If this is correct, RC-101 becomes an even stronger candidate as a 
microbicide for further studies in clinical trials. 
So far, no microbicide product has been approved.  Microbicide product development has 
been, as with any other pharmaceutical product, a long-term process. The incomplete 
understanding of HIV transmission and the lack of appropriate in vitro methods and animal 
models have contributed to the challenging process of microbicide product development.  Recent 
setbacks in the microbicide field have raised concerns with methods used for preclinical 
evaluations and their correlation with human studies.  In January 2007, the Contraceptive 
Research and Development Program (CONRAD) announced that two Phase 3 clinical trials with 
the candidate microbicide cellulose sulfate, a poly-anion, were stopped (33).  Cellulose sulfate 
use was associated with a trend towards an increase in HIV infectivity.  On February 2008 
another unexpected setback occurred.  The completion of a Carraguard Phase 3 clinical trial 
showed that no significant protection against HIV was observed when the product was compared 
to a placebo; however, the Carraguard product was shown to be safe for use in humans, and is 
still being investigated as a vehicle for other microbicide candidates (37, 38). 
Taking into consideration the lack of suitable methods to predict the response of 
microbicides in vivo, the work presented in this dissertation attempts to provide new strategies to 
overcome this obstacle.  One of the first barriers to the delivery of a microbicide product is the 
presence of biological fluids.  The impact of human vaginal fluid and cervical mucus on the 
microbicide stability and bioactivity should be considered as a screening tool for the 
development of microbicides.  The study conducted in this dissertation used freshly collected 
HVF.  Certain limitations apply to this approach.  It should be taken into consideration that ex 
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vivo use of biological fluid may underestimate the enzymatic activity present, therefore not 
accounting for all the potential degradation pathways for RC-101.  Ideally, the results of this 
study should be correlated with findings in in vivo human clinical trials to validate the use of 
collected fluids as a predictive tool.  It is also important to conduct more studies with biological 
fluids in the normal and pathological state, in view of the immediate loss of RC-101 in the 
presence of fluid positive for BV.  Nevertheless, this is the methodology closest to an in vivo 
situation used to understand the impact of fluids on a microbicide available so far.  The presence 
of RC-101 for at least 48 h is an important finding and provides a significant stimulus to pursue 
the further development of this peptide into a microbicide product. 
Another aspect to be studied in future research projects is the stability of the microbicide 
candidate in seminal fluid.  During male to female sexual transmission of HIV, the vaginally 
applied microbicide product will be in contact with semen.  Some characteristics of the semen 
such as pH (pH = 7.8), strong buffering capacity, and high protein (224) content may inhibit the 
activity of a microbicide.  It has been shown that the HIV-1 inhibitory activity of several 
polymeric candidate microbicides is diminished in the presence of seminal plasma (225).  No 
studies have been conducted for RC-101 activity in the presence of semen up to now, and these 
studies are strongly recommended. 
7.2.3 RC-101 formulation into a drug delivery system 
Several surveys and research studies have centered on the user preferences for the dosage form 
of a microbicide product.  In addition to women’s preferences, the dosage form of choice must 
be such that it will deliver the microbicide candidate effectively and maintain its stability during 
shelf-life and in the biological environment.  The use of a film formulation for vaginal drug 
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delivery has several advantages over alternative formulations.  When compared to semi-solid 
gels, film products are easier to apply, quickly release the drug, eliminate the need for an 
applicator, and can improve stability of drugs that are sensitive to water.  In contrast, 
conventional gel vaginal dosage forms are associated with limitations of poor retention in the 
vaginal lumen, leakage, messiness, in addition to being a poor vehicle of choice for peptide 
formulations.  Due to the several advantages as a drug delivery system for microbicides, vaginal 
films were selected as the final dosage form for RC-101. 
The RC-101 film product developed in this dissertation work is clear, flexible, and 
completely dissolves in water in less than 5 min.  RC-101 films were effective against HIV (in 
vitro and ex vivo) and safe to human tissue (ex vivo) and animals (ex vivo and in vivo).  However, 
stability of RC-101 in films over time was compromised.  A decrease in RC-101 as determined 
by HPLC was observed over time, without the presence of secondary peaks, suggesting loss of 
the peptide by other mechanisms than those studied in the preformulation studies (Chapter 3).  
Despite these losses observed by HPLC, preliminary studies have shown that after storage for 6 
months at room temperature, RC-101 films still maintain their bioactivity.  In vitro suppression 
of more than 90% HIV was obtained with these RC-101 films stored over time (personal 
communication – Dr. Alexander Cole, University of Central Florida).  This result indicates that 
the loss of RC-101 by HPLC involves a process different than oxidation or thermal degradation, 
and does not affect bioactivity.  This loss can be attributed to reversible binding of RC-101 to the 
polymers in the formulation.  Future studies should include evaluation of the aggregation of RC-
101 with the polymer, and investigation of sample preparation methods that are able to extract 
the peptide from the formulation for HPLC analysis. 
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Several models exist to determine bioactivity of microbicide candidates; however, 
limitations of the bioactivity methods should be taken into consideration.  In vitro HIV-1 
efficacy studies have been used extensively to screen microbicide candidates.  Most of the in 
vitro methods published are cell-based assays to determine the suppression of HIV-1 transfection 
by microbicide candidates (15, 89, 199).  In our studies, we have investigated the efficacy of RC-
101 films against HIV using an in vitro cell-based assay and an ex vivo model.  Results from in 
vitro assays show an IC50 of 2.2 µM for RC-101 films, three times higher than unformulated RC-
101 in solution (IC50 = 0.66 µM).  This increase in the IC50 may be attributed to the lower 
availability of RC-101 in the formulation when compared to solutions.  In studies with the ex 
vivo model, RC-101 formulated into film displayed an IC90 of 57.5 µM, at least 5 times higher 
than RC-101 in solution using the same model (IC90 = 10 µM).  Again, the increase in the IC90 
may be attributed to the lower availability of RC-101 in the formulation when compared to 
solutions.  In addition to the differences observed using RC-101 solution and RC-101 film 
formulation, an increase (factor of 10) was observed from the in vitro to the ex vivo model.  In 
the drug development process, efficacy and toxicity studies are conducted starting with less 
complex systems and progressing to systems of greater complexity, finally ending with human 
studies, as discussed in Section 5.4.  An increase in IC50 or IC90 going from simple to more 
complex models is expected.  A cell-based assay consists of a monolayer of cells and does not 
represent the squamous epithelial structure of ectocervical and vaginal mucosa.  The ex vivo 
model, using excised human tissue, is more representative of the conditions found in vivo; 
however it still has limitations and is not an absolute predictor of concentrations necessary for in 
vivo efficacy.  The lack of blood and oxygen, absence of other STIs, and lack of inflammatory 
response are some examples of the limitations of using an ex vivo model.  Further studies should 
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be conducted to evaluate the efficacy of RC-101 in animals.  Even when using animals for 
efficacy studies, there is still the question of which model would be the most suitable.  This is a 
recent topic of discussion in the microbicide field.  Initially, the monkey model using SHIV 
transmission had been used to predict doses for human clinical trials.  However, the recent 
failures of microbicide products in Phase 2 and 3 have prompted the microbicide research 
community to re-evaluate the in vivo animal models used.  Current methods to investigate 
efficacy in vivo include: SCID mice engrafted with human PBMCs, humanized mouse models, 
and non-human primates (226).  The last model is the closest to the HIV transmission in humans, 
but still has been shown to fail in the case of cellulose sulfate (33, 227) and Carraguard (37) 
trials to predict results seen in humans.  Based on these results, are non-human primates a valid 
model?  There is no answer to this question yet.  Until proof of concept is established for 
microbicide efficacy, there is no way of deciding which of these assays might best predict the 
physiological events in humans.  There are no perfect models and caution should be taken when 
interpreting results from these models.  In any case, in vitro and ex vivo models are helpful tools 
for microbicide screening during pre-clinical evaluation and provide valuable information for 
further studies. 
The same discussion applies to the models used for safety evaluations.  The classical 
example of safety studies conducted in animals not predictive of results in humans is the use of 
nonoxynol-9 (N-9).  Nonoxynol-9, a nonionic surfactant, was initially tested for anti-HIV 
activity in clinical trials after being used in the market for over 25 years as a contraceptive.  The 
product was safe in a rabbit vaginal irritation model, and safe to humans in Phase 1.  However, 
when a larger study was conducted in humans, damage to the epithelial vaginal mucosa was 
observed especially in the frequent users of the product.  It was also shown that the groups using 
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the product had a higher incidence of HIV when compared to the placebo group.  Studies 
concluded that the therapeutic window for N-9 was very narrow, and toxicity included induction 
of inflammatory responses and cytotoxicity to epithelial cells (34-36).  Most of the safety study 
(Phase 1) trials in humans are based on the colposcopy evaluations as a traditional endpoint of 
toxicity.  However, investigations to identify biomarkers, inflammatory response, changes in pH, 
and changes in normal flora have been conducted in an effort to establish a more comprehensive 
toxicity evaluation (228).  In our studies, ex vivo safety of RC-101 and RC-101 films were 
conducted by exposing human and monkey reproductive tract tissues to the solution or product.  
The product was considered safe when no gross morphological changes (H & E staining) such as 
loss of nuclei, sloughed epithelial layer, or changes in cytoplasm-to-nucleus ratio in the epithelial 
cells were observed.  After the initial safety screening in excised tissue, in vivo safety studies 
were conducted using a monkey model.  RC-101 film was shown to be safe when colposcopy, 
pH, and vaginal flora were investigated.  Once again, within the limitations of the model, the 
safety studies show encouraging results and suggest safety of the product in humans, but only 
human clinical studies may be able to confirm these findings and better validate the use of 
monkey studies as a safety model.  
7.2.4 Permeability and tissue localization of RC-101 
Important findings described throughout this dissertation work have validated RC-101 as a 
promising microbicide candidate, encouraging further investigation of the molecule.  The dual 
mechanism of action observed for RC-101 (binding to the glycoprotein of the virus and binding 
to the receptor of the host cell) offers a strong incentive to develop RC-101 as a topical vaginal 
microbicide product.  In order to take advantage of this dual mechanism, RC-101 must be 
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targeted to both the epithelium and vaginal lumen.  The ability of RC-101 to penetrate into 
human (ectocervical and endometrium) and monkey (vaginal and endometrium) tissues was 
assessed.  In addition, the permeability of human and monkey female reproductive tract tissues to 
RC-101 was investigated.  The distribution and permeability of RC-101 in a solution and a 
formulated state were analyzed using an ex vivo system. 
Permeability studies conducted using a Franz-cell model showed that no more than 10% 
of RC-101 was found in the receptor compartment after 6 h exposure to human or monkey 
excised tissue, suggesting that only negligible systemic absorption would occur.  To confirm this 
finding, pharmacokinetics studies are planned for the next safety evaluation in monkeys.  These 
results have an essential implication for the safety of this microbicide.  We are developing a 
topical vaginal microbicide that will offer protection against HIV.  A limited penetration of RC-
101 into the tissue is advantageous to target immune cells within the epithelial layer, but 
systemic absorption of RC-101 is not desirable.  Systemic concentrations of RC-101 do not add 
to the mechanism of protection, and have not been studied regarding safety.  A low permeability 
of RC-101 through tissues is beneficial to the development of RC-101 as a topical microbicide, 
keeping the peptide in its target tissue.  From the experiments in the Franz-cell system, 
calculations of the median concentration of RC-101 in the donor compartment for RC-101 film 
represents that 63.2 μg/mL cannot be accounted for by mass balance and were not found in the 
donor or receptor compartment.  Given the fact that the IC90 for RC-101 film described in 
Section 5.3 using an ex vivo model was estimated to be 57.5 µM (108.6 μg/mL), and assuming 
that the decrease in the RC-101 from the donor compartment in the Franz-cell represents 
penetration into the tissue, we can suggest that about 60% of the RC-101 necessary to suppress 
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90% of HIV is within the tissue, being available to bind to CD4 of the host cell.  The remaining 
40% of RC-101 is in the vaginal lumen being available to bind to glycoproteins of the virus. 
Clearly, there are advantages and limitations to using an ex vivo model for permeability 
studies.  The advantages are that human excised tissues are more comparable to in vivo, making 
it more suitable than cell-based models, as discussed in Section 6.4.  Excised tissue resembles the 
structure of what will be encountered in vivo.  However, results obtained from ex vivo models 
cannot be assumed to be identical to what would be obtained from whole animal or human 
studies.  Excised tissues start to deteriorate from the moment they are removed during surgery, 
lacking a physiological blood and oxygen supply.  Studies conducted in our laboratory have 
shown that the tissue is viable (as determined by MTT assay) for up to 8 h in a Franz-cell system, 
when maintained at body temperature.  However, due to the lack of blood and oxygen supply, 
there is no guarantee that the permeability will be the same as in an in vivo model, and viability 
does not guarantee that regular physiological functions are intact.  The concern with using an 
excised tissue model is similar to what has been discussed in Section 7.1.3 for use of ex vivo 
models for microbicide efficacy evaluations.  Permeability studies conducted with RC-101 
indicate that penetration of RC-101 occurs in an ex vivo model, and this represents further 
encouragement to conduct further studies with animal models followed by human clinical trials. 
Further characterization of the permeability of RC-101 in whole animal models is recommended. 
In addition to the Franz-cell system, tissue localization of RC-101 was also evaluated in 
another ex vivo model: full excised monkey female reproductive tract.  In the full female monkey 
reproductive tract, RC-101 films were vaginally inserted and immunostaining conducted after 2 
h exposure to the film.  Results have shown that RC-101 penetrated into the epithelial mucosa, 
being evident throughout all epithelial layers, including submucosal and basal layers, as detected 
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by immunostaining of RC-101.  This result suggests that RC-101 penetrates the epithelial 
mucosa, being available to target immune cells.  Contrary to the findings in the full reproductive 
tract, when monkey and human tissue were used in a Franz-cell system, tissue localization 
studies showed that RC-101 was predominantly found in the upper epithelial layer only.  
Differences between the two excised models must be elucidated in order to explain variation in 
the penetration of RC-101 observed.  Full excised tissues and excised monkey tissue used in the 
Franz-cell experiments are obtained after the monkeys are euthanized, then the whole 
reproductive tract is removed, placed in media, and shipped on ice to our laboratory, taking up to 
24 h to arrive.  Upon arrival, the tissue is warmed to 37 °C and immediately used for the 
experiments.  When a tissue is removed from the whole animal, it is immediately deprived of its 
physiological supportive and protective mechanisms.  There is no supply of nutrients to the cells, 
no removal of waste products, and no maintenance of pH and osmotic pressure.  When 
comparing the same type of tissue (monkey) in the two different models (full reproductive tract 
and Franz-cell), less penetration of RC-101 was observed when using the Franz-cell model.  
Considering that both tissues lack the physiological supporting and protective mechanisms, and 
have been excised at least 24 h prior to testing, we had expected to see similar results.  Deeper 
penetration of RC-101 in the full reproductive tract tissue may be associated with a more 
complete organ structure that facilitates RC-101 penetration.  We are unable to obtain full human 
reproductive tracts to repeat the experiments and verify if deeper penetration also takes place in 
human tissues. 
Despite the limitations of the method, penetration of RC-101 into the deeper layers of the 
tissue was observed when using a full reproductive tract.  This penetration may allow targeting 
of RC-101 to the immune host cells, increasing the activity of RC-101 against HIV.  For future 
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studies, we recommend to test the tissues used in RC-101 ex vivo permeability/distribution 
studies and challenge against HIV-1.  We have shown that RC-101 in film formulation protected 
against HIV using an ex vivo human ectocervical model (Section 5.3).  Based on these results, 
we would anticipate that in vivo protection against HIV-1 infection will be achieved.  In addition, 
when safety evaluations in animals are conducted, future studies should include biopsies 
obtained from the animal studies after exposure to RC-101 film to be challenged against HIV-1.  
These studies have already been planned by our laboratory and collaborators.  Certainly, results 
obtained by ex vivo methods are only useful when they correlate with in vivo results.  Our 
findings suggest that exposure to RC-101 in vivo will offer a deeper penetration of the drug into 
the tissue enhancing the protection against HIV.  However, future studies are required to confirm 
this finding. 
7.3 FURTHER DEVELOPMENT OF RC-101 AS A MICROBICIDE 
Findings from this dissertation work show that: RC-101 formulated in a film drug delivery 
system protected the peptide from degradation prior to administration; anti-HIV activity of RC-
101 was maintained in the formulation; RC-101 was stable for at least for 48 h in the presence of 
human vaginal fluid; and penetration of RC-101 into epithelial tissue was demonstrated.  These 
results contribute significant information to the development of RC-101 into a successful 
microbicide product. 
As discussed in Section 7.1, future studies are recommended to address the limitations of 
the methods used and progress the RC-101 film formulation forward into product development.  
Future studies are summarized below:   
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? Confirm results of degradation of RC-101 in the presence of HVF positive for BV. 
? Develop a quantitative method to quantify the loss, if any, of RC-101 over time after 
exposure to HVF. 
? Evaluate if the RC-101 detected after exposure to HVF is still active against HIV. 
? Conduct in vivo human clinical studies to validate the use of collected fluids as a 
predictive tool for stability of RC-101 and other molecules. 
? Study the stability of RC-101 in human seminal fluid. 
? Identify the mechanism of loss of RC-101 observed in the dosage form, and re-
formulate the product. 
? Perform safety studies in animals and include biopsies for RC-101 distribution 
analysis, and efficacy evaluations. 
? Include pharmacokinetic studies in animal models. 
? Perform efficacy of RC-101 in animal models. 
In addition, further development of the RC-101 film into a successful microbicide 
product should include strategies presented by the Alliance of Microbicide Development (143), 
and FDA (229) recommendations that have not been addressed in this dissertation project.  These 
recommendations include: toxicology studies in at least two animal species; absorption, 
disposition, metabolism, and excretion (ADME) analysis; rabbit vaginal irritation tests; 
hypersensitivity and photosensitivity; genotoxicity effects; reproductive toxicology; 
carcinogenicity tests; condom compatibility tests; penile skin irritation tests; contraceptive 
effects; toxicity to normal human vaginal flora;  and activity against other STDs. 
Another important aspect in the development of a successful microbicide is the cost of 
the final product.  A microbicide product containing a peptide might be expensive and unviable 
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for future commercialization.  However, it should be considered that the production costs will be 
substantially reduced when the peptide is produced on a larger scale, as explained below.  It is 
common knowledge that high production costs are associated with synthetic peptides, at 
approximately US$ 75 – 100 per gram per amino acid residue.  These assumptions are based on a 
small scale synthesis.  Based on a recent assessment of peptide production costs, if one scales-up 
the manufacturing process to approximately 100 kg, then the cost would drop to US$ 7.5 – 10 
per gram per amino acid residue (230).  Estimating the RC-101 film production costs, at a dose 
of 2 mg/film (used in the safety studies), the amount of RC-101 necessary for each film would 
cost US$ 0.36 (=10 x 18 x 0.002) if the peptide is produced at a scale of 100 kg batches.  This 
cost comparison demonstrates that an economical product is possible.  Additionally, the ability to 
manufacture adequate amounts of the drug substance is required for commercialization.  If a 
woman uses RC-101 films every 2 days, each woman would receive a dose of 0.36 g/year.  As a 
comparison, enfurvirtide, a 36-amino acid peptide used for HIV therapy, has been produced at a 
scale of 3 tons/year, and patients receive a dose of 80 g/year (230).  This demonstrates that 
capacities required are easily achievable in commercialization.  Another factor to reduce the cost 
of this peptide is the intensive efforts being conducted to produce RC-101 as a recombinant 
product.  However, this strategy has not been successful so far. 
Overall, it has been shown in this dissertation work that RC-101 developed in a film 
formulation is a promising candidate as a safe and effective microbicide product.  The future 
development of RC-101 in greatly encouraged. 
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7.4 CONTRIBUTIONS TO THE MICROBICIDE FIELD 
It is challenging, although fascinating, to be in a research field where no molecules have been 
approved yet.  Limitations in the methods used are a constant concern, and until a successful 
microbicide is approved on the market, these limitations will not be defeated.  This dissertation 
work not only provides encouraging results for RC-101 as a microbicide product, but also 
provides a systematic tool for the development of other microbicide molecules. 
The dosage form selected for the delivery of RC-101 can be used for other microbicides. 
Polymeric films are not limited to the delivery of peptides and proteins only.  In fact, this 
approach is being investigated in our laboratory for smaller molecules as well as larger proteins, 
and by other research groups such as the studies conducted with sodium polystyrene sulfonate 
(PSS) (231) and cellulose acetate 1,2-benzenedicarboxylate (CAP) (208).  Polymeric films are 
also not limited to HIV protection only.  This drug delivery system is currently in use in the 
market for the delivery of the contraceptive nonoxynol-9 (N-9).  The product, Vaginal 
Contraceptive Film (VCF, Apothecus Pharmaceutical Corp., Oyster Bay, NY) is a PVA based 
film which contains 28% of N-9.  The idea of a vaginal polymeric film can be expanded for use 
in other sexually transmitted diseases. 
In conclusion, the approach used in this dissertation for the development of RC-101 as a 
microbicide product should be adopted as a tool for the development of other microbicide 
candidates.  The impact of HVF (normal and pathological state) on the stability of RC-101 and 
the evaluation of RC-101 distribution in the epithelial mucosa are novel methodologies 
implemented to provide valuable information for the further development of RC-101.  These 
methodologies can be utilized in development of other potential microbicide drugs and represent 
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a fundamental strategy for the evaluation of a microbicide candidate.  In the future, human 
clinical studies will be able to validate this approach as a screening tool for microbicides.  
Finally, a female-controlled microbicide RC-101 film (or any other microbicide product) 
is only one aspect in the fight against HIV-1.  Any program to eradicate the HIV pandemic level 
needs to include a multi-disciplinary approach.  Women and men should be educated on the 
proper use of preventive methods, in addition to the use of a microbicide.  Although prevention 
of HIV infection is an overwhelming task, an ideal microbicide product will be achieved with 
focused and thorough scientific efforts.  The work presented in this dissertation provides a 
significant contribution towards this goal. 
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APPENDIX A 
MICROBICIDES IN THE PIPELINE 
A.1 MICROBICIDE CANDIDATED IN ADVANCED PRE-CLINICAL STUDIES 
 
ADVANCED PRE-CLINICAL STUDIES 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
CAP  Fusion inhibitor The New York Blood Center, NIAID  
Cyanovirin-N  Entry/fusion inhibitor NIH, Osel Inc., University of Pittsburgh  
D-peptides  Entry/fusion inhibitor  NIH, University of Utah School of 
Medicine 
DS001/L-860,167  Entry/fusion inhibitor  International Partnership for Microbicides 
(IPM) 
Mapp66 Combination of 
antibodies, neutralization 
Mapp Biopharmaceutical Inc.  
Nisin Combination National Institute for Research on 
Reproductive Health 
Octylglycerol  Surfactant  NY State Institute for Basic Research, 
Magee-Women’s Research Institute, 
University of Pittsburgh  
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 ADVANCED PRE-CLINICAL STUDIES (Continued) 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
Opuntia spp  Entry/fusion inhibitor, 
Replication inhibitor  
CIDEPLAN, SELADIS  
PEHMB  Entry/fusion inhibitor  Drexel University College of Medicine, 
Novaflux, Biosciences, Inc.  
Persulfated 
molecular 
umbrellas  
Entry/fusion inhibitor  Albert Einstein College of Medicine, 
Lehigh University, Mount Sinai School of 
Medicine  
Polycarboxylated 
aryl oligomer 
Entry/fusion inhibitor  Albert Einstein College of Medicine 
TOPCAD/Rush University, YASO  
PSC-RANTES  Entry/fusion inhibitor 
CCR5 inhibitor 
La Jolla Foundation for Microbicide 
Research, Mintaka Foundation, NIAID, 
NIH, Scripps Research Institute, University 
of Pittsburgh  
Retrocyclins  Entry/fusion inhibitor  NIH, UCLA, University of Central Florida, 
University of Pittsburgh, University of 
Washington  
SJ-3991  Multiple mechanisms  ImQuest, IPM  
Adapted from the Alliance for Microbicide Development website. 
http://www.microbicide.org/cs/microbicide_pipeline - consulted on 10/24/2008. 
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A.2 MICROBICIDE CANDIDATES IN DISCOVERY AND EARLY PRECLINICAL 
STUDIES 
 
DISCOVERY/EARLY PRECLINICAL 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
C5A  Vaginal defense enhancer  
Mechanism ruptures the 
integrity of both the viral 
membrane and the 
mature core. 
NIH, Scripps Research Institute, 
Viriome  
Cyclotriazadisul 
fonamides (CADA) 
Entry/fusion inhibitor, 
Uncharacterized 
mechanism(s)  
Rega Institute, University of Nevada, 
EMPRO (D Schols, TW Bell)  
CAP and combinations 
with NNRTIs and ZFIs  
Combination  NIH  
Diterpene  Combination  
Noncompetitive inhibitor 
of reverse transcriptase: 
FAP, FIOCRUZ, UFF  
DS003/BMS-599793  Entry/fusion inhibitor  
gp120 binder 
IPM  
DS004/L-860,872  Entry/fusion inhibitor  
CCR5 blocker, 
IPM  
DS005/L-860,882  Entry/fusion inhibitor  
CCR5 blocker 
IPM  
EBd peptides  Entry/fusion inhibitor  NIH, University of Wisconsin School 
of Medicine  
Flavonoids (EGCG)  Entry/fusion inhibitor  NIAID, NY State Institute for Basic 
Research, University of Pittsburgh  
 247 
 DISCOVERY/EARLY PRECLINICAL (Continued) 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
Fully synthetic 5P12- 
5P14- and 6P4- 
RANTES 
Entry/fusion inhibitor La Jolla Foundation for Microbicide 
Research, Mintaka Foundation, 
NIAID, NIH, Scripps Research 
Institute, University of Pittsburgh 
Glycerol monolaurate 
(GML)  
Uncharacterized 
mechanism(s)  
NIAID, University of Minnesota  
HHA, KRV2110, T20 
Combinations  
Combination  ANRS- Multi Micro Project  
ISIS 5320  Entry/fusion inhibitor  ImQuest  
K5-N, OS(H), K50SH  Entry/fusion inhibitor  San Raffaele Scientific Institute and 
Glycores 2000, EMPRO  
KP1, KP17  Replication inhibitor, 
Combination  
CONRAD  
L’644 peptide  Entry/fusion inhibitor gp41 
inhibitor 
IPM  
Maraviroc  Entry/fusion inhibitor 
CCR5 blocker 
IPM  
Nanobodies™  Entry/fusion inhibitor  University College London, 
University of Utrecht, Ablynx NV, 
EMPRO  
NCp7 Thioesters 
(SAMTs)  
Replication inhibitor  ImQuest  
Novasomes  Combination, entry/fusion 
inhibitor, Uncharacterized 
mechanism(s)  
Novavax  
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DISCOVERY/EARLY PRECLINICAL (Continued) 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
Optimized dendrimers Combination, entry/fusion 
inhibitor 
NIH (DAIDS), Reprotect, Starpharma 
Pty Ltd. 
PC-710  Combination Carraguard 
(entry/fusion inhibitor) and 
Zinc – appears highly 
effective against HSV-2 
Population Council  
Pyrimidindiones  Multiple mechanisms  ImQuest  
Pyrimidindiones and 
ISIS 5320  
Combination (2 products)  ImQuest  
RANTES peptides  Entry inhibitor  San Raffaele Scientific Institute, Osel, 
Inc.  
Recombinant 
lactobacillus (LAB)  
Entry/fusion inhibitor  Aaron Diamond AIDS Research 
Center, NIH  
REP 9C, REP 9AC  Entry inhibitor  REPLICor Inc., NIH/NIAID  
sCD4-17b  Entry/fusion inhibitor  NIH  
Single-chain ICAM  Entry inhibitor  Osel, Inc.  
siRNA  Combination, Entry/fusion 
inhibitor  
Immune Disease Institute, Harvard 
Medical School, NIH, IPM  
Sodium Rutin Sulfate 
(SRS)  
Entry/fusion inhibitor  Zhejiang CONBA Pharmaceutics 
Company  
Soluble DC-SIGN  Entry/fusion inhibitor  Mintaka Foundation, Scripps Research 
Institute  
Syndecan  Combination neutralize 
either the mucosal 
syndecans or the syndecan-
binding of HIV-1, gp120; 
Scripps Research Institute  
Talactoferrin  Entry/fusion inhibitor, 
Uncharacterized mechanism 
Aggenix, Inc.  
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DISCOVERY/EARLY PRECLINICAL (Continued) 
Candidate  Mechanism of Action  Developer/Researcher/Sponsor  
TATC-D peptides  Entry/fusion inhibitor  NIH, University of Wisconsin School 
of Medicine 
Unipron  Vaginal defense enhancer  Institute of Primate Research – Dept 
Reproductive Health  
x-REPLAB  Vaginal defense enhancer, 
Combination  
Makerere College of Health Sciences, 
Restrizymes Canada Corporation, 
Restrizymes Biotherapeutics LTD  
ZCM  Combination  Population Council  
Zinc tetra-ascorbo-
camphorate derivative 
“C14”  
Combination  MGB Pharma  
Adapted from the Alliance for Microbicide Development website. 
http://www.microbicide.org/cs/microbicide_pipeline - consulted on 10/24/2008. 
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APPENDIX B 
SCREENING FOR HUMAN SUBJECTS 
B.1 PHONE SCREENING 
Phone Screening Script 
 
Thank you for calling to find out more about our research study.  My name is Alex Sassi, 
and I am a researcher at the Magee-Womens Research Institute.  The purpose of this research 
study is to evaluate the potential effects of cervical mucus and vaginal fluid on the activity of a 
vaginal product.  This study will be towards the development of a vaginal product, a female 
controlled method to prevent transmission and acquisition of HIV.  You will not be in contact 
with the virus or any drug during the course of this study.  Your participation will only be to 
donate vaginal fluid. 
We are recruiting pre-menopausal women from 18 to 45 years old. You will not be 
eligible to participate in this study if you have been recently exposed to any sexually transmitted 
disease, if you currently experience vaginal bleeding, if you are pregnant, if you delivered a baby 
in less than 90 days, if you are breast feeding, if you had a miscarriage or abortion in less than 90 
days, or if you have a tilted uterus.  If you qualify to take part in this research study, you will be 
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asked to sign a consent, take a pregnancy test, answer a questionnaire, and place flexible 
diaphragm like device (INSTEAD Softcup®) into your vagina.  After 30 min, a physician will 
remove the cup.  The same physician will conduct a test swab to verify presence of sexually 
transmitted diseases.  No other visits are required.  The total estimated time is 60 min, which 
includes reading and signing the consent form, answering the questionnaire, taking the 
pregnancy test, and placing and removing the device.  
Do you think you might be interested in participating in that study? 
 
If NO:  Thank you very much for calling. 
 
If YES:  Before enrolling people in this study, we need to determine if they are 
eligible.  And so what I would now like to do is to ask you a series of questions about your 
gynecologic history, including your menstrual cycle, age, and method of birth control used. 
There is a possibility that some of these questions may make you uncomfortable or distressed; if 
so, please let me know.  You don’t have to answer those questions if you don’t want to.  You 
also need to understand that all information that I receive from you by phone, including your 
name and any other identifying information, will be strictly confidential and will be kept under 
lock and key.  The purpose of these questions is only to determine whether you are eligible for 
our larger study.  Remember, your participation is voluntary; you do not have to complete these 
questions. 
Do I have your permission to ask you these questions? 
 
If NO:  Thank you very much for calling. 
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 If YES:   How old are you? _____ 
  Are you pregnant? _______ 
  Do you use any type of Intra Uterine Device or Vaginal ring? ______ 
Are you currently using any vaginal products? (creams, gels, douches, 
foams, or lubricants)  _______ 
  What was the first day of your last menstrual period? _________ 
  We can now schedule a time for you to come to the clinic to sign the 
consent form, answer the questionnaire, and collect vaginal fluid.  It is important that you abstain 
from sexual intercourse and do not use any vaginal products for 48 hours before the test. 
 
Phone screening conducted on: _____________   By: __________________________ 
B.2 QUESTIONNAIRE 
B.2.1 Questionnaire: Hormonal Status of premenopausal women 
Please answer every question as best as you can; if something doesn’t apply to you, please write 
N/A. Please do NOT leave any questions in blank. 
Date form completed_______________________________ 
1. Age range:  
  18 – 20 
  21 – 25 
  26 – 30 
  31 – 35 
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  36 – 40 
  41 – 45 
 
2. Race/ ethnicity 
_____  American Indian 
_____ Asian 
_____ African American 
_____ Hispanic 
_____ Caucasian 
_____ Other 
 
3. Have you ever in your life consumed an alcoholic beverage?  
Yes ___ No ______ 
  If yes, when was the date of your last consumption? ____________ 
  How often do you drink per week? ________________ 
4. Smoking history: 
  
_______ Not currently smoking, but have in the past. 
 How long ago did you quit? ____ 
_______ Never smoked 
_______ Currently smoke. How many cigarettes do you smoke a day? _______ 
 
MEDICAL HISTORY 
1. At what age did your menstrual period begin? _________________ 
 
2. When was your last period? (day/month) ________________ 
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3. What is the duration of your period? ____________ 
 
4. What is the duration (days) between your periods) ___________ 
 
5. Have you ever undergone any of the following gynecological procedures: 
  
Procedure YES/ NO Age Month/ year 
Hysterectomy (removal of the uterus)    
Both ovaries removed    
One ovary (or part of an ovary) removed    
Tubal ligation    
6. How many pregnancies have you had? ___________ 
7. Are you pregnant?   Yes __________  No _________ 
8. Have you ever had any problems with your uterus or ovaries such as ovarian cysts, 
fibroids, or endometriosis? Yes ______         No _________ 
 If yes, please describe the problem and any associated 
surgeries___________________________________________________________________
___________________________________________________________________________ 
9. Are you sexually active?  Yes ________ No ________ 
10. When was your last sexual intercourse?________________________________ 
11. Are you currently taking any birth control pills? ___________ 
 If yes, please provide the name of the medication_________________________  
 
12. What type of birth control do you currently use? ________________________________ 
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 13.  Do you use any type of Intra Uterine Device or Vaginal ring?  
 Yes _________   No _______ 
 
14.  Are you currently using any vaginal products? (creams, gels, douches, foams, or 
lubricants)  Yes _________   No _______ 
If yes, when you the last time you used it? ____________ 
What was the name of the product? _________________ 
 
15.  Are you currently using any medications? Including over-the-counter products, allergy 
medicines and vitamins. Yes ________    No ________ 
 If yes, please provide the names______________________________________ 
_____________________________________________________________________ 
 
16.  Do you have any medical conditions for which you are currently being treated?  
 Yes _______  No _____ If yes, please list the conditions: 
 
 
You will now be asked to perform the procedure. Before you start it, please take a 
moment to read the instructions sheet provided to you. 
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APPENDIX C 
LC-MS/MS CHROMATOGRAMS 
Representative LC-MS/MS chromatograms of the samples prepared in Chapter 4 are presented 
here.  Representative chromatograms include Samples A, B, D, BF (described in Table 4-1) from 
the solution obtained from the cell lysate at time 0 and at the end of the experiment. 
Sample A (blank HVF control) -
cells
RT: 0.00 - 30.00
0 5 10 15 20 25 30
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
RT: 19.97
RT: 22.88
NL: 5.50E3
Base Peak
m/z= 578.10-579.10 
F: + c NSI 
sid=10.00  SRM ms2 
473.400@cid18.00 
[573.650-574.150,
578.350-578.850, 
596.650-597.150] 
MS  Genesis 
Acells_t=0_090208_02
 
Figure Appendix C 1. Sample A (blank HVF control) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, at time 0. 
 257 
Sample B (RC-101 solution + HVF) –
cells
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Figure Appendix C 2. Sample B (RC-101 + HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, at time 0. 
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Figure Appendix C 3. Sample B (RC-101 + HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, after 72 h exposure. 
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Figure Appendix C 4. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, at time 0. 
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Figure Appendix C 5. Sample D (RC-101 film + HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, after 72 h exposure. 
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Figure Appendix C 6. Sample BF (RC-101 + frozen HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, at time 0. 
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Figure Appendix C 7. Sample BF (RC-101 + frozen HVF) representative LC-MS/MS chromatogram 
of solution obtained from cell lysate, after 48 h exposure. 
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APPENDIX D 
LIST OF AMINO ACIDS AND ABBREVIATIONS 
Amino acid 3-letter abbreviation 1 letter –abbreviation 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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